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DEDICATION 
 
The Road Not Taken 
 
Two roads diverged in a yellow wood, 
And sorry I could not travel both 
And be one traveler, long I stood 
And looked down one as far as I could 
To where it bent in the undergrowth; 
 
Then took the other, as just as fair, 
And having perhaps the better claim 
Because it was grassy and wanted wear, 
Though as for that the passing there 
Had worn them really about the same 
 
And both that morning equally lay 
In leaves no step had trodden black. 
Oh, I marked the first for another day! 
Yet knowing how way leads on to way 
I doubted if I should ever come back. 
 
I shall be telling this with a sigh 
Somewhere ages and ages hence: 
Two roads diverged in a wood, and I, 
I took the one less traveled by, 
And that has made all the difference. 
          By Robert Frost 
 
This work is dedicated to my parents, Mr. Andrew Ditse and Mrs Tiny Ditse, who have always 
been my rock and pillar of strength, my sisters; Dudu and Palesa, my niece Andile, my brother, 
Mpho and Bafana Vumasi. Thank you all for your support, encouragement and always believing 
in me even when everything seemed impossible. Without you, I would have not gone this far.  
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ABSTRACT 
 
Background: Due to the high cost and limited serotype coverage of pneumococcal conjugate 
vaccines (PCV), surface proteins of Streptococcus pneumoniae are being investigated for their 
role as potential vaccine candidates. There are limited data on natural antibody kinetics against 
pneumococcal surface proteins arising through exposure to pneumococcal nasopharyngeal (NP) 
colonization in African populations.  
Objectives: To characterize the natural antibody kinetics and sero-prevalence to 15 
pneumococcal proteins with respect to age, PCV vaccination and HIV status as well as to explore 
the association between antibody titers and pneumococcal nasopharyngeal colonization in 
infants, older children and adults. 
Methods: We established a 15-plex Luminex assay for the following proteins: PspA, PspC, 
LytB, IgA1-proteinase, SP 0082, PdB, PcsB, PsaA, SP 0609, SP 0749, PpmA, SlrA, StkP, SP 
2027 and SP 2194, and also validated the Luminex assay comparing it to a standard ELISA 
method for PspA, PspC, PsaA and PdB. We used the Luminex method to characterize the 
prevalence and dynamics of serum IgG antibodies against the pneumococcal proteins. The study 
involved 2 166 human subjects which included: i. A longitudinal cohort of children less than 2 
years of age, who were vaccinated with the seven-valent pneumococcal conjugate vaccine (PCV-
7) and were either a) HIV-exposed infected, b) HIV-exposed uninfected or c) HIV-unexposed 
uninfected. ii. A longitudinal cohort of PCV-7 unvaccinated children less than 2 years of age 
who were either: a) HIV-unexposed uninfected or b) HIV-exposed uninfected. The PCV-7 
vaccinated and unvaccinated children were followed up from approximately 4 to 24 months of 
age. In addition, samples were also analyzed from HIV-uninfected and HIV-infected children 
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aged between 4 to 7 years who received either a primary series of PCV-9 or placebo during 
infancy. Lastly, we analyzed cross-sectional samples from HIV-uninfected and HIV-infected 
women. 
Results: The multiplex Luminex assay correlated well with singleplex ELISAs for all four 
analyzed proteins with correlation coefficients of 0.86, 0.90, 0.87 and 0.96 for PspA, PspC, PdB 
and PsaA respectively. Antibody titers to PspC, PdB, LytB, SP 0082, PcsB and StkP showed 
increases in titer with respect to increasing age. Prevailing nasopharyngeal pneumococcal 
colonization in young children was associated with higher antibody titers to PspA, PspC, PdB, 
SP 0082, LytB, IgA1-proteinase, PpmA, PcsB and StkP. Conversely higher antibody titers to 
PspC, PdB, LytB, SP 0082, PcsB and StkP were associated with lower prevalence of 
pneumococcal colonization in older children and adults. In children under two years of age, PCV 
vaccination was associated with lower antibody titers to PspA, PspC, LytB, PdB, IgA1-
proteinase, PcsB and StkP as well as higher antibody titers against SP 0082 and PpmA at 
multiple time-points. In PCV-vaccinated children under two years of age, those who were HIV-
unexposed , -uninfected had higher antibody titers to PspA, PspC, SP 0082, IgA1-proteinase, 
PpmA and StkP compared to HIV-exposed, uninfected children.  
Conclusion: There was an age-related increase in antibody titers to PspA, PspC, PdB, SP 0082, 
LytB, IgA1-proteinase, PpmA, PcsB, and StkP in children under two years of age. PCV 
immunization was, however, associated with lower antibody titers to PspA, PspC, LytB, PdB, 
IgA1-proteinase, PcsB and StkP in young children which was not attributed to differences in the 
prevalence of nasopharyngeal colonization. Furthermore, HIV-infection status in young children 
was associated with higher antibody responses to PspA, PspC, PdB, SP 0082, LytB, IgA1-
proteinase, PpmA, PcsB and StkP proteins in HIV-unexposed uninfected children compared to 
HIV-exposed uninfected and HIV-exposed infected children. Higher antibody concentrations to 
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PspC, PdB, LytB, SP 0082, PcsB and StkP was negatively associated with nasopharyngeal 
pneumococcal colonization in older children and adults; indicating a protective role against 
colonization and a potential role as vaccine candidates.  
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LM       phospholipid membrane  
LTA      lipoteichoic acid  
LTFU     loss-to-follow-up 
LytB     Endo-beta-N-acetylglucosamidase  
LPXTG    Leucine-Proline-X-Threonine-Glycine, X is any amino acid 
M-/I-     HIV unexposed, uninfected children 
M+/I-     HIV exposed, uninfected children 
M+/I+     HIV exposed, infected children 
MFI       mean fluorescent intensity   
NP     nasopharyngeal 
OP     oropharyngeal 
PBS      phosphate buffer saline  
PCho      phosphocholine 
PCV      pneumococcal conjugate vaccine 
PCV-7     seven-valent pneumococcal conjugate vaccine 
PCV-9     nine-valent pneumococcal conjugate vaccine 
PdB     pneumolysoid 
PG        peptidoglycan  
Ply      pneumolysin 
Pnc     pneumococci 
Pneumococcus      Streptococcus pneumoniae 
PpmA      putative proteinase maturation protein A 
PPV23     23-valent polysaccharide pneumococcal vaccine 
PsaA      pneumococcal surface adhesion A 
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PscB                                                   protein required for cell separation of group B streptococci 
PspA      pneumococcal surface protein A 
PspC     pneumococcal surface protein C 
R-PE      R-phycoerythryn  
S. pneumoniae    Streptococcus pneumoniae  
SD       standard deviation  
SktP      serine-threonine kinase P 
SlrA      streptococcal lipoprotein rotamase A 
STGG     skim milk, tryptone, glucose and glycerin 
StkP     serine threonine kinase  
Sulpho-NHS      N-hydroxy-sulphosuccinimide  
TA        teichoic acid  
TIGR     The Institute for Genomic Research 
TIGR4     Streptococcus pneumoniae virulent serotype 4 
U/ml     arbitrary units per millilitre 
ULOQ     upper limit of quantification  
Zmp         zinc metalloprotease 
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Chapter 1: Introduction  
 
Streptococcus pneumoniae (S. pneumoniae) was discovered more than a century ago, yet severe 
pneumococcal diseases (pneumonia, meningitis, bacteremia and septicaemia) kill approximately 
870 000 children per annum, especially in industrializing countries (O'Brien et al., 2009). The 
most effective strategy for preventing pneumococcal disease is vaccination. The two currently 
available vaccines that are based on immunity to capsular polysaccharides of the pneumococcus, 
of which at least 92 serotypes exist (Bratcher et al., 2011), have limitations. The polysaccharide-
based vaccine, PPV23, which consists of 23 purified capsular polysaccharide antigens, is not 
immunogenic in young children for most serotypes (Käyhty et al., 1987). The polysaccharide-
protein conjugate vaccine (PCV) has varying potential for reducing pneumococcal disease, due 
to the limited number of serotypes included in the vaccine, as well geographic and temporal 
variations in serotypes causing pneumococcal disease in children (Hausdorff et al., 2001, 
Shinefield et al., 2002a, Siber et al., 2008). In addition, the potential for replacement disease 
from non-vaccine serotypes increases following immunization with PCV (Singleton et al., 2007). 
Furthermore, access to PCV is likely to be hampered because of the high costs of these vaccines, 
which require complex biotechnology to manufacture.   
 
Consequently, surface proteins of S. pneumoniae are being investigated for their role in 
pneumococcal pathogenicity and as candidate antigens for protein-based vaccines (Bogaert et al., 
2004a). Thus far, proteins associated with pneumococcal virulence which have shown the 
greatest potential as vaccine-antigen candidates are the two choline-binding surface proteins, 
Project ID: Pneumococcal protein antigens  
    Student: Zanele Ditse  
      Date: 04 October 2011  
 
- 23 - 
 
pneumococcal surface protein A (PspA) (Crain et al., 1990, McDaniel et al., 1987) and choline-
binding protein A (CbpA) (Brooks-Walter et al., 1999) and a metal-binding lipoprotein 
pneumococcal surface antigen A (PsaA) (Dintilhac et al., 1997, Sampson et al., 1994) and the 
thiol-activated toxin pneumolysin, Ply (Paton and Ferrante, 1983). 
 
The natural immune responses and interaction thereof, with pneumococcal nasopharyngeal 
colonization were evaluated for fifteen pneumococcal protein candidates in this study (see Table 
1). The antigens were PspA, PspC, PsaA and pneumolysoid (PdB), the non-toxic variant of Ply, 
serine-threonine kinase P (SktP), protein required for separation of group B streptococci (PscB), 
putative proteinase maturation protein A (PpmA), IgA1-proteinase, streptococcal lipoprotein 
rotamase A (SlrA), endo-beta-N-acetylglucosamidase (LytB), and some exploratory proteins 
obtained from Intercell AG, which were only described according to their Streptococcus 
pneumoniae virulent serotype 4 (TIGR4) annotation i.e. SP 0609, SP 0082, SP 0749, SP 2194 
and SP 2027.  
 
The advantages of pneumococcal proteins include: i.) proteins elicit a T-cell dependent immune 
response and consequently are likely to be immunogenic and induce anamnestic immune 
responses even when administered during early infancy; ii.) they could potentially protect against 
all pneumococcal serotypes; and iii) they are likely to be less expensive in production and cost 
than PCV. Previous studies measured antibodies to PspA in healthy adults and children, in 
children with invasive infection due to pneumococci and in children with invasive infection 
caused by other bacteria (Virolanein et al., 2000). Antibodies to Ply have been evaluated in 
elderly adults infected with S. pneumoniae among whom antibody responses were detected in 92 
% of serum samples (Musher et al., 2001). In children with acute otitis media, antibodies to Ply 
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were detected from early infancy but there was no association between the concentration of anti-
Ply antibodies and future risk of developing pneumococcal AOM (Simell et al., 2001).  
 
Previous studies in European and Filipo children also evaluated the prevalence and the natural 
development of antibodies to PspA, PspC, PsaA and Ply in young infants and their association to 
pneumococcal colonization and carriage (Holmlund et al., 2006, Rapola et al., 2000, Simell et 
al., 2009). In addition, there have been studies in European children on the natural development 
of antibodies to PpmA, SlrA and IgA1-proteinase in young infants in response to 
colonization(Adrian et al., 2004). No such studies have however been undertaken in an African 
population, among whom the dynamics of pneumococcal exposure and nasopharyngeal 
colonization is more intense compared to children from developed countries (O'Brien et al., 
2003). In addition, to our knowledge there has been no other single study which has evaluated 
the natural kinetics of antibody responses to all 15 proteins evaluated in our study.  
 
The objective of this study was to characterize the natural development of antibodies to 15 
pneumococcal proteins and determine whether age, PCV vaccination and HIV status have an 
impact on naturally acquired antibodies to these proteins. The study also explored the association 
of development of antibodies to the prevalence of pneumococcal colonization in children and 
adults. 
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Chapter 2: Literature Review 
 
2.1 Identification and classification of the pneumococcus  
 
S. pneumoniae or pneumococcus is a Gram positive, bile soluble, alpha-hemolytic diplococcus. It 
is a member of the human commensal flora and the genus Streptococcus. It is one of the most 
important bacterial pathogens that cause both mucosal and invasive disease. S. pneumoniae is 
responsible for approximately 1.5 million deaths worldwide and is the most common cause, from 
any single pathogen, of childhood deaths in the developing world. In addition, it kills more 
people than any other vaccine-preventable disease (Centers for Disease and Prevention, 2007).  
 
2.2 Pneumococcal colonization 
 
Mucosal colonization by pneumococcus is a crucial step in the pathogenesis of all pneumococcal 
diseases (Musher et al., 2000). S. pneumoniae is known to be associated with asymptomatic 
colonization of the mucosal surface of the human nasopharynx in up to 40-90 % of healthy 
children and 10-30 % of healthy adults (Bridy-Pappas et al., 2005, Hill et al., 2010). The survival 
of pneumococci in the nasopharynx is dependent on the ability of these organisms to compete or 
interact synergistically with other organisms in the nasopharynx, as well as engage with innate 
and acquired immune effectors. The prevalence of pneumococcal colonization is greater in 
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settings with over-crowding including in hospitals, and day-care centers (Kellner and Ford-
Jones, 1999, Principi et al., 1999).  
 
Nasopharyngeal pneumococcal colonization in children from developing countries may be 
established within days after birth. Up to 90 % of children from Gambia are found to be 
colonized by 5 years of age (Hill et al., 2010). Whilst the prevalence of nasopharyngeal 
colonization declines to 10% and remains constant through adulthood in developed countries, 
(Goldblatt et al., 2005, Gray and Dillon Jr, 1988), a high prevalence of colonization may persist 
in African settings among children (97%) and in adults (85%) (Hill et al., 2010). Children, may 
experience a number of carriage episodes with different serotypes and the duration of carriage 
varies with the age of the carrier and the type of serotype (Dagan et al., 2004). The duration of 
colonization in young children lasts for one to two months, whereas duration of colonization in 
older individuals is shorter, suggesting development of natural immunity against colonization 
(Gray et al., 1980, Hill et al., 2010).  
 
High prevalence of pneumococcal nasopharyngeal colonization in children in the developing 
world are frequently associated with the carriage of pneumococci of more than one serotype 
(Gratten et al., 1989). The distribution of pneumococcal serotypes associated with 
nasopharyngeal colonization may vary with age with sero-groups 6, 19 and 23 being the frequent 
colonizers in children. These sero-groups are not only found in the asymptomatic carriage state 
in children but also are common causes of invasive pneumococcal disease in this age group 
(Bogaert et al., 2004b, Gray and Dillon Jr, 1988, O'Brien et al., 2008). 
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Pneumococcal colonization induces a variety of immune responses in humans, including 
production of antibodies directed at surface proteins antigens (Adrian et al., 2004, Bogaert et al., 
2006, Cao et al., 2007, Giefing et al., 2008, Gosink et al., 2000, Hermans et al., 2006, Holmlund 
et al., 2006, McCool et al., 2002, Ogunniyi et al., 2007b, Rapola et al., 2000) and polysaccharide 
capsule epitopes (Soininen et al., 2009). This process requires direct interaction between the 
pnemococcal cell surface proteins and mucosal immune cell mediators. There is evidence which 
suggests that pneumococcal colonization in human infants can stimulate immunity, and prevent 
re-colonization by the same or different serotypes of pneumococci, although the mechanism for 
such protection is yet to be established (Granat et al., 2009).  
 
2.3 Pneumococcal infections 
 
The spectrum of pneumococcal infection and disease differs with age and ethnic groups. Several 
risk factors for pneumococcal infection, such as age, race, immunodeficiency, antibiotic 
resistance, socio-economic status and day care attendance have been reported (O'Brien and 
Santosham, 2004). Disease rates are particularly high in young children, the elderly, and patients 
with predisposing conditions such as, chronic illnesses and/or immunosuppressive illnesses 
including AIDS (Gray and Dillon Jr, 1988, Johnston, 1991, Musher, 1992). The relationship of 
carriage to the development of natural immunity is poorly understood. Children acquire a variety 
of serotypes early in life (Gray et al., 1980, Leach et al., 1994) and are considered to be the most 
important sources of pneumococcus transmission in communities (Gray and Dillon Jr, 1988).  
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2.4 Bacterial transformation 
 
Pneumococci may be both un-encapsulated and encapsulated. Un-encapsulated pneumococci are 
present in 0.5 -2 % of invasive isolates from normally sterile sites (Broome and Facklam, 1981, 
Carvalho et al., 2003), in 20 % of conjunctival isolates (Finland and Barnes, 1977) and in up to 
10 % of isolates identified in the sputum and nasopharynx (Carvalho et al., 2003). Pneumococci 
are able to acquire new phenotypic traits through natural transformation from a “smooth” 
encapsulated form to a “rough” un-encapsulated form, so that they are genetically flexible 
(Avery et al., 1944).  
 
Frequent recombination between individual strains allows gene mosaicism (Bruckner et al., 
2004, Musher, 1992). Recombination at the capsular level may enable the bacteria to escape the 
immune system, by serotype switching into phylogenetically related strains with a different 
capsule type (Jefferies et al., 2004). Genetic exchanges of virulence factors among streptococcal 
species as well as the emergence and spread of antibiotic resistant strains of diverse serotypes 
have been widely documented (Klugman, 1990, Lister, 1995, Nissinen et al., 1995, Whitney et 
al., 2000).  
 
2.5 The capsular polysaccharide and serotypes 
 
S. pneumoniae, like most human pathogenic bacteria, consists of a polysaccharide capsule that 
surrounds the bacterial cell wall. The antiphagocytic capsule forms the basis for pneumococcal 
classification into at least 92 serotypes, which are further divided into 46 serogroups. The 
Project ID: Pneumococcal protein antigens  
    Student: Zanele Ditse  
      Date: 04 October 2011  
 
- 29 - 
 
stratification of these serotypes is based on the structural and chemical composition of 
polysaccharides, and on the basis of antigenic properties of the capsular polysaccharides 
(Bratcher et al., 2010, Henrichsen, 1995). There is varying invasive potential between the 
serotypes (Pantosti et al., 2003). The thick capsular polysaccharide is one of the most important 
virulence factors of pneumococci. It protects bacterial cells from phagocytosis, inhibits 
complement activation and plays a major role in the competition with other bacteria to enable 
colonization of the human nasopharynx (Gehre et al., 2008, Werner, 2000, Jedrzejas, 2004). The 
polysaccharide capsule is immunogenic and may induce immune responses (Jedrzejas, 2001). 
 
2.6 Pneumococcal vaccination strategies 
 
2.6.1 Polysaccharide- and protein-polysaccharide based vaccines 
 
Pneumococcal vaccines have been developed to prevent pneumococcal infections. The first 
pneumococcal vaccines were the polysaccharide vaccines, however, they have been shown to be 
protective in adults, but not in the elderly, immuno-compromised patients and children under 2 
years of age (Musher et al., 2001). The lack of protection in these at-risk groups relates to the 
poor immunogenicity of polysaccharide antigen and failure thereof to induce immunologic 
memory or maturation of the immune response (Käyhty et al., 1987). The polysaccharide-protein 
conjugate vaccines (PCV), however, are immunogenic and protective in infants. Nevertheless, 
protection is largely specific to serotypes included in the vaccine (Eskola et al., 2001, Shinefield 
et al., 2002b). Other limitations associated with PCV are the risk for natural serotype switching 
(Coffey et al., 1998), serotype replacement by non-vaccine type pneumococci in both 
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colonization (Eskola et al., 2001, Mbelle et al., 1999) and invasive diseases (Singleton et al., 
2007) as well as geographic and temporal variations in serotype distribution (Hausdorff et al., 
2000).  
 
2.6.2 Protein-based vaccines  
 
A promising alternative approach for new-generation pneumococcal vaccines is the use of 
pneumococcal proteins that are highly conserved among most pneumococcal strains (Bergmann 
and Hammerschmidt, 2006, Bogaert et al., 2004a). Antibody production against pneumococcal 
proteins begins in infancy, whereas the production of antibodies directed to capsular 
polysaccharides does not begin until the second or third year of life (Bogaert et al., 2004a). The 
relevance of this naturally acquired immunity to proteins in modifying colonization may identify 
potential vaccine candidate targets (Bogaert et al., 2004a). Immunological response against 
proteins may provide protection against nasopharyngeal colonization and/or pneumococcal 
infections independent of capsular antibodies.   
 
Previous studies in animal models targeted single candidate proteins such as PspA, PsaA and Ply 
based on their roles in pneumococcal pathogenicity (McDaniel et al., 1991, Paton and Ferrante, 
1983, Rosenow et al., 1997). These proteins are common to all pneumococcal isolates and have 
been shown to be immunogenic and protective against subsequent challenge with different 
strains of pneumococci in animal model studies (Russell et al., 1990, Tart et al., 1996, White et 
al., 1999, Wu et al., 1997). Reverse vaccinology and systemic analysis of multiple genomes 
together with thorough understanding of the molecular epidemiology of the disease plays a 
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crucial role in the development of a vaccine based on the combination of antigens from a 
representative species (Barocchi et al., 2007). Identification of immunogenic surface proteins and 
assessment of their role against pneumococcal colonization and/or disease is crucial in the 
development of a vaccine with the ability to protect independent of serotype (Barocchi et al., 
2007). 
 
2.7 Pneumococcal protein vaccine candidates  
 
The identification of virulence determinants can facilitate the development of new vaccines. The 
major virulence factor required for all pneumococcal diseases is the extracellular capsular 
polysaccharide. In addition to the capsule, many surface-exposed proteins and toxins that are 
released after the autolysis of pneumococci, contribute significantly to the pathogenesis of S. 
pneumoniae disease as indicated in Table 1.  
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Table 1: Table of the 15 pneumococcal proteins studied in this project as potential vaccine candidates and their role 
in pneumococcal pathogenicity. 
* Pneumococcal proteins from Intercell AG that were described according to their TIGR4 annotation. **N/A: their function(s) are 
unknown, as they have not been characterized yet.  
Classification Antigen 
Role and function in 
pathogenicity 
Model References 
Choline-binding 
proteins 
Pneumococcal surface 
protein A (PspA) 
Inhibits complement activation, 
cross-protective, colonization 
Humans and 
mice 
(Briles et al., 2000, Briles et al., 1996, 
Hammerschmidt et al., 2000, Wu et al., 
1997)  
Pneumococcal surface 
protein C (PspC/ CbpA) 
Adherence, colonization 
 
Rat, mouse, 
humans 
(Balachandran et al., 2002, Cundell and 
Tuomanen, 1994, Hammerschmidt et al., 
2000, McCool et al., 2002, Rosenow et 
al., 1997)  
Endo-beta-N-
acetylglucosamidase 
(LytB) 
Colonization 
 
Rats, mice (Gosink et al., 2000, Lopez et al., 2000)  
Sortase-
dependent 
proteins 
(LPXTG motif) 
IgA1-proteinase Colonization, adherence Mice 
(Kilian et al., 1996, Ogunniyi et al., 2000, 
Weiser et al., 2003)  
*SP 0082 
Cell wall surface anchor family 
protein 
**N/A (Tettelin et al., 2001)  
Lipoproteins:     
ABC-transporters 
Pneumococcal surface 
adhesion A (PsaA) 
ABC-transporter, adherence, 
colonization 
Mice, humans 
(Dintilhac et al., 1997, Johnson et al., 
2002, Rapola et al., 2000, Romero-Steiner 
et al., 2003)  
*SP 0749 
Amino acid transport and 
metabolism 
**N/A (Tettelin et al., 2001)  
*SP 0609 
Amino acid transport and 
metabolism 
**N/A (Tettelin et al., 2001)  
Non-ABC 
transporters 
Streptococcal 
lipoprotein rotamase A 
(SlrA) 
Colonization, adherence 
Mouse, humans 
 
(Adrian et al., 2004, Hermans et al., 
2006)  
Putative proteinase 
maturation protein A 
(PpmA) 
Adherence, colonization Mice, humans 
(Cron et al., 2009, Hermans et al., 2006, 
Overweg et al., 2000)  
Integral 
membrane 
lipoproteins 
Serine-threonine kinase 
P (StkP) 
Growth, competence and 
colonization 
Humans 
(Giefing et al., 2008, Rajagopal et al., 
2003, Rajagopal et al., 2006) 
Secreted 
proteins 
Pneumolysoid (PdB) 
Aids penetration of host tissues, 
inhibits immune responses, 
colonization 
Mice, humans 
(Ferrante et al., 1984, Holmlund et al., 
2006, Musher et al., 2001, Paton and 
Ferrante, 1983, Rapola et al., 2000) 
PcsB 
Cell division, colonization, 
bacterial survival and growth 
Humans 
(Giefing et al., 2008, Mills et al., 2007, 
Ng et al., 2004) 
Other 
pneumococcal 
proteins 
Caseinolytic protease 
(Clp) 
Virulence gene expression, 
adherence 
Mice (Kwon et al., 2003, Kwon et al., 2004)  
*SP 2027 Conserved hypothetical protein **N/A **N/A 
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2.7.1 Pneumococcal proteins 
 
It is estimated that the pneumococcal genome encodes over 100 surface proteins, most of which 
play a role in pathogenicity and virulence (Wizemann et al., 2001). Bacterial surface proteins are 
essential for the interaction of bacterial pathogens with their environment during infection and 
contribute to the disease pathogenesis. Three clusters of surface proteins can be distinguished by 
genome analysis: the choline-binding proteins, the lipoproteins and sortase-dependent surface 
proteins that are anchored in the cell wall (Figure 1). Non-classical surface proteins that lack a 
leader peptide and membrane-anchoring motifs have also been identified on the pneumococcal 
surface. 
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Figure 1: Diagram showing pneumococcal cell-wall and surface-exposed proteins; the choline-binding proteins, lipoproteins and the sortase-dependent proteins. The 
pneumococcal cell wall consists of a phospholipid membrane (LM) containing peptidoglycan (PG), teichoic acid (TA) and lipoteichoic acid (LTA). Phosphocholine (PCho) 
anchors choline-binding proteins to the cell wall, as indicated in the diagram (Bergmann and Hammerschmidt, 2006). CBP = choline-binding proteins and LPXTG = Leucine-
Proline-X-Threonine-Glycine sequence, where X is any amino acid. This motif is shared by a majority of sortase-dependent proteins as depicted in the diagram.  
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2.7.1.1 Choline-binding proteins (CBPs) 
 
Choline-binding proteins (CBPs) are a diverse super family of proteins which are attached to the 
pneumococcal surface via non-covalent interactions with phosphoryl-choline properties on cell 
wall teichoic acid and membrane lipoteichoic acid. In vaccine development studies, CBPs are of 
particular interest since a number of proteins interact with the cell wall non-covalently through a 
choline-binding domain consisting of 2 - 10 sequence repeats (Fernandez-Tornero et al., 2001). 
Pneumococci can produce 13 to 16 different CBPs; including four cell wall hydrolases that are 
important for virulence: autolysin LytA, LytB, LytC and a phosphorylcholine esterase. CBPs 
have diverse functions, including cell wall modification, adherence to host cell surface molecules 
and the modulation of complement activation. In spite of the similarity of the choline-binding 
repeat domains, the CBP molecules are structurally and functionally different (Swiatlo et al., 
2004). The following CBPs: PspA, PspC and LytB (SP 0498) were evaluated in this project.  
 
2.7.1.1.1 Pneumococcal surface protein A (PspA) 
 
Pneumococcal surface protein A (PspA) is one of the most studied pneumococcal proteins. It is a 
highly variable protein found on all strains of pneumococci (Crain et al., 1990). PspA is divided 
into three families, which are further stratified into clades based upon relatedness of DNA and 
protein sequences. PspA family 1 is composed of clades 1 and 2, family 2 is composed of clades 
3 – 5 and family 3 is equivalent to clade 6, which is very distant from all of the other clades. The 
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biological properties of PspA reside in the N-terminal of the protein, which forms a highly 
charged, alpha-helical anti-parallel coiled-coil structure (Hollingshead et al., 2000, Jedrzejas et 
al., 2000). The alpha-helical region of PspA is exposed on the surface of the pneumococcus, 
however, the presence of the capsule does not prevent accessibility to antibodies, suggesting that 
antibodies against PspA could be opsonophagocytic (Gor et al., 2005). The proline-rich region 
has been found to be effective in eliciting cross-protective immunity across different serotypes 
(McDaniel et al., 1994, Nabors et al., 2000).   
 
PspA plays a pivotal role in preventing complement-mediated opsonization, is capable of 
binding to and preventing killing by lactoferrin and is involved in iron uptake and thus 
contributes to pneumococcal growth (Hammerschmidt et al., 1999, Ogunniyi et al., 2007b, Tu et 
al., 1999). Studies with PspA deletion mutants have shown that PspA is a virulence factor (Crain 
et al., 1990, McDaniel et al., 1987). Although this antigen is structurally variable, antibody 
responses raised to it are cross-reactive to heterologous PspA proteins, and immunization with 
one PspA protein can protect mice against pneumoccoci that contain a heterologous PspA clade 
and capsule type. PspA has been used for intranasal, intraperitoneal and subcutaneous 
immunization in mice, which could elicit significant protection against pneumococcal infection, 
making it a promising candidate vaccine (Nguyen et al., 2011, Ogunniyi et al., 2007a, Ogunniyi 
et al., 2007b). Previous studies in humans have demonstrated that antibodies against PspA 
increase during colonization and pre-existing low antibody titers against this protein were 
associated with pneumococcal colonization (McCool et al., 2002). In addition to its promise as a 
potential vaccine antigen capable of preventing systemic disease, PspA exhibits promise as a 
mucosal vaccine antigen for the prevention of nasopharyngeal carriage (Wu et al., 1997). A 
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vaccine capable of preventing carriage is likely to prevent disease in vaccinated individuals and 
contribute to indirect protection by reducing transmission of pneumococcus.  
 
2.7.1.1.2 Pneumococcal surface protein C 
 
Pneumococcal surface protein C (PspC) also known as choline-binding protein A (CbpA), is one 
of the 15 proteins identified in the genome of TIGR4 strains that exhibit multiple C-terminal 
repeats of an approximately 19-amino-acid motif that binds choline moieties present on the 
bacterial cell wall. PspC is structurally related to PspA and is present in 75 - 100 % of all 
pneumococcal strains (Ianelli et al., 2002, Ogunniyi et al., 2000). Sequence analyses have shown 
that there are many variants of the PspC protein, and different functions have given these 
variants different names (eg. PspC, Hic, PbcA). PspC proteins can be classified into 11 groups, 
their common features being an N-terminal signal peptide, followed by an alpha-helical region, a 
proline-rich region and a C-terminal anchor. The N-terminal region consists of an alpha-helical 
structure with its size varying between 118 - 589 amino acids resulting in the size variation of 
PspC across different pneumococcal strains (Ianelli et al., 2002). 
 
PspC mediates adherence to cytokine-activated lung cells via a human-specific interaction with 
the polymeric immunoglobulin receptor, pIgR (Hammerschmidt et al., 2000). It plays a major 
role in colonization of the nasopharynx, adherence to the nasopharyngeal and lung epithelium 
and the brain microvascular endothelium (Cundell and Tuomanen, 1994). It also mediates the 
invasion of host cells at these locations. PspC allows bacteria to cross through the blood-brain 
barrier, implying that it plays an essential role in pneumococcal meningitis (Cao et al., 2007, 
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Linder et al., 2007, Ogunniyi et al., 2007b, Brooks-Walter et al., 1999). Furthermore, PspC has 
been suggested to protect pneumococci from opsonization with the components of the alternative 
pathway by binding to factor H, which accelerates the degradation of C3b by factor I (Janulczyk 
et al., 2000, Jarva et al., 2002). 
 
Antibodies directed against PspC are able to elicit protection against nasopharyngeal 
colonization in a mouse model (Balachandran et al., 2002), and conferred protection against 
death when mice were challenged with the highly virulent pneumococcal strain D39 (Ogunniyi 
et al., 2001). Studies have also shown that rabbits immunized with recombinant PspC elicited 
cross-protective antibodies to PspA and provided protection against pneumococcal bacteraemia 
and sepsis (Brooks-Walter et al., 1999, Ogunniyi et al., 2000). Antibody responses, in an 
experimental human pneumococcal colonization model, indicated that PspC is exposed and 
immunogenic (McCool et al., 2002, Overweg et al., 2000). There are currently no published data 
on whether vaccination with PspC elicits protection against heterologous PspC type strains.  
 
2.7.1.1.3 Endo-beta-N-acetylglucosamidase (LytB) 
 
Endo-beta-N-acetylglucosamidase (LytB) is a glucosaminidase that belongs to a family of 
murein hydrolases. The lysis of pneumococci during stationary growth or antibiotic treatment is 
the result of murein hydrolases that require choline for activity (Hollingshead and Briles, 2001). 
It is highly expressed in the early exponential growth phase and has been shown to be important 
for cell separation of pneumococci at the end of cell division (Garcia et al., 1999a, Garcia et al., 
1999b)(Garcia et al. 1999a; Garcia et al. 1999b). LytB and LytC are unusual in that their 
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choline-binding domains are located in the N-terminal parts of the molecule, while the C-
terminal portions have murein hydrolase activity (Lopez et al., 2000). LytB plays a significant 
role in colonization and the significant loss of ability to colonize the nasopharynx in the LytB 
mutant with slight changes in adherence in vitro, could possibly suggests that LtyB could also 
play a role in toxin release. Loss of function of LytB or LytC was associated with reduced 
nasopharyngeal colonization in rats (Gosink et al., 2000). Studies by Wizeman et al. 
demonstrated that immunization with LytB conferred protection against disseminated S. 
pneumoniae infection, in mouse models (Wizemann et al., 2001). 
 
2.7.1.2 Sortase-dependent proteins 
 
Sortase-dependent surface proteins of gram-positive bacteria are characterized by the presence of 
a C-terminal motif, which consists of a conserved Leucine-Proline-X-Threonine-Glycine, 
LPXTG sequence, where X is any amino acid. This motif is recognized by a sortase, which is a 
protease that cleaves between the T and G residues and covalently links the protein to the 
peptidoglycan cross-bridges (Schneewind et al., 1993). Pneumococcal strains produce up to four 
zinc metalloproteases, including IgA1-protease, ZmpB, ZmpC and ZmpD, which are anchored to 
the cell wall by an N-terminal LPXTG motif.  
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2.7.1.2.1 Immunoglobulin A1 (IgA1) proteinase 
 
Immunoglobulin A1 (IgA1) is the major immunoglobulin isotype involved in immunity of the 
mucosal membrane of the respiratory tract in humans. IgA1-proteinases are extracellular bacterial 
enzymes that cleave human IgA1. All streptococcal IgA1-proteinases cleave the same Proline-
Threonine (Pro-Thr) bond at position 227 and 228 in the region of human IgA1, thus preventing 
opsonophagocytosis. Cleavage of surface-bound serotype specific IgA1 by the IgA1-proteinase 
enhances adherence of pneumococci to host cells (Weiser et al., 2003). 
 
IgA1-proteinase is produced by virtually all strains of pneumococci. The N-terminal region of this 
protein is essential for proper function and surface localization (Bender and Weiser, 2006). Most 
human pathogens, including S. pneumoniae, which invade mucosal membranes, possess IgA1-
cleaving activity. Studies by Polissi et al. have shown that IgA1-proteinase plays a role in 
pneumococcal lung infections and bacteraemia (Polissi et al., 1998). Previous studies have also 
demonstrated that IgA1 protease is diverse and heterologous among Haemophilus influenzae 
strains and is involved in immune escape by allowing a number of clones of the same species to 
colonize one host (Lomholt et al., 1993). There is some evidence that suggests that IgA1-
proteinase enables bacteria to evade the mucosal immune barrier and therefore plays a role in 
colonization (Kilian et al., 1996). Previous studies in humans demonstrated that IgA1-proteinase is 
highly immunogenic early in life (Adrian et al., 2004). 
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2.7.1.2.2 SP 0082  
 
SP 0082 is a cell wall surface anchor protein. This protein has not been characterized yet, 
therefore, it is only represented by its TIGR4 annotation gene symbol. It consists of the LPXTG 
motif at the C-terminal region and is homologous to IgA1-proteinase (Tettelin et al., 2001). Due 
to its surface localization and homogeneity to IgA1-proteinase, SP 0082 is predicted to be 
involved in adherence and pneumococcal colonization.   
 
2.7.1.3 Lipoproteins 
 
S. pneumoniae have over 30 putative lipoproteins, with pro-lipoprotein signal peptidase 
recognition sequences. They are located beneath the cell wall and the capsule, which suggests 
that they are not exposed on the cell surface. This implies that they do not elicit opsonic 
antibodies (Siber et al., 2008). Lipoproteins are anchored into the membrane by the N terminus 
Leucine-X-X-Cysteine motif (LXXC, where X represents any amino acid) that is cleaved and 
covalently attached to palmitic acid in the membrane (Gilson et al., 1988, Pearce et al., 1994). 
Cell surface lipoproteins are important for the full virulence of a number of both Gram -negative 
and –positive bacterial pathogens. The most important role of lipoproteins is to serve as 
substrate-binding components of ATP-binding cassette (ABC) transport systems. ABC 
transporters contribute in many bacterial processes such as acquisition of vital nutrients, stress 
responses and intracellular signalling, which is vital for bacterial growth and survival in vivo and 
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in vitro. Lipoproteins studied in this project include the pneumococcal surface adhesion A 
(PsaA), SP 0749, SP 0609, PpmA, SlrA and StkP.  
 
 
2.7.1.3.1 ABC transporters  
 
2.7.1.3.1.1 Pneumococcal surface adhesion A (PsaA) 
  
Pneumococcal surface adhesion A (PsaA) is a member of the metal-binding lipoproteins and a 
highly conserved 37 kDa lipoprotein that is produced by all strains of pneumococci. It is the 
substrate-binding lipoprotein of an ABC-type manganese-transport system (Dintilhac et al., 
1997). Antibodies against PsaA are associated with reduction in adherence of pneumococci to 
nasopharyngeal epithelial cells (Romero-Steiner et al., 2003). This is consistent with the finding 
that mucosal immunization of mice with PsaA is highly protective against pneumococcal 
carriage (Johnson et al., 2002). 
 
Mutations in the PsaA gene have been reported to have pleiotropic effects on various 
pneumococcal functions, including adherence, autolysis virulence and increased sensitivity to 
oxidative stress (Novak et al. 1998; Berry & Paton 1996; Claverys et al. 1999). PsaA is highly 
immunogenic and antibodies directed against PsaA are protective against pneumococcal carriage 
and invasive infection in animal models (Briles et al. 2000a; Talkington et al. 1996). Oral 
vaccination with PsaA also elicited significant protection against colonization, pneumonia as 
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well as septicemia in mice (Seo et al. 2002). Studies have shown that PsaA and PspA have 
different functions in virulence and promising results have been reported for the combination of 
PsaA and PspA in prevention of colonization and otitis media in animal models (Briles et al. 
2000b; Ogunniyi et al. 2000).  
 
2.7.1.3.1.2 SP 0749 
 
SP 0749 is a branched-chain amino acid ABC transporter. This protein has also not been 
characterized, and therefore, it is only represented by its TIGR4 annotation gene symbol 
(Tettelin et al., 2001).  
 
2.7.1.3.1.3 SP 0609 
 
SP 0609 is an amino acid ABC transporter. This protein has also not been characterized, and 
therefore, it is only represented by its TIGR4 annotation gene symbol (Tettelin et al., 2001). Like 
other ABC-transporters, SP 0749 and SP 0609 are predicted to play a role in transportation of 
amino acids, metabolism and bacterial growth (Dintilhac et al., 1997). 
 
2.7.1.3.2 Non ABC transporters  
 
Pneumococci produce two conserved, non-ABC transporter, surface-exposed lipoproteins 
belonging to a family of chaperones, the peptidyl-prolyl isomerases (PPIases). These proteins are 
the putative proteinase maturation protein A (PpmA) and streptococcal lipoprotein rotamase A 
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(SlrA) (Cron et al., 2009). PPIases are ubiquitous foldases, which accelerate the cis–trans 
conformational changes at the Xaa-Pro bonds (where X represents any amino acid and Pro = 
Proline residue) during protein folding in eukaryotes and prokaryotes (Hermans et al., 2006). 
They are involved in secretion and activation of cell surface molecules. There is evidence that 
PPIases contribute to bacterial virulence (Hermans et al., 2006). There are three discrete classes 
of PPIases: the cyclophilins, which bind the immunosuppressant cyclosporin A, the FK506-
binding proteins and the parvulins (Cron et al., 2009).  
 
2.7.1.3.2.1 Putative proteinase maturation protein A (PpmA) 
 
Putative proteinase maturation protein A (PpmA) is a 35 kDa lipoprotein that contains an N-
terminal sequence which is essential for translocation and cell membrane anchoring. PpmA 
shares sequence homology with the parvulins, which belongs to the family of peptidyl-prolyl cis-
trans isomerases. However, to date, no detectable PPIase activity in PpmA has been found 
(Hermans et al., 2006, Overweg et al., 2000). PpmA is identified frequently in nasopharynx 
isolates of the transparent phenotype, suggesting that this protein plays a role in pneumococcal 
adherence through maturation of surface components (Cron et al., 2009). It induces antibodies 
with opsonophagocytic activity which are species-specific and cross-reactive among 
heterologous pneumococcal strains (Overweg et al., 2000). Studies also demonstrated that PpmA 
plays a role in pneumococcal virulence, elicits protective antibodies that are species-specific and 
antibodies against this protein are induced early in life (Adrian et al., 2004). 
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2.7.1.3.2.1 Streptococcal lipoprotein rotamase A (SlrA) 
 
Streptococcal lipoprotein rotamase A (SlrA) is a cyclophilin lipoprotein that catalyzes cis/trans 
isomerization of proline containing peptides (Cron et al., 2009). Previous studies have shown 
that SlrA is involved in colonization, by modulating the biological function of important 
virulence proteins, but does not contribute significantly to invasive pneumococcal disease 
(Hermans et al., 2006). Previous studies demonstrated that SlrA and PpmA are both 
immunogenic and elicit antibody responses early in life (Adrian et al., 2004) contribute to 
pneumococcal colonization, avoidance of phagocytosis and pulmonary infections (Hermans et 
al., 2006). 
 
2.7.1.3.3 Integral membrane protein(s) 
 
 2.7.1.3.3.1 Serine-threonine kinase P (StkP) 
 
Serine- threonine kinases play an important role in signal transduction and control various 
cellular functions i.e. cellular adaptation to different environments. Serine-threonine 
phosphorylation plays an important role in the regulation of growth and competence in S. 
pneumoniae (Osaki et al., 2009). StkP shares amino acid sequence with serine/threonine kinases 
with an important role in cell-cell signalling and competence signalling as well as stress 
conditions by acting as a transcriptional regulator (Bogaert et al., 2006, Novakova et al., 2005). 
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Immuno-precipitation and cellular organization data suggests that StkP is associated with the 
lipid membrane (Osaki et al., 2009). The N-terminal region of StkP contains the eukaryotic-type 
serine threonine kinase domain with 35 % identity to the corresponding human protein; therefore 
the C-terminal region is used for immunogenicity studies. They also contribute to regulatory and 
developmental processes (Adler et al., 1997). 
 
Previous studies on Streptococcus agalactiae, demonstrated that StkP plays a role in virulence by 
modifying cytotoxin production and purine metabolism (Rajagopal et al., 2003, Rajagopal et al., 
2005, Rajagopal et al., 2006). Previous studies have demonstrated that StkP is immunogenic in 
both the elderly and very young children, is expressed during invasive disease as well as 
colonization and induces opsonophagocytic antibodies suggesting that they it might be a good 
candidate for a protein-based pneumococcal vaccines (Giefing et al., 2008).  
 
2.7.1.4 Secreted proteins 
 
2.7.1.4.1 Pneumolysin (Ply)  
 
Pneumolysin (Ply) is a 53-kDa thiol-activated hemolysin produced by all strains of 
pneumococci. Unlike other pneumococcal antigens, it is not surface-exposed. Ply has both direct 
cytotoxic and complement activation properties, mediated by different domains within the toxin 
(Boulnois et al., 1991). The cytotoxic property is essential for inhibition of specific and non-
specific immune responses, (Ferrante et al., 1984, Paton and Ferrante, 1983) and the stimulation 
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of inflammatory cytokine release from host cells (Houldsworth et al., 1994). Direct activation of 
the classical complement pathway is the result of the binding of Ply to the Fc region of 
immunoglobulin G, which also contributes to inflammation and depletes serum opsonic activity 
(Mitchell et al., 1991, Paton et al., 1984). 
 
In vitro studies using purified antigen have demonstrated that Ply functions in pneumococcal 
pathogenesis by interfering with ciliary clearance of pneumococci, blocking humoral immune 
responses and by aiding the penetration of host tissues (Cundell and Tuomanen, 1994, Gray and 
Dillon Jr, 1988). Antibodies against Ply are produced early in life in response to pneumococcal 
carriage and infection (Musher et al., 2001). In humans, colonized patients with non-bacteraemic 
pneumococcal pneumonia had higher levels of antibodies to Ply compared to patients with 
bacteraemic pneumococcal pneumonia, suggesting that antibodies against Ply may protect the 
host against bacteraemic pneumococcal disease(Musher et al., 2001). Antibody titers to Ply rise 
in humans following pneumococcal infection, suggesting that the protein is synthesized by the 
bacteria while they are growing in the host (Jalonen et al., 1989). Wild-type Ply is not suitable as 
a human vaccine antigen because of its toxicity. In this study, pneumolysoid (PdB), which is a 
non-toxic variant carrying a mutation of tryptophan residue to phenylalanine at position 433 
(Trp433 – Phe), of the wild-type Ply protein, was used. Previous studies have indicated that Ply 
may also be suitable as a vaccine adjuvant (Ogunniyi et al., 2001). 
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2.7.1.4.2 Protein required for cell separation in group B streptococci (PcsB)  
 
Protein required for cell separation in group B streptococci (PcsB) is one of the essential 
hydrolases identified in S. pneumoniae. It is involved in important bacterial mechanisms, 
maintenance of cell morphology and bacterial growth (Ng et al., 2004, Reinscheid et al., 2001). 
Recent studies by Mills et al showed that PcsB is secreted and is associated with the plasma 
membrane (Mills et al., 2007). PcsB expression increases as a result of oxidative stress, high 
temperatures and the presence of salts. This suggests that PcsB is involved in the response to 
changes of environment incurred in pathogenesis of illness. Previous studies showed that PscB 
protected mice against death caused by S. pneumoniae serotype 1 strain in an intranasal sepsis 
model. These studies also showed that this protein is highly immunogenic in both children and 
the elderly, and is expressed during invasive diseases, colonization and exposure (Giefing et al., 
2008).  
 
2.7.1.5 Other pneumococcal proteins  
 
2.7.1.5.1 Heat shock proteins 
 
S. pneumoniae may encounter heat stress after penetration from the nasal mucosa (30 to 34°C) 
into the blood and/or meninges (37°C) during colonization (Lindemann et al., 2002). Changes in 
temperature induce the production of highly conserved proteins, referred to as heat shock 
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proteins (HSPs). The induction of HSPs protects bacteria against stress, therefore increasing their 
prevalence (Neidhardt and Van Bogelen, 1987). HSPs can be classified into different families 
depending on molecular weight and are present in both eukaryotes and prokaryotes. They are 
induced during infection and have been shown to play a role in adherence and invasion, and have 
a major role in protein folding (Charpentier et al., 2000, Nair et al., 2000). One of the HSPs, 
caseinolytic protease (Clp), contains two ATP-binding regions and functions as a chaperone and 
modulates virulence gene expression (Kwon et al., 2004). 
 
Studies performed on this antigen demonstrated that immunization of mice with pneumococcal 
caseinolytic protease P, ClpP, elicited protective immunity against systemic challenge with 
pneumococcal strain D39 (an encapsulated and virulent strain of pneumococcus) to a level 
comparable to that of well-studied vaccine candidates PspA and PdB. Antigen-specific antibody 
responses elicited in immunized mice prior to challenge suggests that protection by this antigen 
could be antibody-mediated (Kwon et al., 2004). Other studies have also shown that the HSP, 
ClpP, is highly immunogenic in S. pneumoniae and modulates virulence gene regulation (Kwon 
et al., 2003). Although Clp has been extensively studied in Gram-negative bacteria, there are 
only limited data for this antigen in Gram-positive bacteria. There are no published data on the 
natural immune response to Clp in humans. HSP, SP 2194, which is predicted to be an ATP 
dependant Clp protease, was evaluated in this study. 
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2.7.1.5.2 SP 2027 
 
SP 2027 is a conserved hypothetical protein found in all strains of S. pneumoniae. There are no 
characteristic data on this protein; therefore, it is only represented by its TIGR4 annotation gene 
symbol.  
 
2.8 Effect of HIV infection on the antibody response  
 
Human immunodeficiency virus (HIV) positive patients have a significantly higher morbidity 
from influenza virus infection and invasive pneumococcal disease compared to HIV-negative 
individuals (Horster et al., 2010). Previous studies have demonstrated that HIV-infected, exposed 
infants with low CD4+ T-cells have an impaired immune response upon T-cell dependent 
antigens like the influenza vaccine, tetanus toxoid, diphtheria toxoid and the conjugated 
Haemophilus infuenzae type b (Kroon et al., 1994, Kroon et al., 1997). Previous studies have 
also shown the impact of HIV on the antibody responses to PCV. These studies demonstrated 
that children with HIV have significantly increased risk of pneumococcal disease compared to 
HIV uninfected children, and that the serotypes included in currently licensed vaccines include 
most serotypes that cause invasive pneumococcal disease (IPD) in HIV-infected children and 
adults (Bliss et al., 2008). Our previous study showed that HIV-uninfected, unexposed infants 
had superior OPA responses, compared with those in HIV+/ART+ infants, who in turn had better 
OPA responses, compared with those in HIV+/ART- infants. These findings suggest that 
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changes in the immune response in HIV-uninfected, exposed infants could contribute to 
increased morbidity and mortality in these children (Madhi et al., 2010). 
 
2.9 Summary 
 
Previous studied in European children looked at the prevalence and the natural development of 
antibodies to PspA, PsaA, PdB, PpmA, SlrA and IgA1-proteinase and the association between 
antibody titers and pneumococcal colonization in young infants and adults(Adrian et al., 2004, 
Holmlund et al., 2006, Rapola et al., 2000, Simell et al., 2009). 
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Chapter 3: Aims and Objectives 
 
The aims of this study were to describe the kinetics of antibodies against select pneumococcal 
proteins with regards to age, HIV infection status and PCV vaccination status. In addition, we 
explored the association between antibody titers and pneumococcal nasopharyngeal colonization 
in infants, older children, and adults. Proteins that were evaluated were PcsB, StkP, PsaA, LytB, 
SP 0082, SP 2027, SP 0609, SP 0749, SP 2194, IgA1-proteinase, SlrA, PpmA, PspA, PspC and 
PdB. To date, no data are available on the natural development of antibodies in African children 
and adults, against these proteins.  
 
 
Specific objectives of this study were to:  
 
1. Compare the correlation between a multiplex Luminex-based assay (Bio-Plex, Bio-Rad 
Laboratories, USA) to a singleplex ELISA assay for four of the proteins, namely; PspA, 
PspC, PsaA and PdB. 
2. Define whether there are any differences in natural development of antibody titers against 
various proteins among PCV-vaccinated children under two years of age who were either 
HIV-unexposed, uninfected (M-/I-), HIV-exposed, uninfected (M+/I-) or HIV-exposed, 
infected (M+/I+).  
3. Define whether there are any differences in the serum antibody titers against various 
proteins between PCV unvaccinated M+/I- and M-/I- children under two years of age.  
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4. Evaluate the effect of PCV vaccination on the dynamics of serum IgG antibody titers 
against various proteins in M+/I- and M-/I- children under two years of age.  
 
5. Cross-sectional determination of the concentration of serum IgG antibodies to the studied 
pneumococcal proteins and their association with pneumococcal colonization in HIV-
infected and -uninfected children between 4 to 7 years of age, stratified by previous PCV 
immunization status during infancy.  
6. Determine the association of HIV-infection status and serum antibody titers against 
various proteins in women. 
7. Explore the association between antibody titers to the proteins and prevalence of 
nasopharyngeal colonization in HIV-infected and -uninfected women. 
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Chapter 4: Materials and Methods  
 
4.1 Study population 
 
The study on natural kinetics of antibody responses to the proteins involved 2166 samples from 
1917 subjects. This included M-/I-, M+/I- and M+/I+ children aged between 4 and 24 months 
who had been vaccinated with the 7-valent vaccine, Prevnar® (Wyeth) containing 2 µg each of 
serotype polysaccharides 4, 9V, 14, 19F and 23F; 4 µg of serotype 6B polysaccharide and 2 µg 
of serotype 18C oligosaccharide, each conjugated individually to a protein carrier CRM197, at 6, 
10 and 14 weeks of age (Madhi et al., 2007a). Two groups of M+/I+ children were co-enrolled 
from the Children with HIV Early Antiretroviral (CHER) Study in South Africa (Violari et al. 
2008) with a CD4
+ T lymphocyte cell percentage ≥ 25%. These children were randomized either 
to initiate antiretroviral therapy (ART) immediately, or to initiate ART when immunologically 
indicated as per prevailing WHO recommendations (World Health Organization 2002). The ART 
regimen included zidovudine, lamivudine and lopinavir-ritonavir. A parallel cohort of M-/I- and 
M+/I- children aged between 4 and 24 months not vaccinated with PCV were enrolled during a 
similar period as the CHER cohort. Nasopharyngeal swabs, for identification of pneumococcal 
colonization, were collected at multiple time- points in these two longitudinal cohorts including 
at 4, 10, 18 and 24 months of age.  
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In addition, the mothers of children who had participated in the above mentioned cohorts were 
also enrolled into a study which explored the dynamics of nasopharyngeal colonization between 
PCV-vaccinated and PCV-unvaccinated mother-child (HIV-uninfected) dyads (Madhi et al., 
2010) None of the mothers received any pneumococcal vaccine formulation. A fourth study 
group were samples from HIV-infected and –uninfected children previously enrolled into a 9-
valent PCV efficacy trial who were subsequently sampled at a single time-point, between 4 and 7 
years of age (Madhi et al., 2007b). These children had been previously randomized to receive 3 
doses of either 9-valent PCV containing 2 µg of capsular polysaccharide serotypes 1, 4, 5, 9V, 
14, 19F and 23F; 4 µg of serotype 6B polysaccharide and 2 µg of serotype 18C oligosaccharide, 
each conjugated individually to a protein carrier or placebo at 5.5, 111.2 and 15.8 weeks of age. 
Figure 2 summarizes the study population (the number of children and women), stratified by 
HIV exposure and PCV-vaccination status. 
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Figure 2: Flow diagram showing all the study participants. PCV-vaccinated children received three doses of the 7-valent pneumococcal conjugate vaccine; Prevnar® (Wyeth), at 6, 10 and 15 
weeks of age, containing 2 µg of each of serotype polysaccharides 4, 9V, 14, 19F and 23F; 4 µg of serotype 6B polysaccharide and 2 µg of serotype 18C oligosaccharide, each conjugated 
individually to a protein carrier CRM197 (Madhi et al., 2007b) and the PCV-unvaccinated children received placebo. Only children were recruited in the PCV-9 efficacy trial and they received 
three doses of the PCV-9 vaccine, at 6.6, 11.2 and 15.8 weeks of age, containing 2 µg of capsular polysaccharide serotypes 1, 4, 5, 9V, 14, 19F and 23F; 4 µg of serotype 6B polysaccharide and 2 
µg of serotype 18C oligosaccharide, each conjugated individually to a protein carrier CRM197 (Madhi et al., 2007b).  NT = total number recruited, but there may have been missing samples at 
later visits. 
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4.2 Materials  
 
Recombinant PspA, CbpA and PdB proteins were obtained from St. Jude Children‟s Hospital 
(Memphis, USA). Recombinant IgA1-proteinase, SlrA, PpmA proteins were expressed and 
purified by Mucosis (Netherlands) and PcsB, StkP, PsaA, SP 0082, SP 2027, SP 0609, SP 0749, 
SP 0498 and SP 2194 proteins were expressed and purified by Intercell AG (Austria). R-
phycoerythryn (R-PE) conjugated goat anti-human IgG (gamma-chain specific) was obtained 
from Jackson ImmunoResearch Laboratories Inc. (Westgrove, USA). Carboxylated microsphere 
beads were obtained from Bio-Rad (Bio-Rad Laboratories, Hercules, USA). Alkaline-
phosphatase-conjugated goat anti-human IgG (Cat # A3188), 4- nitrophenyl phosphate disodium 
salt hexadydrate (Cat # 71768) substrate and N-hydroxy-sulphosuccinimide, Sulpho-NHS, (Cat # 
56485), were purchased from Sigma (Sigma-Aldrich, Germany). 1-ethyl-3 (3-dimethylamino-
propyl) carbodiimide-HCl, EDC, (Cat # 77149) was obtained from Thermo Scientific (Thermo 
Scientif, Rockford IL, USA). 96 well ELISA plates Maxisorb (Cat # 442404) and Costar (Cat # 
9017) were obtained from Nunc, Denmark and Costar, USA, respectively. AcroPrep multi-well 
filter-plates, 1.2 µm, were purchased from Pall (Pall Corporation, USA).  
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4.3 Reference and serum samples 
 
Purified pooled human immunoglobulin (Polygam, National Bioproducts Institute, Pinetown 
South Africa) was used as an in-house standard/ reference sera for determining titers of natural 
antibodies against the 15 pneumococcal proteins studied. The reference serum was given an 
arbitrary titer of 100 units/ml (U/ml) for each protein. In-house high and low controls consisting 
of pooled adult serum were used on each Luminex and ELISA run. The low control was 
adsorbed with whole pneumococci to reduce the titer of the serum. Serum samples, for 
comparison of the ELISA to multiplex Luminex assay were undertaken on archived samples of 
100 HIV-uninfected participants. These included children who had been enrolled into an 
immunogenicity study of PCV and included samples from 10, 18 and 28 months of age(Madhi et 
al., 2010), HIV uninfected adults and children between 4 and 7 years of age (Madhi et al., 2007a, 
Madhi et al., 2007b). For further details of cohorts refer to section 4.3.  
 
The natural antibody responses to the 15 pneumococcal proteins involved analysis of archived 
samples from different cohorts of children and adults previously enrolled into studies as detailed 
in section 4.3. Consent for collection, storage, and further testing of these samples was included 
in initial trial consent forms. Serum samples were stored at -80 °C. 
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4.4 ELISA for anti-PspA, -PspC, -PdB and –PsaA 
 
ELISA assays for anti-PspA, -PspC, -PdB and –PsaA were performed as previously reported 
(Quataert et al., 2001), with some modifications. Antigens were diluted in phosphate buffered 
saline (PBS) containing 0.05% Tween-20 and 0.05% sodium azide (PBS-T-N), pH 7.3. Nunc 
Maxisorb microtiter plates were coated with 0.5 µg/ ml PspA antigen. PspC, PdB and PsaA 
antigens were coated onto Costar Polysorb microtiter plates with coating concentrations of 0.25, 
4 and 1 µg/ml at 4 °C overnight. Plates were washed with PBS-T buffer and blocked with PBS 
buffer containing 10% foetal bovine serum (PBS-F) pH 7.3, for an hour, at 37 °C. Pre-dilutions 
of the reference, controls and unknown sera were done in PBS-F. Samples were then serially 
diluted (100 µl/well) in the pre-coated microtiter plates. Following 2 hours incubation at 37 °C, 
plates were washed three times with PBS-T and the alkaline-phosphatase conjugated goat anti-
human IgG was added across all wells, and incubated for 2 hours at 37 °C. After incubation, the 
plates were washed three times with PBS-T and twice with distilled water and the colour was 
developed using p-nitrophenyl phosphate substrate. Plates were read at 405 nm using the RS-
232C Labsystem Multiskan RC plate reader (Labsystems, Finland). 
 
4.5 Coupling of antigens to Luminex carboxylated microspheres 
 
Pneumococcal proteins were coupled to Luminex carboxylated microspheres using a two-step 
carbodiimide reaction (Grabarek and Gergely, 1990). The carboxylated Luminex microspheres 
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were activated by the addition of 50 mg/ml 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC-HCl) and 50 mg/ml N-hydroxysulfosuccinimide (Sulpho-NHS) diluted in 
PBS-F buffer, pH 6.1. The activated microspheres were then washed with PBS buffer, pH 7.3 
and incubated with 15 µg/ml of each antigen. The microspheres were incubated in a shaker, at 
room temperature, overnight to allow the proteins to attach. The conjugated beads were then 
washed and stored in PBS-F buffer, containing 0.05% sodium azide, (PBS-F-N) pH 7.3, at 4°C 
in the dark (Pickering et al., 2002b). Beads coated with PdB were stored at -20°C in PBS-F with 
10% glycerol. 
 
4.6 Multiplexed fluorescent covalent microsphere immunoassay (FCMIA) for 
quantification of antibodies against pneumococcal proteins  
 
A standard curve was prepared from seven 4-fold dilutions (1:50 to 1: 204800) of the reference 
serum in PBS-F. Controls and unknown sera were diluted in PBS-F at 1:100. Samples that were 
above the detection limit were re-diluted. Reference, controls and unknown sera, were mixed 
with the coupled Luminex microsphere beads in a 96-well 1.2 micron filter plate (3500 
microspheres/region/well) and incubated for 1 hour at room temperature with shaking. 
Microspheres were collected by vacuum filtration and washed with PBS-T. R-phycoerythrin-
conjugated anti-human IgG was added across all wells and incubated for 30 min, in a shaker, at 
room temperature. Following incubation, the plates were washed and the beads were re-
suspended in PBS-T buffer and transferred into a 96-well round-bottom plate, and read with a 
Luminex platform Bio-Plex 200 instrument (Bio-Rad Laboratories, Hercules, CA, USA) for 
quantification of IgG antibodies. Antibody concentrations in arbitrary units were determined 
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relative to the standard curve, with a five parameter logistic log model with the BioPlex software 
(Bio-Rad Laboratories, Hercules, CA, USA) (Pickering et al., 2002a).  
 
4.7 Validation of the Luminex method  
 
4.7.1 Competitive inhibition studies  
 
To determine the specificity of both ELISA and Luminex assays, inhibition studies were 
performed as described by Pickering et al with slight modifications (Pickering et al., 2002a). A 
serum with known high concentrations of IgG antibodies directed against PspA, PspC, PsaA and 
PdB was diluted 1:500 times. Four aliquots of each serum dilution were prepared. Each aliquot 
was incubated with an equal volume of one of the four purified antigens in a concentration of 
15µg/ml for 1 hour at room temperature. A 1:1000 dilution of the serum was used as a control. 
The serum aliquots were analysed as per fluorescent covalent microsphere immunoassay 
(FCMIA). Inhibition studies were initially performed for PspA, PspC, PsaA and PdB proteins, 
for comparison and validation of the Luminex assay and then optimized for the remaining 11 
proteins that were included in the second phase of this study. 
 
4.7.2 Assay sensitivity 
 
For the determination of the sensitivity of the assay, the reference serum was diluted in eight-
steps of 4-fold dilutions (1:50 to 1: 204800) respectively. The average mean fluorescent intensity 
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(MFI) and the standard deviation of the blank were calculated for each protein. The lower limit 
of quantification (LLOQ) was interpolated from the standard curve of the reference serum and 
was calculated by adding 3 SD to the MFIs of twenty blanks and reported in arbitrary units per 
millilitre (U/ml). Estimation of the upper limit of quantification (ULOQ) was based on the cut-
off value of 2.5 optical densities for the ELISA method and for the Luminex method; it was the 
highest fluorescent value where there is still sufficient linearity to accurately quantify a sample 
relative to the standard curve of the reference serum. The ULOQ was reported in U/ml for the 
ELISA and Luminex methods (Pickering et al., 2002a). 
 
4.7.3 Assay reproducibility 
 
Reproducibility of the assay was assessed by determining the variation between intra- and inter-
assays of replicate ELISA results with that of the Luminex assay. Intra-assay variation was 
determined from testing sera assayed on different wells within one plate. Inter-assay variation 
was assessed by testing samples in different assays and time- points, and then calculating the 
percentage of variation between results from each assay (Lal et al., 2005).  
 
4.8 Data analysis 
 
Data were analyzed using STATA software (version 11.0, StataCorp, Tx, USA). Antibody titers 
were reported as geometric mean titers (GMTs) in U/ml. The correlation between the ELISA and 
Luminex assay was measured with Spearman‟s correlation coefficients. Data were log 
transformed (log base 10) to obtain normal distributions. Student t-test was used for comparison 
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between two groups. P ≤ 0.05 was considered to be statistically significant. Analysis of variance 
(ANOVA) test was used for comparison of more than two groups. Multivariate linear regression 
analysis was used to determine whether antibody titers were associated with PCV vaccination, 
HIV status and/or nasopharyngeal pneumococcal exposure. 
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Chapter 5: Results 
5.1 Validation of Luminex assay 
 
5.1.1 Comparison of Luminex with ELISA 
 
The correlation of antibody titers measured by a multiplex Luminex assay was compared to a 
single-plex ELISA for IgG antibodies against PspA, PspC, PsaA and PdB. The same reference 
sera, controls and sera (n=100) were used for comparison of antibodies against all four proteins. 
Twenty serum samples from each of five different age groups of HIV-uninfected subjects; i.e. 
children at ages 10 months, 18 months, 24 months, 5 years and mothers, were tested with both 
methods. The mean age for mothers was 27 years (standard deviation [SD] ± 6.2 years). Samples 
that fell outside of the upper detection limit for the assays were repeated at a higher dilution. 
Serum antibody titers against the proteins were determined by both methods and were subjected 
to linear regression analysis and the correlation coefficients were determined as shown in Figure 
3. The linear regression model was adjusted for age. The correlation coefficients for PspA, PspC, 
PdB and PsaA were 0.85, 0.90, 0.86 and 0.96 respectively. The correlation coefficients between 
age groups were greater than 0.90 for PspA, PspC, PsaA and PdB. Overall, there was good 
agreement between the two methods for all the antigens tested. 
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Figure 3: Comparison of the IgG concentrations against PspA, PspC, PdB and PsaA proteins determined by 
multiplex Luminex assay and single-plex ELISA. Sera from 100 patients were quantitated by both ELISA and 
Luminex methods. Antibody titers against all 4 proteins were reported in arbitrary units per ml (U/ml).  
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5.1.2 Specificity of Luminex and ELISA assays  
 
Competitive inhibition experiments were performed in order to confirm the specificity of both 
assays, and were reported as percent change in titer in response to the addition of individual 
antigens to the serum. The addition of the homologous protein to the serum at saturated 
concentrations (15µg/ml), resulted in inhibition of over 90% of signal compared to the control 
sample in both ELISA and Luminex assays for PspA (93% and 97%, respectively), PspC (97% 
and 98%, respectively) and PsaA (94% and 96%, respectively). Inhibition of signal by the 
addition of PdB was slightly lower with 89% of the signal being suppressed in the ELISA, and 
92 % of the signal being suppressed in the Luminex assay. The addition of non-homologous 
antigens to the assays had minimal effect on the assay specific titers (Figure 4 A and B). Similar 
results were reported for the additional 11 proteins included in the 15-plex Luminex assay 
(Figure 4 C). These data suggest that both assays were highly specific for the antigens tested. 
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Figure 4: Inhibition of antigen specific titers by the addition of homologous and non-homologous antigen for PspA, 
PspC, PsaA and PdB with ELISA (A) and Luminex (B). Additional antigen targets included in the multiplex 
Luminex assay are shown in (C). The subscript (c) in each antigen represents the % change for serum absorbed with 
non-homologous antigen and (ab) represents the serum absorbed with homologous antigen.   
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5.1.3 Sensitivity of Luminex and ELISA assays and reproducibility 
 
The lower limit of quantitation (LLOQ) for the Luminex assay was determined from the 
recorded blank values from independent runs (n=20) for each protein. This value was 
given as the equivalent antibody concentration of the reference at the point where the 
fluorescence intensity (FI) was equal to the blank plus three standard deviations. A 
similar method was employed to calculate the LLOQ of ELISA for PspA, PspC, PsaA 
and PdB proteins. The calculated LLOQ and the fold difference between assays are 
shown in Table 2A.  
 
The Luminex assays were 67-, 75-, 100-, and 89-fold more sensitive than ELISA for 
PdB, PsaA, PspA and PspC respectively. The LLOQs for the additional 11 proteins were 
also calculated as part of optimization for the Luminex method as shown in Table 2B. 
There was no upper limit of detection since all the samples which were above the 
measurable range were re-diluted to fall within the measurable range of the standard 
curve of the reference serum. The Luminex method was reproducible; the percentage for 
the coefficient of variation (CV) of the high and low control samples was less than 30% 
in both intra- and inter-assay comparisons.  
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Table 2A: Lower limit of quantitation of specific IgG antibodies (U/ml) against PspA, PspC, PsaA and 
PdB proteins determined by ELISA and Luminex methods, and the fold difference in sensitivity of 
Luminex over ELISA 
LLOQ: lower limit of quantification (arbitrary units/ml). **Fold difference between assays was calculated as ELISA LLOQ/ Luminex 
LLOQ 
 
 
Table 2B: Lower limit of quantitation of specific IgG antibodies (U/ml) against the 11 additional proteins 
under study, calculated by the Luminex method 
 *LLOQ: lower limit of quantification (arbitrary units/ml).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antigen ELISA 
*LLOQ(U/ml) 
Luminex  
*LLOQ(U/ml) 
**Fold difference between 
assays 
PdB 2 0.03 67 
PsaA 6 0.08 75 
PspA 2 0.02 100 
PspC 8 0.09 89 
Antigen SP 0498 SP 0749 
SP 
0082 
SP 
0609 
SP 
2027 
SP 
2194 
SP 
1723 
SP 
2216 
IgA1-
proteinase 
SlrA PpmA 
*LLOQ 0.02 0.11 0.03 0.04 0.03 0.08 0.03 0.01 0.03 0.11 0.01 
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5.2 Antibody responses against pneumococcal proteins in PCV-7 unvaccinated 
children aged between 4 and 24 months   
 
Serum samples from PCV-7 unvaccinated children at 4, 10, 18 and 24 months of age 
were analyzed. The number of samples analyzed varied between time-points depending 
on sample availability. The demographic features of study participants are indicated in 
Table 3.1. Of the 250 PCV-7 unvaccinated childhood cohort, samples were available for 
90% (451/500) of the four time- points in M-/I- children and 83% (414/500) of the four 
time-points in M+/I- children (as shown in Figure 5 below).  
 
Table 3.1: Demographic features of the PCV-7 unvaccinated children less than 2 years of age, children 
were stratified according to vaccination, HIV and pneumococcal colonization status at the time of blood 
sampling. 
Nasopharyngeal swabs from children were collected at each time- point (4, 10, 18 and 24 months). NT = total number 
of participants recruited for the study. N = total number of samples that were present at that time- (visit).M = mother‟s 
HIV status and I = infant‟s HIV status. 
M+/I-: HIV exposed, uninfected children and M-/I-: HIV unexposed, uninfected, children.  
** The values in square brackets indicate the percentage of samples that were available at each time-point for each 
group of children. 
Study group 
Sampling 
time-points 
Total 
number of 
samples (N) 
Median 
age 
(months) 
M-/I- 
(N) 
Colonized 
(M-/I-) 
infants 
M+/I- 
(N) 
Colonized 
(M+/I-) 
infants NT = 125 NT = 125 
PCV 
unvaccinated 
children 
1
st
 time-
point 
243 
5 
(3-8) 
124 
[99 %] 
(65/124) 
52 % 
119 
(96 %) 
(77/119) 
64 % 
2
nd
 time-
point 
225 
10 
(5-12) 
114 
[91 %] 
(76/114) 
65 % 
111 
(89 %) 
(78/111) 
70 % 
3rd time-
point 
206 
17 
(10-20) 
107 
[86 %] 
(73/107) 
68 % 
99 
(79 %) 
(76/99) 
75 % 
4
th
 time-
point 
191 
26 
(19-30) 
106 
[85 %] 
(77/106) 
72 % 
85 
(70 %) 
(68/85) 
79 % 
Total number 
of samples 
evaluated (N)  
- 865 - - - - - 
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Figure 5: Flow diagram indicating sample availability at different time-points for PCV-7 unvaccinated 
children. Children were stratified by HIV exposure and pneumococcal colonization status.  
LTFU = loss to follow up, *finished = sample used up.  
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5.2.1 Anti-pneumococcal protein antibodies in M-/I- and M+/I- children 
 
Comparison of antibody titers at each of the four time-points was adjusted for prevailing 
pneumococcal nasopharyngeal colonization status. Significantly higher antibody titers 
were observed in M-/I- infants compared to M+/I- infants against 10 of the 15 proteins, 
namely: PspA, PspC, PdB, SP 0082, LytB, IgA1-proteinase, PpmA, SlrA, PcsB and StkP, 
at 4 months of age. Differences in GMTs (in U/ml) between M-/I- and M+/I- infants at 
this time-point are shown in Table 3.2. However, lower antibody titers against PsaA were 
observed in M-/I- children compared to M+/I- children at this age, as shown in Table 3.2. 
 
At the 10 month time-point, M-/I- children had higher antibody titers against PpmA (47 
vs 30 U/ml; p = 0.037) and SrlA (185 vs 138 U/ml; p = 0.012) and lower antibody titers 
against SP 0609 (88 vs 136 U/ml; p = 0.002) compared to M+/I- children. However, no 
differences were observed at the subsequent time-point of 18 months between M-/I- and 
M+/I- children to any of the analyzed proteins.  
 
At 24 months, significantly higher antibody titers were also observed in M-/I- children 
compared to M+/I- children against PspA (158 vs. 119 U/ml; p = 0.040), PspC (169 vs. 
139 U/ml; p = 0.009), PsaA (176 vs 137 U/ml; p = 0.036), SP 0082 (189 vs. 146 U/ml; p 
= 0.009), SP 0609 (113 vs 64 U/ml; p = 0.001) and IgA1-proteinase (134 vs. 84 U/ml; p = 
0.015) as shown in Table 3.2).  
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5.2.2 Relationship between antibody titers and concurrent pneumococcal colonization 
in PCV unvaccinated children 
 
The overall prevalence of nasopharyngeal pneumococcal colonization in M-/I- and M+/I- 
children increased with age from 59% (142/243) at 4 months, 68% (154/225) at 10 
months, 72% (149/206) at 18 months and 76% (145/191) by 24 months. There were 
differences between the M-/I- and M+/I- groups, in that the latter had a higher prevalence 
of colonization at the 1
st
 time-point (52% [65/124] in M-/I- infants vs 64% [77/119] in 
M+/I- infants, p = 0.015). No differences were observed in the prevalence of 
nasopharyngeal pneumococcal colonization between M-/I- and M+/I- infants at 
subsequent time-points including the 2
nd
 time-point (65% [76/114] in M-/I- infants vs 
70% [78/111] in M+/I- infants, p = 0.10), at the 3rd time-point (68% [73/107] in M-/I- 
infants vs 75% [76/99] in M+/I- infants, p = 0.37)] and at the 4
th
 time-point (72% 
[77/106] in M-/I- infants vs 79% [68/85] in M+/I- infants, p = 0.68) of the children were 
colonized with pneumococci. 
 
In the M-/I- group, at 4 months, higher antibody titers against PcsB (39 vs 28; p = 0.050) 
were observed in children colonized with pneumococci compared to uncolonized 
children. At 10 months, higher antibody titers against PspC (126 vs 44; p < 0.0001), PdB 
(114 vs 57; p = 0.003), SP 0082 (105 vs 37; p < 0.0001), LytB (106 vs 38; p < 0.0001), 
PpmA (60 vs 23; p = 0.007), PcsB (131 vs 32; p < 0.0001) and StkP (35 vs 17; p = 0.011) 
were also observed in children colonized with pneumococci than -uncolonized children. 
Differences in antibody titers between the pneumococcal-colonized and -uncolonized 
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children declined with an increase in age in the M-/I- group, such that by 24 months of 
age, children had similar antibody titers regardless of pneumococcal colonization status 
(refer to Tables 3.3 – 3.6).  
 
In the M+/I- group, at 4 months, pneumococcal-colonized children had higher antibody 
titers compared -uncolonized children for PspC (54 vs 37; p = 0.016) and PcsB (35 vs 14; 
p = 0.005). At 10 months, higher antibody titers against PspC (106 vs 70; p = 0.043) and 
lower antibody titers against SP 0609 (120 vs 180; p = 0.022) were observed in 
pneumococcal-colonized compared to -uncolonized children, respectively. There were no 
differences in antibody titers between pneumococcal-colonized and -uncolonized children 
at 24 months of age (see Tables 3.3 – 3.6).  
 
Overall, when adjusting for HIV exposure status, higher antibody titers against PspC 
were observed in pneumococcal-colonized children compared to -uncolonized children at 
all four time-points. Most of the differences in antibody titers between pneumococcal-
colonized and -uncolonized children were observed early in infancy at approximately 4 
and 10 months of age. These differences at the 1
st
 and 2
nd
 time-points were higher 
antibody titers against PdB, SP 0082, LytB, PpmA, PcsB and StkP in pneumococcal-
colonized children compared to -uncolonized children (refer to Tables 3.3 – 3.6). 
Differences in antibody titers between pneumococcal-colonized children and -
uncolonized children were less evident at the 3
rd
 and 4
th
 time-points; i.e. at approximately 
18 and 24 months of age. 
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Table 3.2: Comparison of the geometric mean titers against the 15 pneumococcal proteins between unvaccinated M-/I- and M+/I- children at approximately 4, 
10, 18 and 24 months of age. 
*GMTs (with 95% CI) were reported in arbitrary units per milliliter (U/ml). M-/I- : HIV unexposed, uninfected children and M+/I-: HIV exposed, uninfected children. GMTs in 
M-/I- significantly higher than in M+/I- are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- are highlighted in blue. **For comparison between M-/I- and 
M+/I- children, p values were adjusted for pneumococcal exposure.  
Protein 
4 months age 
**p 
(adj.) 
10 months age 
**p 
(adj.) 
18 months age 
**p 
(adj.) 
24 months age 
**p 
(adj.) 
M-/I- 
*GMT 
(95 % CI) 
M+/I- 
*GMT 
(95 % CI) 
M-/I- 
*GMT 
(95 % CI) 
M+/I- 
*GMT 
(95 % CI) 
M-/I- 
*GMT 
(95 % CI) 
M+/I- 
*GMT 
(95 % CI) 
M-/I- 
*GMT 
(95 % CI) 
M+/I- 
*GMT 
(95 % CI) 
PspA 
47 
(40-55) 
33 
(29-37) 
0.001 
116 
(98-138) 
101 
(84-120) 
0.25 
131 
(105-164) 
111 
(91-135) 
0.26 
158 
(129-192) 
119 
(101-140) 
0.040 
PspC 
60 
(54-67) 
47 
(42-55) 
0.002 
100 
(83-120) 
93 
(78-110) 
0.97 
131 
(110-155) 
113 
(95-134) 
0.31 
169 
(152-188) 
139 
(126-154) 
0.009 
PsaA 
182 
(158-211) 
249 
(223-278) 
0.001 
174 
(153-199) 
193 
(167-222) 
0.27 
158 
(134-186) 
180 
(155-209) 
0.24 
176 
(150-207) 
137 
(116-162) 
0.036 
PdB 
45 
(39-52) 
35 
(30-41) 
0.008 
98 
(80-119) 
73 
(58-93) 
0.09 
130 
(108-156) 
108 
(86-135) 
0.20 
147 
(125-173) 
131 
(111-156) 
0.33 
SP 2027 
571 
(491-663) 
556 
(444-696) 
0.82 
561 
(445-706) 
483 
(366-638) 
0.40 
285 
(222-365) 
191 
(125-290) 
0.07 
476 
(403-562) 
449 
(310-648) 
0.75 
SP 0609 
79 
(67-94) 
67 
(56-81) 
0.23 
88 
(73-107) 
136 
(115- 162) 
0.002 
121 
(90-164) 
171 
(140-209) 
0.07 
113 
(91-139) 
64 
(50-81) 
0.001 
SP 0082 
39 
(35-45) 
30 
(24-36) 
0.010 
83 
(67-104) 
72 
(58-89) 
0.55 
130 
(106-159) 
101 
(87-118) 
0.05 
189 
(116-215) 
146 
(125-170) 
0.009 
SP 0749 
124 
(102-151) 
107 
(91-126) 
0.26 
57 
(44-73) 
56 
(42-75) 
0.99 
84 
(58-121) 
87 
(62-122) 
0.89 
106 
(84-134) 
99 
(80-121) 
0.63 
(SP 0498) 
LytB 
38 
(34-43) 
26 
(21-31) 
< 0.0001 
85 
(67-106) 
81 
(67-99) 
0.98 
164 
(135-200) 
155 
(132-181) 
0.67 
204 
(176-236) 
187 
(159-218) 
0.41 
IgA1-
proteinase 
61 
(53-69) 
31 
(26-38) 
< 0.0001 
77 
(60-10) 
100 
(80-123) 
0.14 
90 
(65-125) 
121 
(97-151) 
0.17 
134 
(106-169) 
84 
(61-115) 
0.015 
PpmA 
41 
(35-48) 
24 
(20-30) 
< 0.0001 
47 
(36-62) 
30 
(24-39) 
0.037 
63 
(46-85) 
42 
(32-56) 
0.07 
98 
(75-128) 
87 
(65-118) 
0.57 
SlrA 
185 
(158-216) 
119 
(104-136) 
< 0.0001 
185 
(157-217) 
138 
(117-163) 
0.012 
124 
(97-158) 
96 
(79-116) 
0.96 
124 
(98-158) 
123 
(101-149) 
0.94 
SP 2216 
(PcsB) 
33 
(28-39) 
26 
(20-34) 
0.027 
96 
(74-124) 
88 
(68-113) 
0.99 
157 
(120-205) 
142 
(121-166) 
0.56 
208 
(185-234) 
197 
(169-230) 
0.55 
SP 1723 
(StkP) 
29 
(26-33) 
21 
(18-23) 
< 0.0001 
30 
(24-37) 
22 
(17-29) 
0.14 
39 
(29-52) 
34 
(26-45) 
0.56 
61 
(49-75) 
46 
(37-57) 
0.07 
SP 2194 
141 
(119-168) 
168 
(145-193 
0.10 
159 
(131-191) 
153 
(126-185) 
0.75 
144 
(113-185) 
150 
(124-181) 
0.96 
125 
(101-153) 
128 
(100-162) 
0.88 
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Table 3.3: GMTs (with 95% CI) against the 15 pneumococcal proteins in children at approximately 4 months of age  
 
**GMTs (with 95% CI) were reported in arbitrary units per milliliter (U/ml). M-/I- : HIV unexposed, uninfected children and M+/I-: HIV exposed, uninfected 
children. GMTs in M-/I- significantly higher than in M+/I- are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- are highlighted in blue. **For 
comparison between M-/I- and M+/I- children, p values were adjusted for pneumococcal exposure.  
Protein 
Overall 
*GMT 
(95 % CI) 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M+/I- *GMT (95 % CI) M-/I-, *GMT (95 % CI) 
Colonized 
Uncolonized 
 
P Colonized 
Uncolonized 
 
p 
PspA 
39 
(36-44) 
38 
(34-42) 
42 
(35-50) 
0.74 
34 
(30-38) 
31 
(25-40) 
0.61 
44 
(36-55) 
50 
(40-64) 
0.45 
PspC 
54 
(49-59) 
59 
(52-66) 
47 
(41-55) 
0.006 
54 
(46-63) 
37 
(29-48) 
0.016 
65 
(56-76) 
55 
(47-65) 
0.14 
PsaA 
213 
(194-233) 
214 
(190-241) 
210 
(180-245) 
0.73 
258 
(227-293) 
232 
(186-289) 
0.40 
170 
(139-208) 
197 
(159-244) 
0.32 
PdB 
40 
(35-44) 
42 
(37-49) 
36 
(30-43) 
0.08 
39 
(32-47) 
28 
(21-36) 
0.052 
47 
(38-58) 
43 
(34-53) 
0.50 
SP 2027 
563 
(493-644) 
567 
(477-673) 
558 
(449-692) 
0.89 
570 
(437-743) 
527 
(339-819) 
0.76 
563 
(458-694) 
578 
(462-725) 
0.86 
SP 0609 
73 
(65-83) 
70 
(60-81) 
79 
(64-97) 
0.40 
65 
(53-81) 
72 
(50-103) 
0.65 
75 
(60-94) 
84 
(65-108) 
0.53 
SP 0082 
34 
(30-38) 
36 
(31-42) 
32 
(26-38) 
0.17 
32 
(26-41) 
25 
(17-35) 
0.21 
41 
(35-48) 
38 
(31-46) 
0.51 
SP 0749 
115 
(102-131) 
114 
(97-134) 
118 
(95-145) 
0.97 
118 
(96-144) 
87 
(67-113) 
0.07 
110 
(84-143) 
143 
(106-192) 
0.18 
(SP 0498) 
LytB 
32 
(28-35) 
33 
(29-38) 
29 
(24-34) 
0.06 
28 
(22-34) 
22 
(15-31) 
0.25 
42 
(36-49) 
35 
(29-41) 
0.09 
IgA1-
proteinase 
44 
(39-49) 
45 
(39-52) 
43 
(35-52) 
0.21 
35 
(29-44) 
25 
(18-34) 
0.06 
60 
(49-73) 
61 
(51-75) 
0.86 
PpmA 
32 
(28-36) 
34 
(29-40 
28 
(23-36) 
0.043 
27 
(22-33) 
20 
(13-30) 
0.17 
46 
(37-57) 
36 
(28-46) 
0.16 
SlrA 
149 
(134-166) 
139 
(122-158) 
166 
(139-199) 
0.30 
122 
(105-141) 
115 
(87-152) 
0.73 
165 
(132-206) 
211 
(169-263) 
0.11 
SP 2216 
(PcsB) 
30 
(25-34) 
36 
(31-43) 
22 
(17-28) 
0.001 
35 
(29-45) 
14 
(8-25) 
0.005 
39 
(31-47) 
28 
(22-36) 
0.050 
SP 1723 
(StkP) 
25 
(22-27) 
26 
(23-29) 
23 
(20-27) 
0.06 
22 
(19-25) 
18 
(14-23) 
0.18 
31 
(27-37) 
27 
(22-32) 
0.19 
SP 2194 
154 
(137-172) 
150 
(129-174) 
159 
(134-189) 
0.45 
174 
(148-204) 
155 
(116-207) 
0.48 
125 
(96-162) 
162 
(131-202) 
0.13 
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Table 3.4: GMTs (with 95% CI) to the 15 pneumococcal proteins in children at approximately 10 months of age 
**GMTs (with 95% CI) were reported in arbitrary units per milliliter (U/ml). M-/I- : HIV unexposed, uninfected children and M+/I-: HIV exposed, uninfected 
children. GMTs in M-/I- significantly higher than in M+/I- are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- are highlighted in blue. **For 
comparison between M-/I- and M+/I- children, p values were adjusted for pneumococcal exposure.  
 
Protein 
Overall 
*GMT 
(95 % CI) 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M+/I- *GMT (95 % CI) M-/I-, *GMT (95 % CI) 
Colonized Uncolonized p Colonized Uncolonized p 
PspA 
108 
(96-123) 
108 
(93-125) 
110 
(87-137) 
0.82 
100 
(82-123) 
102 
(71-146) 
0.95 
115 
(93-142) 
122 
(97-152) 
0.70 
PspC 
96 
(85-109) 
116 
(103-131) 
58 
(43-77) 
< 0.0001 
106 
(89-127) 
70 
(49-101) 
0.043 
126 
(107-148) 
44 
(27-73) 
< 0.0001 
PsaA 
183 
(167-201) 
187 
(167-209) 
174 
(146-208) 
0.45 
199 
(168-236) 
179 
(138-233) 
0.50 
177 
(151-206) 
167 
(133-211) 
0.69 
PdB 
85 
(73-99) 
93 
(78-111) 
65 
(48-89) 
0.06 
74 
(56-98) 
71 
(45-113) 
0.89 
114 
(92-142) 
57 
(38-86) 
0.003 
SP 2027 
521 
(435-622) 
516 
(415-640) 
535 
(388-739) 
0.78 
494 
(351-697) 
459 
(279-755) 
0.80 
534 
(404-707) 
664 
(464-951) 
0.34 
SP 0609 
109 
(96-126) 
102 
(87-119) 
133 
(105-169) 
0.14 
120 
(97-148) 
180 
(136-239) 
0.022 
88 
(71-111) 
87 
(60-127) 
0.94 
SP 0082 
77 
(66-91) 
91 
(77-109) 
50 
(36-67) 
0.001 
78 
(60-101) 
61 
(40-91) 
0.31 
105 
(83-133) 
37 
(23-60) 
< 0.0001 
SP 0749 
57 
(47-68) 
58 
(46-73) 
52 
(38-74) 
0.64 
60 
(42-86) 
49 
(30-78) 
0.47 
57 
(42-76) 
59 
(35-97) 
0.90 
(SP 0498) 
LytB 
83 
(71-96) 
92 
(77-110) 
62 
(47-83) 
0.027 
78 
(60-100) 
89 
(65-121) 
0.52 
106 
(83-135) 
38 
(23-63) 
< 0.0001 
IgA1-
proteinase 
88 
(74-104) 
88 
(72-107) 
87 
(63-121) 
0.83 
89 
(69-116) 
126 
(86-183) 
0.14 
87 
(64-117) 
52 
(30-90) 
0.10 
PpmA 
38 
(32-45) 
45 
(37-56) 
23 
(16-33) 
0.003 
34 
(25-45) 
24 
(16-37) 
0.19 
60 
(43-78) 
23 
(12-41) 
0.007 
SlrA 
160 
(142-180) 
159 
(138-183) 
162 
(132-199) 
0.67 
135 
(110-166) 
144 
(108-193) 
0.70 
183 
(150-222) 
191 
(143-256) 
0.80 
SP 2216 
(PcsB) 
92 
(77-110) 
116 
(96-139) 
49 
(33-73) 
< 0.0001 
100 
(76-134) 
66 
(40-111) 
0.16 
131 
(103-167) 
32 
(17-60) 
< 0.0001 
SP 1723 
(StkP) 
26 
(22-31) 
29 
(24-35) 
19 
(13-27) 
0.048 
23 
(17-32) 
21 
(12-35) 
0.72 
35 
(28-45) 
17 
(10-28) 
0.011 
SP 2194 
156 
(136-178) 
153 
(130-180) 
164 
(130-206) 
0.64 
157 
(124-198) 
145 
(103-204) 
0.70 
150 
(119-187) 
194 
(143-264) 
0.17 
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Table 3.5: GMTs (with 95% CI) to the 15 pneumococcal proteins in children at approximately 18 months of age 
 
**GMTs (with 95% CI) were reported in arbitrary units per milliliter (U/ml). M-/I- : HIV unexposed, uninfected children and M+/I-: HIV exposed, uninfected 
children. GMTs in M-/I- significantly higher than in M+/I- are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- are highlighted in blue. **For 
comparison between M-/I- and M+/I- children, p values were adjusted for pneumococcal exposure.  
 
Protein 
Overall 
*GMT 
(95 % CI) 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M+/I- *GMT (95 % CI) M-/I-, *GMT (95 % CI) 
Colonized Uncolonized p Colonized Uncolonized p 
PspA 
121 
(104-140) 
118 
(99-141) 
131 
(101-169) 
0.51 
108 
(85-135) 
121 
(81-181) 
0.60 
128 
(97-168) 
143 
(101-201) 
0.61 
PspC 
122 
(108-138) 
135 
(119-153) 
90 
(67-122) 
0.005 
122 
(101-148) 
93 
(64-135) 
0.19 
147 
(125-173) 
87 
(52-147) 
0.06 
PsaA 
168 
(150-188) 
170 
(149-194) 
162 
(131-201) 
0.67 
189 
(159-225) 
159 
(117-215) 
0.31 
155 
(128-188) 
167 
(120-232) 
0.69 
PdB 
118 
(102-137) 
118 
(100-140) 
118 
(90-158) 
0.91 
109 
(84-143) 
103 
(65-162) 
0.81 
126 
(101-157) 
141 
(101-198) 
0.58 
SP 2027 
234 
(185-298) 
203 
(153-270) 
357 
(233-547) 
0.032 
153 
(92-254) 
332 
(159-690) 
0.08 
260 
(193-349) 
389 
(253-597) 
0.12 
SP 0609 
144 
(120-172) 
134 
(108-168) 
174 
(129-236) 
0.26 
160 
(125-204) 
203 
(141-292) 
0.27 
115 
(81-165) 
146 
(87-247) 
0.45 
SP 0082 
115 
(101-131) 
116 
(99-135) 
113 
(90-141) 
0.95 
94 
(77-114) 
122 
(98-152) 
0.07 
139 
(111-176) 
102 
(67-157) 
0.20 
SP 0749 
85 
(67-109) 
86 
(64-117) 
82 
(55-122) 
0.85 
91 
(59-141) 
76 
(45-128) 
0.59 
82 
(53-127) 
89 
(46-174) 
0.83 
(SP 0498) 
LytB 
159 
(141-181) 
164 
(142-190) 
147 
(114-188) 
0.46 
144 
(119-176) 
184 
(142-238) 
0.14 
183 
(148-227) 
113 
(72-177) 
0.05 
IgA1-
proteinase 
104 
(86-127) 
97 
(76-123) 
130 
(93-181) 
0.24 
114 
(88-148) 
141 
(90-221) 
0.41 
84 
(56-124) 
118 
(69-201) 
0.30 
PpmA 
52 
(42-64) 
55 
(43-70) 
44 
(29-65) 
0.38 
43 
(31-60) 
40 
(23-71) 
0.81 
68 
(48-97) 
48 
(26-89) 
0.32 
SlrA 
109 
(93-128) 
105 
(87-126) 
124 
(93-165) 
0.30 
90 
(72-111) 
114 
(76-171) 
0.29 
120 
(89-161) 
136 
(88-211) 
0.62 
SP 2216 
(PcsB) 
149 
(128-175) 
154 
(128-186) 
136 
(103-181) 
0.53 
146 
(123-173) 
132 
(92-190) 
0.62 
161 
(117-223) 
142 
(89-226) 
0.64 
SP 1723 
(StkP) 
37 
(30-45) 
38 
(30-48) 
33 
(23-48) 
0.54 
33 
(24-46) 
37 
(22-62) 
0.74 
43 
(30-60) 
29 
(16-50) 
0.22 
SP 2194 
147 
(126-172) 
127 
(105-154) 
226 
(181-282) 
0.001 
131 
(104-164) 
214 
(156-293) 
0.012 
124 
(92-167) 
240 
(173-334) 
0.004 
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Table 3.6: GMTs (with 95% CI) to the 15 pneumococcal proteins in children at approximately 24 months of age 
**GMTs (with 95% CI) were reported in arbitrary units per milliliter (U/ml). M-/I- : HIV unexposed, uninfected children and M+/I-: HIV exposed, uninfected 
children. GMTs in M-/I- significantly higher than in M+/I- are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- are highlighted in blue. **For 
comparison between M-/I- and M+/I- children, p values were adjusted for pneumococcal exposure.  
 
Protein 
Overall 
*GMT 
(95 % CI) 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M+/I- *GMT (95 % CI) M-/I-, *GMT (95 % CI) 
Colonized Uncolonized p Colonized Uncolonized p 
PspA 
140 
(122-160) 
145 
(125-168) 
125 
(92-169) 
0.32 
118 
(99-141) 
122 
(79-189) 
0.89 
169 
(135-212) 
127 
(82-197) 
0.24 
PspC 
156 
(144-168) 
163 
(153-174) 
133 
(104-169) 
0.016 
147 
(136-159) 
115 
(80-166) 
0.18 
177 
(161-195) 
146 
(105-205) 
0.27 
PsaA 
159 
(141-178) 
165 
(143-189) 
141 
(112-177) 
0.23 
141 
(117-172) 
124 
(88-177) 
0.51 
185 
(156-224) 
152 
(111-209) 
0.29 
PdB 
140 
(124-157) 
148 
(129-168) 
118 
(90-153) 
0.10 
133 
( 110-161) 
124 
(82-189) 
0.75 
160 
(133-191) 
113 
(79-162) 
0.09 
SP 2027 
460 
(369-574) 
414 
(320-536) 
647 
(425-986) 
0.09 
446 
(365-544) 
600 
(455-790) 
0.08 
391 
(253-605) 
680 
(338-1368) 
0.18 
SP 0609 
88 
(75-104) 
88 
(73-107) 
88 
(64-121) 
0.89 
61 
(46-81) 
72 
(43-123) 
0.56 
117 
(92-150) 
100 
(65-154) 
0.51 
SP 0082 
169 
(153-187) 
175 
(159-194) 
151 
(115-199) 
0.18 
155 
(137-177) 
117 
(67-205) 
0.32 
192 
(166-223) 
179 
(135-236) 
0.64 
SP 0749 
103 
(88-120) 
104 
(87-125) 
98 
(71-137) 
0.74 
106 
(84-134) 
76 
(47-122) 
0.20 
103 
(78-135) 
117 
(74-185) 
0.63 
(SP 0498) 
LytB 
196 
(176-218) 
201 
(178-226) 
182 
(143-232) 
0.79 
189 
(158-225) 
179 
(123-261) 
0.79 
210 
(179-248) 
184 
(131-259) 
0.48 
IgA1-
proteinase 
109 
(90-133) 
117 
(94-146) 
88 
(60-131) 
0.19 
84 
(58-123) 
81 
(43-152) 
0.91 
150 
(116-194) 
94 
(55-160) 
0.11 
PpmA 
93 
(76-113) 
95 
(75-119) 
88 
(58-133) 
0.73 
83 
(59-117) 
104 
(52-206) 
0.55 
105 
(77-143) 
78 
(45-137) 
0.35 
SlrA 
124 
(105-145) 
126 
(105-151) 
117 
(81-168) 
0.70 
126 
(102-156) 
112 
(67-186) 
0.65 
126 
(102-156) 
112 
(67-186) 
0.65 
SP 2216 
(PcsB) 
203 
(185-223) 
209 
(190-230) 
185 
(143-239) 
0.26 
208 
(180-240) 
163 
(98-271) 
0.34 
210 
(185-239) 
201 
(151-269) 
0.78 
SP 1723 
(StkP) 
54 
(47-63) 
58 
(49-69) 
43 
(31-60) 
0.08 
49 
(38-63) 
37 
(24-58) 
0.26 
66 
(52-83) 
47 
(29-78) 
0.22 
SP 2194 
126 
(108-147) 
124 
(104-148) 
131 
(93-186) 
0.76 
133 
(103-170) 
111 
(56-220) 
0.61 
118 
(92-151) 
147 
(99-218) 
0.34 
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5.3 Antibody titers against pneumococcal proteins in PCV-vaccinated children aged 
between 4 and 24 months.   
 
Serum samples from PCV-7 vaccinated children at approximately 4, 10, 18 and 24 
months of age were analyzed. The number of samples analyzed varied between time-
points based on availability. The demographic features of study participants are indicated 
in Table 4.1. Of the 565 PCV-7 vaccinated children enrolled, samples were available for 
87% (433/496) of the four time-points in M-/I- children, 82% (412/500) of the four time-
points in M+/I- children and 75% (940/1260) of the 4 time-points in M+/I+ children as 
shown in figure 6.  
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Table 4.1: Demographic features of the PCV-7 vaccinated children less than 2 years of age, stratified by vaccination, HIV and pneumococcal colonization status 
at the time of blood sampling. 
 
Nasopharyngeal swabs from children were collected at each time-point (i.e. approximately 4, 10, 18 and 24 months of age) to determine pneumococcal colonization status. N: total 
number of samples that was present at that time-point (visit).  M+/I+: HIV exposed, infected children, M+/I-: HIV exposed, uninfected children and M-/I-: HIV unexposed, 
uninfected children. NT: total number of participants that were recruited for the study. 
* M+/I+ children who were on ART were combined with M+/I+ children who were not on ART since no statistically significant differences in antibody titers against all proteins 
were observed between these groups. 
** The values in square brackets indicate the percentage of samples that were available at each time-point in each group of children. 
Study group 
Sampling 
time points 
Total 
number of 
samples 
(NT) 
Median 
age 
(months) 
**
M+/I+ 
(N) 
Colonized 
(M+/I+) 
infants 
M+/I- (N) 
Colonized 
(M+/I-) 
infants 
M-/I- (N) 
Colonized 
(M-/I-) 
infants 
NT=315  NT=125  NT=125  
PCV-7 
vaccinated 
children 
1
st
 time 
point 
508 
5 
(4-7) 
276 
[88 %] 
(114/276) 
41 % 
117 
[94 %] 
(59/117) 
50 % 
115 
[92 %] 
(61/115) 
53 % 
2
nd
  time 
point 
462 
10 
(5-18) 
243 
[77 %] 
(135/243) 
55 % 
106 
[85 %] 
(63/106) 
59 % 
113 
[90 %] 
(66/113) 
58 % 
3rd time 
point 
438 
17 
(9-25) 
235 
[75 %] 
(138/235) 
58 % 
96 
[77 %] 
(60/96) 
62 % 
107 
[86 %] 
(64/107)  
60 % 
4
th
 time 
point 
377 
27 
(17-33) 
186 
[60 %] 
(55/186) 
64 % 
93 
[75 %] 
(62/93) 
66 % 
98 
[78 %] 
(70/98) 
71 % 
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Figure 6: Flow diagram indicating sample availability at different time-points for PCV-7 vaccinated children. Children 
were stratified according to HIV exposure and pneumococcal colonization status.  
LTFU = loss to follow up, *finished = sample used up. M/I- children were stratified according to those who were on 
ART (NT = 211) and children who were not on ART (NT = 104).  
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5.3.1 Antibody titers against pneumococcal proteins in PCV-vaccinated infants in 
relation to HIV status 
 
M-/I- children had significantly higher antibody titers than M+/I+ children against PspA, 
PspC, SP 0082, IgA1-proteinase, PpmA, and StkP at all four time-points. In addition, 
antibody titers against SP 2027, SlrA, PcsB, were consistently higher in M-/I- children 
compared to M+/I+ children, reaching statistical significance in at least two time-points 
(see Table 4.2 and 4.3). 
 
Compared to M+/I- children at 4 months, M-/I- children had higher antibody titers (in 
U/ml) against PspA (11 vs 4; p < 0.0001), PspC (21 vs 9; < 0.0001), PdB (8 vs 5; p = 
0.011) SP 0082 (39 vs 22; p = 0.006), LytB (29 vs 17; p < 0.0001), IgA1-proteinase (25 
vs 13; p < 0.0001) PpmA (16 vs 9; p = 0.002), PcsB (39 vs 21; p = 0.005) and StkP (16 
vs 12; p = 0.012). At 10 months higher antibody titers against SP 0082 (162 vs 88; p = 
0.028), PpmA (78 vs 37; p = 0.006), SlrA (109 vs 62; p = 0.004) and StkP (17 vs 9; p = 
0.009) were also evident in M-/I- children compared to M+/I- children. Differences in 
antibody titers between these groups was less evident with increasing age, such that by 24 
months M+/I- children had similar antibody titers as M-/I- children against all proteins 
(see table 4.2 and 4.3). 
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Table 4.2: Comparison of the geometric mean titers against the 15 pneumococcal proteins between M-/I- , M+/I- and M+/I+ children at approximately 4 and 10 months of age 
GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml). *P-values: statistical differences between different groups of children and they were adjusted for pneumococcal 
exposure. **M-/I- children were used as a reference group for calculating the adjusted p-values. M+/I+: HIV exposed, infected; M+/I-: HIV exposed, uninfected and M-/I-: HIV unexposed, uninfected.  
*p1= M-/I- vs M+/I+, p2 = M-/I- vs M+/I-. „GMTs in M-/I- significantly higher than in M+/I- (p2) or in M+/I+ (p1) are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- (p2) or in 
M+/I+ (p1) are highlighted in blue. 
Protein 
4 months age 10 months age 
**M-/I- 
GMT 
(95 % CI) 
M+/I+ 
GMT 
(95 % CI) 
M+/I- 
GMT 
(95 % CI) 
*p1 
adjusted 
*p2 
Adjusted 
**M-/I- 
GMT 
(95 % CI) 
M+/I+ 
GMT 
(95 % CI) 
M+/I- 
GMT 
(95 % CI) 
*p1 
adjusted 
*p2 
adjusted 
PspA 
11 
(9-14) 
2 
(2-3) 
4 
(3-6) 
< 0.0001 < 0.0001 
46 
(37-57) 
26 
(22-30) 
34 
(28-43) 
< 0.0001 0.08 
PspC 
21 
(17-(25) 
6 
(5-8) 
9 
(7-12) 
< 0.0001 < 0.0001 
75 
(55-104) 
40 
(30-54) 
66 
(47-93) 
0.020 0.96 
PsaA 
13 
(10-17) 
11 
(9-14) 
11 
(8-14) 
0.74 0.39 
93 
(83-104) 
88 
(78-98) 
81 
(72-92) 
0.62 0.21 
PdB 
8 
(6-9) 
6 
(5-7) 
5 
(5-6) 
0.13 0.011 
50 
(37-67) 
30 
(24-38) 
31 
(23-43) 
0.027 0.06 
SP 2027 
258 
(219-303) 
220 
(195-248) 
227 
(195-268) 
0.08 0.28 
611 
(512-729) 
357 
(288-443) 
624 
(517-752) 
0.001 0.89 
SP 0609 
131 
(108-159) 
117 
(101-135) 
107 
(88-130) 
0.31 0.17 
134 
(107-168) 
125 
(100-156) 
103 
(86-124) 
0.71 0.17 
SP 0082 
39 
(32-47) 
14 
(11-18) 
22 
(17-28) 
< 0.0001 0.006 
162 
(121-218) 
72 
(54-97) 
88 
(64-121) 
0.001 0.028 
SP 0749 
30 
(25-35) 
41 
(35-47) 
33 
(27-40) 
0.015 0.45 
79 
(56-112) 
98 
(74-130) 
66 
(47-93) 
0.36 0.52 
SP 0498 
(LytB) 
29 
(24-35) 
15 
(13-17) 
17 
(15-21) 
< 0.0001 < 0.0001 
54 
(40-73) 
38 
(30-49) 
53 
(39-72) 
0.16 0.91 
IgA1-
proteinase 
25 
(22-30) 
13 
(12-15) 
13 
(11-16) 
< 0.0001 < 0.0001 
49 
(36-66) 
28 
(23-34) 
32 
(24-44) 
0.003 0.06 
PpmA 
16 
(12-20) 
7 
(6-9) 
9 
(7-11) 
< 0.0001 0.002 
78 
(58-105) 
32 
(24-42) 
37 
(26-52) 
< 0.0001 0.006 
SlrA 
26 
(21-31) 
25 
(21-29) 
29 
(23-35) 
0.88 0.49 
109 
(85-138) 
62 
(51-76) 
62 
(48-79) 
0.002 0.004 
SP 2216 
(PcsB) 
39 
(30-51) 
14 
(11-17) 
21 
(15-28) 
< 0.0001 0.005 
72 
(51-102) 
50 
(35-71) 
70 
(52-94) 
0.30 0.82 
SP 1723 
(StkP) 
16 
(14-20) 
8 
(7-9) 
12 
(10-14) 
< 0.0001 0.012 
17 
(13-23) 
8 
(6-10) 
9 
(7-13) 
0.001 0.009 
SP 2194 
127 
(105-154) 
117 
(102-134) 
110 
(90-134) 
0.41 0.29 
134 
(109-166) 
124 
(101-151) 
105 
(86-128) 
0.56 0.16 
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Table 4.3: Comparison of the geometric mean titers against the 15 pneumococcal proteins between M-/I- , M+/I- and M+/I+ children at approximately 18 and 24 months of age 
GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml). *P-values: statistical differences between different groups of children and they were adjusted for pneumococcal 
exposure. **M-/I- children were used as a reference group for calculating the adjusted p-values. M+/I+: HIV exposed, infected; M+/I-: HIV exposed, uninfected and M-/I-: HIV unexposed, uninfected.  
Protein 
18 months age 24 months age 
M-/I- 
GMT 
(95 % CI) 
M+/I+ 
GMT 
(95 % CI) 
M+/I- 
GMT 
(95 % CI) 
*p1 
adjusted 
*p2 
adjusted 
M-/I- 
GMT 
(95 % CI) 
M+/I+ 
GMT 
(95 % CI) 
M+/I- 
GMT 
(95 % CI) 
*p1 
adjusted 
*p2 
adjusted 
PspA 
53 
(43-66) 
35 
(31-40) 
40 
(33-49) 
< 0.0001 0.054 
70 
(59-85) 
50 
(44-58) 
67 
(54-82) 
0.016 0.68 
PspC 
144 
(110-189) 
64 
(50-80) 
78 
(58-105) 
< 0.0001 0.003 
152 
(126-185) 
86 
(65-114) 
107 
(74-155) 
0.013 0.11 
PsaA 
156 
(142-171) 
129 
(111-150) 
122 
(111-135) 
0.09 0.045 
290 
(268-315) 
322 
(291-357) 
260 
(228-297) 
0.30 0.15 
PdB 
87 
(72-106) 
75 
(63-90) 
81 
(64-103) 
0.38 0.58 
111 
(91-135) 
85 
(68-105) 
98 
(78-125) 
0.15 0.50 
SP 2027 
693 
(585-822) 
444 
(372-530) 
512 
(415-633) 
0.001 0.08 
457 
(389-537) 
365 
(296-452) 
383 
(308-476) 
0.14 0.28 
SP 0609 
102 
(83-125) 
102 
(86-120) 
53 
(40-70) 
0.94 < 0.0001 
106 
(86-130) 
106 
(87-130) 
77 
(61-99) 
0.58 0.07 
SP 0082 
264 
(209-332) 
185 
(149-231) 
224 
(160-314) 
0.054 0.40 
434 
(357-529) 
178 
(135-234) 
310 
(199-484) 
< 0.0001 0.15 
SP 0749 
218 
(171-278) 
276 
(228-335) 
173 
(123-242) 
0.15 0.33 
162 
(122-215) 
130 
(95-178) 
149 
(105-212) 
0.41 0.72 
SP 0498 
(LytB) 
75 
(57-97) 
63 
(52-76) 
72 
(58-88) 
0.29 0.72 
92 
(68-123) 
48 
(36-65) 
94 
(66-134) 
0.007 0.99 
IgA1-proteinase 
96 
(74-123) 
62 
(52-72) 
48 
(33-69) 
0.006 < 0.0001 
73 
(53-99) 
36 
(28-46) 
76 
(50-116) 
0.001 0.81 
PpmA 
126 
(96-165) 
64 
(50-81) 
99 
(78-127) 
< 0.0001 0.30 
146 
(104-205) 
77 
(56-104) 
120 
(83-174) 
0.003 0.41 
SlrA 
135 
(115-159) 
94 
(79-110) 
80 
(67-97) 
0.005 0.001 
93 
(68-126) 
61 
(47-79) 
101 
(81-125) 
0.034 0.74 
SP 2216 
(PcsB) 
151 
(115-196) 
108 
(83-140) 
143 
(98-209) 
0.13 0.71 
275 
(224-338) 
179 
(138-233) 
216 
(140-335) 
0.051 0.32 
SP 1723 
(StkP) 
30 
(22-41) 
15 
(12-19) 
25 
(17-35) 
0.001 0.39 
59 
(41-84) 
30 
(23-40) 
55 
(37-81) 
0.002 0.72 
SP 2194 
150 
(119-190) 
167 
(141-199) 
90 
(70-116) 
0.47 0.007 
74 
(59-93) 
72 
(55-94) 
70 
(57-86) 
0.99 0.80 
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*p1= M-/I- vs M+/I+, p2 = M-/I- vs M+/I-. „GMTs in M-/I- significantly higher than in M+/I- (p2) or in M+/I+ (p1) are highlighted in red; GMTs in M-/I- significantly lower than in M+/I- (p2) or in 
M+/I+ (p1) are highlighted in blue.  
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5.3.2 Relationship between antibody titers and concurrent pneumococcal colonization 
in PCV vaccinated children  
 
Significance testing between groups was adjusted for concurrent pneumococcal 
colonization status. The overall prevalence of nasopharyngeal pneumococcal colonization 
increased with age in all groups (M-/I-, M+/I- and M+/I+). The prevalence of 
pneumococcal colonization in M-/I- children was 53 % (61/115) at 4 months of age, 58 % 
(66/113) at 10 months, 60 % (64/107) at 18 months and 71 % (70/98) by 24 months of 
age. The prevalence of pneumococcal colonization in M+/I- children was 50% (59/117) 
at 4 months of age, 59 % (63/106) at 10 months, 62 % (60/96) at 18 months and 66 % 
(62/93) by 24 months of age. The prevalence of nasopharyngeal pneumococcal 
colonization in M+/I+ children was lower compared to M-/I- children at all time-points, 
but only significantly so at 4 months of age, [41% (114/276) vs 53 % (61/115); p = 
0.024)]. Other time-point comparisons included 55% (135/243 vs 58 % (66/113); p 
=0.13) at 10 months, 58% (138/235 vs 60 % (64/107); p = 0.51) at 18 months and 64% 
(55/186) vs 71 % (70/98); p = 0.33) by 24 months age.  
 
 
Differences were observed among M-/I- PCV-vaccinated children, between 
pneumococcal-colonized compared to -uncolonized at the initial three sampling time- 
points. Significantly higher antibody titers in pneumococcal-colonized children compared 
to –uncolonized children were observed at the 4 month age time-point for PsaA, SP 0082 
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and PcsB; at the 10 month sampling point to PspC, PdB, LytB and PcsB and at the 18-
month sampling point to PspC, PsaA, and SP 0082 (refer to tables 5.1 to 5.3). By 24 
months of age, with the exception of PspA, there were no differences in antibody titers in 
PCV-7 vaccinated M-„I- children in relation to prevailing pneumococcal-colonization 
status.  
 
 
Differences in antibody titers among M+/I- children between pneumococcal-colonized 
and -uncolonized children followed similar patterns to M-/I- children in the first year of 
life; i.e. significantly higher titers were observed at both the 4 and 10 month sampling 
time-points for PspC, PdB, and PcsB (tables 5.1 and 5.2). In addition, higher titers were 
also observed in the pneumococcal-colonized children compared to -uncolonized children 
for PspA, PspC, PdB, and StkP at 4 months of age; and for SlrA and StkP at 10 months of 
age. Antibody titers against PdB, and PcsB were significantly higher in pneumococcal-
colonized compared to -uncolonized children at 18 months of age.  
 
 
M+/I+ infants colonized by pneumococci were similar to colonized M-/I- infants and 
M+/I- infants in terms of the antigens for which antibody titers showed an increase at 4 
and 10 months of age. In addition M+/I+ children who were colonized with pneumococci 
had higher antibody titers against PpmA at the 4 and 10 month age time-points compared 
to -uncolonized children. After one year of age, higher antibody titers associated with 
pneumococcal colonization were less evident in the M+/I+ group. Exceptions to this were 
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higher titers in pneumococcal-colonized compared to -uncolonized children against PspC 
and PcsB at 18 months and titers against PspC, PsaA and LytB at 24 months.  
 
 
Adjusting for HIV infection status, overall pneumococcal-colonized children had higher 
antibody titers against PspC compared to -uncolonized children at all four sampling time-
points. In addition higher antibody titers to PsaA, PdB, SP 0082, LytB, PpmA, SlrA, 
PcsB and StkP in pneumococcal-colonized compared to -uncolonized children were 
observed at the 4 and 10 month age time-points. These differences were however less 
evident in older children at the 18 to 24 months age-group sampling points; tables 5.1 to 
5.4.  
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Table 5.1: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV vaccinated M-/I-, M+/I- and M+/I+ children at approximately 4 months of age, in 
relation to pneumococcal colonization status. 
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **For differences between overall colonized and uncolonized children, p-values were adjusted for HIV exposure. 
M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in pneumococcal-colonized children significantly higher than in –uncolonized 
children are highlighted in red; GMTs in pneumococcal-colonized children significantly lower than in uncolonized children are highlighted in blue. 
Protein 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M-/I-, *GMT (95 % CI) M+/I- *GMT (95 % CI) M+/I+-, *GMT (95 % CI) 
Col. Un-col. P Col. Un-col. P Col. Un-col. P 
PspA 
6 
(5-7) 
3 
(3-4) 
< 
0.0001 
13 
(10-18) 
9 
(7-14) 
0.11 
6 
(4-8) 
3 
(2-5) 
0.008 
3 
(2-5) 
2 
(2-3) 
0.004 
PspC 
16 
(13-19) 
6 
(5-7) 
< 
0.0001 
24 
(18-30) 
18 
(14-25) 
0.18 
16 
(12-23) 
5 
(4-7) 
< 0.0001 
12 
(9-17) 
4 
(3-5) 
< 0.0001 
PsaA 
17 
(14-20) 
9 
(7-10) 
< 
0.0001 
19 
(15-25) 
8 
(5-13) 
0.002 
14 
(10-20) 
8 
(5-13) 
0.041 
16 
(12-22) 
9 
(7-11) 
0.002 
PdB 
9 
(7-10) 
4 
(4-5) 
< 
0.0001 
9 
(7-11) 
7 
(5-9) 
0.11 
7 
(5-10) 
4 
(3-4) 
< 0.0001 
10 
(7-13) 
4 
(3-5) 
< 0.0001 
SP 2027 
216 
(191-243) 
242 
(215-271) 
0.13 
268 
(211-342) 
246 
(197-308) 
0.60 
194 
(159-237) 
264 
(205-340) 
0.06 
200 
(166-241) 
231 
(197-270) 
0.25 
SP 0609 
113 
(96-132) 
120 
(106-137) 
0.50 
129 
(99-168) 
133 
(99-177) 
0.90 
97 
(72-131) 
117 
(90-153 
0.34 
114 
(88-148) 
117 
(98-140) 
0.84 
SP 0082 
27 
(22-34) 
16 
(13-19) 
0.001 
47 
(36-61) 
31 
(23-42) 
0.040 
28 
(19-40) 
18 
(13-25) 
0.07 
19 
(13-29) 
11 
(9-15) 
0.022 
SP 0749 
34 
(30-40) 
37 
(32-42) 
0.68 
31 
(25-39) 
28 
(21-36) 
0.47 
33 
(24-44) 
33 
(25-44) 
0.95 
37 
(29-47) 
43 
(35-52) 
0.37 
(SP 0498) 
LytB 
21 
(18-25) 
16 
(14-18) 
0.015 
32 
(26-41) 
26 
(19-34) 
0.21 
19 
(15-25) 
16 
(13-20) 
0.36 
18 
(13-23) 
13 
(11-16) 
0.06 
IgA1-
proteinase 
16 
(14-19) 
15 
(13-16) 
0.55 
24 
(20-30) 
27 
(21-34) 
0.46 
15 
(11-20) 
12 
(10-14) 
0.16 
13 
(11-17) 
13 
(11-15) 
0.80 
PpmA 
12 
(10-15) 
7 
(6-9) 
< 
0.0001 
18 
(13-24) 
13 
(9-19) 
0.22 
10 
(7-14) 
8 
(6-10) 
0.20 
10 
(7-15) 
6 
(5-7) 
0.002 
SlrA 
30 
(25-35) 
23 
(20-27) 
0.033 
30 
(22-39) 
22 
(17-29) 
0.15 
31 
(23-41) 
27 
(20-35) 
0.48 
29 
(22-38) 
22 
(18-27) 
0.13 
SP 2216 
(PcsB) 
34 
(27-43) 
12 
(10-15) 
< 
0.0001 
51 
(35-74) 
29 
(20-42) 
0.030 
37 
(25-56) 
12 
(8-17) 
< 0.0001 
25 
(17-38) 
9 
(7-12) 
< 0.0001 
SP 1723 
(StkP) 
12 
(11-14) 
9 
(8-10) 
0.003 
18 
(14-23) 
15 
(11-19) 
0.25 
14 
(11-17) 
10 
(8-13) 
0.051 
9 
(7-12) 
7 
(6-8) 
0.034 
SP 2194 
110 
(95-126) 
124 
(109-142) 
0.19 
138 
(106-179) 
116 
(87-156) 
0.38 
97 
(73-130) 
124 
(93-164) 
0.24 
102 
(83-125) 
128 
(107-153) 
0.11 
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Table 5.2: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV vaccinated M-/I-, M+/I- and M+/I+ children at approximately 10 months of age, in 
relation to pneumococcal colonization status. 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **For differences between overall colonized and uncolonized children, p-values were adjusted for HIV exposure. 
M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMT‟s in pneumococcal-colonized children significantly higher than in –uncolonized 
children are highlighted in red; GMTs in pneumococcal-colonized children significantly lower than in uncolonized children are highlighted in blue. 
Protein 
Colonized
 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M-/I-, *GMT (95 % CI) M+/I- *GMT (95 % CI) M+/I+-, *GMT (95 % CI) 
Col. Un-col. P Col. Un-col. P Col. Un-col. P 
PspA 
34 
(29-39) 
30 
(25-36) 
0.45 
48 
(37-64) 
41 
(29-58) 
0.17 
39 
(30-50) 
29 
(19-43) 
0.17 
25 
(20-31) 
27 
(21-34) 
0.66 
PspC 
108 
(90-129) 
19 
(14-26) 
< 0.0001 
118 
(88-160) 
31 
(16-61) 
< 0.0001 
119 
(86-166) 
28 
(15-51) 
< 0.0001 
96 
(70-131) 
12 
(8-19) 
< 0.0001 
PsaA 
94 
(86-103) 
78 
(69-87) 
0.009 
98 
(84-114) 
83 
(69-99) 
0.18 
85 
(73-99) 
76 
(61-95) 
0.40 
97 
(84-112) 
76 
(64-90) 
0.032 
PdB 
50 
(42-61) 
20 
(15-25) 
< 0.0001 
66 
(47-93) 
29 
(17-49) 
0.007 
43 
(30-62) 
19 
(11-33) 
0.010 
47 
(35-63) 
17 
(12-24) 
< 0.0001 
SP 2027 
314 
(392-342) 
448 
(360-558) 
0.64 
671 
(542-830) 
508 
(368-703) 
0.14 
666 
(534-829) 
566 
(402-798) 
0.40 
340 
(259-447) 
376 
(260-543) 
0.66 
SP 0609 
126 
(107-148) 
114 
(92-142) 
0.51 
149 
(112-198) 
109 
(75-158) 
0.19 
112 
(88-141) 
92 
(68-126) 
0.31 
121 
(91-160) 
131 
(91-189) 
0.72 
SP 0082 
147 
(119-182) 
47 
(34-64) 
< 0.0001 
195 
(138-277) 
113 
(65-195) 
0.07 
170 
(121-238) 
34 
(21-55) 
< 0.0001 
113 
(79-163) 
38 
(24-62) 
< 0.0001 
SP 0749 
88 
(69-113) 
76 
(58-101) 
0.43 
91 
(57-146) 
61 
(39-95) 
0.27 
65 
(41-103) 
69 
(41-114) 
0.87 
103 
(70-151) 
89 
(57-138) 
0.63 
(SP 0498) 
LytB 
64 
(53-78) 
30 
(21-35) 
< 0.0001 
72 
(52-100) 
31 
(18-55) 
0.007 
87 
(61-123) 
26 
(15-42) 
< 0.0001 
50 
(37-69) 
26 
(18-39) 
0.009 
IgA1-
proteinase 
38 
(32-46) 
27 
(22-34) 
0.041 
51 
(35-74) 
45 
(27-76) 
0.70 
40 
(26-60) 
24 
(16-37) 
0.10 
31 
(24-41) 
23 
(17-32) 
0.15 
PpmA 
62 
(50-77) 
23 
(17-31) 
< 0.0001 
91 
(65-127) 
58 
(32-107) 
0.16 
48 
(32-74) 
25 
(13-46) 
0.06 
56 
(39-80) 
15 
(10-23) 
< 0.0001 
SlrA 
91 
(76-108) 
50 
(42-61) 
< 0.0001 
111 
(82-149) 
105 
(69-159) 
0.84 
80 
(58-110) 
42 
(29-62) 
0.012 
86 
(64-116) 
40 
(31-53) 
< 0.0001 
SP 2216 
(PcsB) 
111 
(90-137) 
24 
(16-34) 
< 0.0001 
106 
(77-146) 
34 
(16-74) 
0.002 
92 
(64-133) 
46 
(28-76) 
0.023 
126 
(87-183) 
14 
(8-25) 
< 0.0001 
SP 1723 
(StkP) 
15 
(12-18) 
6 
(4-7) 
< 0.0001 
20 
(14-28) 
13 
(8-23) 
0.20 
13 
(9-19) 
5 
(3-9) 
0.006 
14 
(10-19) 
4 
(3-6) 
< 0.0001 
SP 2194 
123 
(105-143) 
117 
(96-143) 
0.76 
153 
(116-200) 
105 
(75-146) 
0.10 
107 
(83-139) 
101 
(71-142) 
0.75 
115 
(88-151) 
133 
(97-183) 
0.49 
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Table 5.3: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV vaccinated M-/I-, M+/I- and M+/I+ children at approximately 18 months of age, in 
relation to pneumococcal colonization status. 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **For differences between overall colonized and uncolonized children, p-values were adjusted for HIV exposure. 
M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMT‟s in pneumococcal-colonized children significantly higher than in –uncolonized 
children are highlighted in red; GMTs in pneumococcal-colonized children significantly lower than in uncolonized children are highlighted in blue. 
Protein 
Colonized
 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M-/I-, *GMT (95 % CI) M+/I- *GMT (95 % CI) M+/I+-, *GMT (95 % CI) 
Col. Un-col. P Col. Un-col. P Col. Un-col. P 
PspA 
40 
(35-46) 
42 
(36-48) 
0.60 
56 
(42-73) 
50 
(36-70) 
0.63 
40 
(31-51) 
41 
(29-58) 
0.89 
33 
(28-40) 
38 
(32-46) 
0.28 
PspC 
107 
(90-128) 
60 
(45-79) 
< 
0.0001 
198 
(154-256) 
93 
(56-157) 
0.005 
92 
(67-127) 
55 
(29-107) 
0.10 
82 
(62-107) 
49 
(33-72) 
0.03 
PsaA 
142 
(127-160) 
126 
(111-143) 
0.14 
173 
(153-196) 
134 
(116-155) 
0.008 
124 
(109-140) 
118 
(101-138) 
0.68 
136 
(109-169) 
124 
(100-153) 
0.53 
PdB 
90 
(77-104) 
69 
(57-83) 
0.027 
102 
(80-129) 
70 
(50-97) 
0.06 
98 
(79-122) 
55 
(31-97) 
0.021 
80 
(62-103) 
72 
(56-92) 
0.56 
SP 2027 
500 
(428-584) 
540 
(457-639) 
0.43 
676 
(546-835) 
717 
(537-957) 
0.73 
518 
(392-685) 
500 
(362-690) 
0.87 
415 
(320-538) 
482 
(377-615) 
0.41 
SP 0609 
83 
(70-98) 
99 
(84-117) 
0.28 
96 
(75-1250 
111 
(78-156) 
0.52 
51 
(36-74) 
57 
(37-87) 
0.73 
95 
(73-124) 
109 
(89-134) 
0.41 
SP 0082 
236 
(195-287) 
184 
(146-231) 
0.11 
320 
(248-414) 
202 
(133-308) 
0.050 
252 
(176-361) 
175 
(82-375) 
0.32 
193 
(139-268) 
178 
(133-238) 
0.71 
SP 0749 
203 
(168-245) 
293 
(239-358) 
0.021 
202 
(146-279) 
240 
(164-352) 
0.49 
131 
(88-196) 
306 
(169-552) 
0.018 
251 
(190-331) 
318 
(243-415) 
0.23 
(SP 0498) 
LytB 
77 
(66-90) 
57 
(46-70) 
0.027 
80 
(60-107) 
68 
(41-111) 
0.53 
81 
(65-100) 
56 
(35-91) 
0.11 
73 
(56-96) 
52 
(41-68) 
0.08 
IgA1-
proteinase 
67 
(57-80) 
65 
(52-79) 
0.65 
97 
(70-134) 
93 
(61-142) 
0.87 
51 
(33-78) 
42 
(21-86) 
0.63 
61 
(50-78) 
61 
(48-77) 
0.85 
PpmA 
88 
(72-109) 
79 
(61-102) 
0.65 
145 
(104-203) 
103 
(64-165) 
0.22 
91 
(67-123) 
120 
(77-187) 
0.29 
66 
(47-93) 
62 
(43-90) 
0.83 
SlrA 
102 
(88-118) 
100 
(86-116) 
0.73 
141 
(114-174) 
128 
(99-165) 
0.56 
83 
(65-104) 
76 
(57-103) 
0.69 
94 
(73-121) 
95 
(76-118) 
0.97 
SP 2216 
(PcsB) 
154 
(127-188) 
94 
(70-128) 
0.008 
156 
(113-215) 
143 
(90-228) 
0.74 
188 
(133-265) 
82 
(33-206) 
0.039 
140 
(100-194) 
80 
(53-122) 
0.038 
SP 1723 
(StkP) 
23 
(18-29) 
17 
(13-22) 
0.11 
35 
(24-52) 
24 
(14-41) 
0.26 
27 
(17-40) 
21 
(9-44) 
0.52 
17 
(12-25) 
13 
(9-19) 
0.33 
SP 2194 
134 
(114-159) 
159 
(132-191) 
0.35 
140 
(102-191) 
167 
(116-241) 
0.45 
96 
(69-135) 
79 
(56-113) 
0.48 
154 
(120-197) 
187 
(145-240) 
0.28 
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Table 5.4: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV vaccinated M-/I-, M+/I- and M+/I+ children at approximately 24 months of age, in 
relation to pneumococcal colonization status. 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **For differences between overall colonized and uncolonized children, p-values were adjusted for HIV exposure. 
M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMT‟s in pneumococcal-colonized children significantly higher than in –uncolonized 
children are highlighted in red; GMTs in pneumococcal-colonized children significantly lower than in uncolonized children are highlighted in blue. 
Protein 
Colonized
 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**p 
(adj.) 
M-/I-, *GMT (95 % CI) M+/I- *GMT (95 % CI) M+/I+-, *GMT (95 % CI) 
Col. Un-col. P Col. Un-col. P Col. Un-col. P 
PspA 
65 
(57-74) 
53 
(45-62) 
0.08 
85 
(67-108) 
48 
(37-63) 
0.004 
60 
(46-79) 
86 
(64-115) 
0.13 
56 
(46-68) 
46 
(36-58) 
0.20 
PspC 
129 
(105-158) 
82 
(62-109) 
0.015 
160 
(126-203) 
133 
(95-188) 
0.37 
98 
(58-163) 
134 
(100-181) 
0.44 
131 
(95-180) 
52 
(32-84) 
0.001 
PsaA 
301 
(277-327) 
276 
(257-296) 
0.10 
293 
(261-328) 
287 
(258-319) 
0.83 
257 
(214-308) 
269 
(244-297) 
0.74 
341 
(298-391) 
271 
(240-307) 
0.020 
PdB 
103 
(89-120) 
85 
(66-108) 
0.18 
114 
(92-141) 
102 
(67-154) 
0.59 
97 
(72-131) 
101 
(69-148) 
0.89 
99 
(77-129) 
71 
(48-106) 
0.15 
SP 2027 
404 
(347-470) 
384 
(313-471) 
0.73 
451 
(374-545) 
467 
(337-647) 
0.84 
391 
(298-515) 
361 
(247-527) 
0.74 
379 
(283-507) 
352 
(252-491) 
0.74 
SP 0609 
107 
(91-127) 
87 
(73-103) 
0.06 
115 
(89-149) 
85 
(60-122) 
0.18 
81 
(58-113) 
69 
(56-85) 
0.55 
123 
(93-161) 
95 
(72-126) 
0.21 
SP 0082 
287 
(228-362) 
254 
(192-336) 
0.71 
409 
(315-531) 
490 
(359-667) 
0.40 
280 
(154-508) 
403 
(242-670) 
0.46 
224 
(158-317) 
147 
(94-229) 
0.13 
SP 0749 
152 
(120-193) 
137 
(100-187) 
0.64 
177 
(123-255) 
139 
(85-228) 
0.43 
133 
(89-197) 
201 
(94-430) 
0.29 
149 
(96-232) 
117 
(73-190) 
0.48 
(SP 0498) 
LytB 
80 
(64-101) 
54 
(38-75) 
0.08 
97 
(68-139) 
81 
(45-146) 
0.58 
90 
(57-140) 
105 
(56-140) 
0.68 
65 
(45-94) 
33 
(19-55) 
0.031 
IgA1-
proteinase 
58 
(46-73) 
44 
(33-60) 
0.32 
71 
(47-106) 
71 
(42-121) 
0.99 
75 
(44-128) 
80 
(42-151) 
0.88 
42 
(31-58) 
27 
(18-41) 
0.10 
PpmA 
113 
(88-144) 
84 
(59-119) 
0.25 
155 
(101-236) 
135 
(72-254) 
0.72 
113 
(71-179) 
140 
(75-263) 
0.60 
89 
(60-132) 
53 
(32-89) 
0.11 
SlrA 
85 
(70-104) 
67 
(50-89) 
0.24 
100 
(70-142) 
80 
(43-150) 
0.50 
98 
(75-128) 
109 
(74-162) 
0.64 
69 
(49-99) 
50 
(33-75) 
0.23 
SP 2216 
(PcsB) 
217 
(172-273) 
214 
(169-271) 
0.97 
249 
(189-328) 
326 
(239-444) 
0.22 
201 
(110-367) 
261 
(187-363) 
0.59 
205 
(144-292) 
156 
(104-233) 
0.31 
SP 1723 
(StkP) 
46 
(35-59) 
37 
(27-50) 
0.45 
61 
(39-96) 
57 
(30-108) 
0.87 
50 
(30-84) 
68 
(44-106) 
0.48 
35 
(23-51) 
23 
(15-35) 
0.14 
SP 2194 
74 
(62-89) 
70 
(54-91) 
0.68 
73 
(54-97) 
76 
(53-111) 
0.83 
71 
(54-92) 
69 
(51-95) 
0.96 
78 
(55-111) 
67 
(42-106) 
0.56 
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5.4 Natural immune responses in M-/I- and M+/I- children aged between 4 and 24 months 
in relation to PCV-vaccination status  
 
Vaccination with PCV-7 was associated with significant differences in antibody titers to selected 
proteins during the first two years of life in M-/I- and M+/I- children, including when adjusted 
for overall pneumococcal colonization status. At 4 months of age, PCV vaccinated children had 
lower antibody titers to PspA, PspC, PsaA, PdB, SP 2027, SP 0749, LytB, IgA1-proteinase, 
PpmA, SlrA and StkP, among M-/I- and M+/I- groups compared to PCV-unvaccinated children. 
Conversely, PCV-recipients had higher antibody titers against SP 0609 compared to PCV-
unvaccinated children. Antibodies against SP 0082 and PcsB did not differ by PCV vaccination 
status in either M-/I- or M+/I- infants at 4 months (refer to tables 6.1 and 6.5).  
 
At 10 months of age, antibodies titers against PspA, PsaA, PdB, IgA1-proteinase, SlrA, and StkP 
remained higher in PCV-unvaccinated compared to -vaccinated infants in M-/I- and M+/I- 
groups. Receipt of PCV was, however, associated with higher antibody titers in the M-/I- group 
to SP 0609, SP 0082, and PpmA. In the M+/I- groups, PCV-vaccination was associated with 
significantly lower antibody titers to SP 0609, LytB, and SP 2194 (refer to tables 6.2 and 6.6). 
 
At 18 months of age, PCV-recipients still had lower antibody titers against PspA, and LytB, but 
higher titers against SP 2027, SP 0082, SP 0749 and PpmA in both M-/I- and M+/I- groups. M-
/I- children had significantly lower titers against PdB in the PCV-vaccinated group, and PCV-
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vaccinated M+/I- children had significantly lower antibody titers against PspC, PsaA, SP 0609, 
IgA1-proteinase and SP 2194 (refer to tables 6.3 and 6.7). 
 
At 24 months of age, differences in the effect of PCV-vaccination and HIV exposure on titers 
against pneumococcal antigens were still noticeable. PCV-vaccination was associated with lower 
antibody titers against PspA, PdB, LytB and SP 2194; but higher antibody titers against PsaA 
and SP 0082 in both M-/I- and M+/I- groups. Additionally, PCV-vaccinated, M+/I- children had 
significantly lower antibody titers against IgA1-proteinase and higher titers against PpmA, SP 
0749 and PcsB. Antibody titers against SP 0749 were  observed to be higher in PCV-vaccinated 
M+/I- children at this time-point (refer to tables 6.4 and 6.8). 
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Table 6.1: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M-/I- children at approximately 4 months of age 
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M-/I- 
PCV-
vaccinated 
*GMT 
(95 % CI) 
M-/I- 
PCV-
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
PCV-
vaccinated 
GMT 
(95 % CI) 
Uncolonized 
PCV-
unvaccinated 
GMT 
(95 % CI) 
p 
Colonized 
PCV-
vaccinated 
*GMT 
(95 % CI) 
Colonized 
PCV-
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
11 
(9-14) 
47 
(40-55) 
< 0.0001 
9 
(7-14) 
50 
(40-64) 
< 0.0001 
13 
(10-18) 
44 
(36-55) 
< 0.0001 
PspC 
21 
(17-(25) 
60 
(54-67) 
< 0.0001 
18 
(14-25) 
55 
(47-65) 
< 0.0001 
24 
(18-30) 
65 
(56-76) 
< 0.0001 
PsaA 
13 
(10-17) 
182 
(158-211) 
< 0.0001 
8 
(5-13) 
197 
(159-244) 
< 0.0001 
19 
(15-25) 
170 
(139-208) 
< 0.0001 
PdB 
8 
(6-9) 
45 
(39-52) 
< 0.0001 
7 
(5-9) 
43 
(34-53) 
< 0.0001 
9 
(7-11) 
47 
(38-58) 
< 0.0001 
SP 2027 
258 
(219-303) 
571 
(491-663) 
< 0.0001 
246 
(197-308) 
578 
(462-725) 
< 0.0001 
268 
(211-342) 
563 
(458-694) 
< 0.0001 
SP 0609 
131 
(108-159) 
79 
(67-94) 
< 0.0001 
133 
(99-177) 
84 
(65-108) 
0.019 
129 
(99-168) 
75 
(60-94) 
0.002 
SP 0082 
39 
(32-47) 
39 
(35-45) 
0.88 
31 
(23-42) 
38 
(31-46) 
0.30 
47 
(36-61) 
41 
(35-48) 
0.40 
SP 0749 
30 
(25-35) 
124 
(102-151) 
< 0.0001 
28 
(21-36) 
143 
(106-192) 
< 0.0001 
31 
(25-39) 
110 
(84-143) 
< 0.0001 
SP 0498 
(LytB) 
29 
(24-35) 
38 
(34-43) 
0.008 
26 
(19-34) 
35 
(29-41) 
0.07 
32 
(26-41) 
42 
(36-49) 
0.051 
IgA1-proteinase 
25 
(22-30) 
61 
(53-69) 
< 0.0001 
27 
(21-34) 
61 
(51-75) 
< 0.0001 
24 
(20-30) 
60 
(49-73) 
< 0.0001 
PpmA 
16 
(12-20) 
41 
(35-48) 
< 0.0001 
13 
(9-19) 
36 
(28-46) 
< 0.0001 
18 
(13-24) 
46 
(37-57) 
< 0.0001 
SlrA 
26 
(21-31) 
185 
(158-216) 
< 0.0001 
22 
(17-29) 
211 
(169-263) 
< 0.0001 
30 
(22-39) 
165 
(132-206) 
< 0.0001 
SP 2216 
(PcsB) 
39 
(30-51) 
33 
(28-39) 
0.28 
29 
(20-42) 
28 
(22-36) 
0.89 
51 
(35-74) 
39 
(31-47) 
0.17 
SP 1723 
(StkP) 
16 
(14-20) 
29 
(26-33) 
< 0.0001 
15 
(11-19) 
27 
(22-32) 
< 0.0001 
18 
(14-23) 
31 
(27-37) 
< 0.0001 
SP 2194 
127 
(105-154) 
141 
(119-168) 
0.41 
116 
(87-156) 
162 
(131-202) 
0.07 
138 
(106-179) 
125 
(96-162) 
0.60 
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Table 6.2: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M-/I- children at approximately 10 months of age 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M-/I- 
vaccinated 
*GMT 
(95 % CI) 
M-/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
*GMT 
(95 % CI) 
Uncolonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT 
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
46 
(37-57) 
116 
(98-138) 
< 0.0001 
41 
(29-58) 
122 
(97-152) 
< 0.0001 
48 
(37-64) 
115 
(93-142) 
< 0.0001 
PspC 
75 
(55-104) 
100 
(83-120) 
0.34 
31 
(16-61) 
44 
(27-73) 
0.35 
118 
(88-160) 
126 
(107-148) 
0.71 
PsaA 
93 
(83-104) 
174 
(153-199) 
< 0.0001 
83 
(69-99) 
167 
(133-211) 
< 0.0001 
98 
(84-114) 
177 
(151-206) 
< 0.0001 
PdB 
50 
(37-67) 
98 
(80-119) 
0.001 
29 
(17-49) 
57 
(38-86) 
0.045 
66 
(47-93) 
114 
(92-142) 
0.006 
SP 2027 
611 
(512-729) 
561 
(445-706) 
0.51 
508 
(368-703) 
664 
(464-951) 
0.35 
671 
(542-830) 
534 
(404-707) 
0.22 
SP 0609 
134 
(107-168) 
88 
(73-107) 
0.004 
109 
(75-158) 
87 
(60-127) 
0.45 
149 
(112-198) 
88 
(71-111) 
0.004 
SP 0082 
162 
(121-218) 
83 
(67-104) 
< 0.0001 
113 
(65-195) 
37 
(23-60) 
0.006 
195 
(138-277) 
105 
(83-133) 
0.003 
SP 0749 
79 
(56-112) 
57 
(44-73) 
0.10 
61 
(39-95) 
59 
(35-97) 
0.95 
91 
(57-146) 
57 
(42-76) 
0.07 
SP 0498 
(LytB) 
54 
(40-73) 
85 
(67-106) 
0.06 
31 
(18-55) 
38 
(23-63) 
0.58 
72 
(52-100) 
106 
(83-135) 
0.06 
IgA1-proteinase 
49 
(36-66) 
77 
(60-10) 
0.040 
45 
(27-76) 
52 
(30-90) 
0.76 
51 
(35-74) 
87 
(64-117) 
0.027 
PpmA 
78 
(58-105) 
47 
(36-62) 
0.004 
58 
(32-107) 
23 
(12-41) 
0.036 
91 
(65-127) 
60 
(43-78) 
0.045 
SlrA 
109 
(85-138) 
185 
(157-217) 
< 0.0001 
105 
(69-159) 
191 
(143-256) 
0.022 
111 
(82-149) 
183 
(150-222) 
0.004 
SP 2216 
(PcsB) 
72 
(51-102) 
96 
(74-124) 
0.47 
34 
(16-74) 
32 
(17-60) 
0.96 
106 
(77-146) 
131 
(103-167) 
0.29 
SP 1723 
(StkP) 
17 
(13-23) 
30 
(24-37) 
0.007 
13 
(8-23) 
17 
(10-28) 
0.50 
20 
(14-28) 
35 
(28-45) 
0.005 
SP 2194 
134 
(109-166) 
159 
(131-191) 
0.25 
105 
(75-146) 
194 
(143-264) 
0.006 
153 
(116-200) 
150 
(119-187) 
0.91 
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Table 6.3: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M-/I- children at approximately 18 months of age  
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M-/I- 
vaccinated 
*GMT 
(95 % CI) 
M-/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
*GMT 
(95 % CI) 
Uncolonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT 
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
53 
(43-66) 
131 
(105-164) 
< 0.0001 
50 
(36-70) 
143 
(101-201) 
0.001 
56 
(42-73) 
128 
(97-168) 
< 0.0001 
PspC 
144 
(110-189) 
131 
(110-155) 
0.15 
93 
(56-157) 
87 
(52-147) 
0.84 
198 
(154-256) 
147 
(125-173) 
0.042 
PsaA 
156 
(142-171) 
158 
(134-186) 
0.64 
134 
(116-155) 
141 
(104-189) 
0.74 
173 
(153-196) 
155 
(128-188) 
0.49 
PdB 
87 
(72-106) 
130 
(108-156) 
0.020 
70 
(50-97) 
114 
(101-198) 
0.051 
102 
(80-129) 
126 
(101-157) 
0.14 
SP 2027 
693 
(585-822) 
285 
(222-365) 
< 0.0001 
717 
(537-957) 
389 
(253-597) 
0.023 
676 
(546-835) 
260 
(193-349) 
< 0.0001 
SP 0609 
102 
(83-125) 
121 
(90-164) 
0.39 
111 
(78-156) 
116 
(87-247) 
0.81 
96 
(75-1250 
115 
(81-165) 
0.39 
SP 0082 
264 
(209-332) 
130 
(106-159) 
< 0.0001 
202 
(133-308) 
102 
(67-157) 
0.031 
320 
(248-414) 
139 
(111-176) 
< 0.0001 
SP 0749 
218 
(171-278) 
84 
(58-121) 
< 0.0001 
240 
(164-352) 
89 
(46-174) 
0.020 
202 
(146-279) 
82 
(53-127) 
0.002 
SP 0498 
(LytB) 
75 
(57-97) 
164 
(135-200) 
< 0.0001 
68 
(41-111) 
113 
(72-177) 
0.16 
80 
(60-107) 
183 
(148-227) 
< 0.0001 
IgA1-proteinase 
96 
(74-123) 
90 
(65-125) 
0.82 
93 
(61-142) 
108 
(69-201) 
0.67 
97 
(70-134) 
84 
(56-124) 
0.61 
PpmA 
126 
(96-165) 
63 
(46-85) 
< 0.0001 
103 
(64-165) 
48 
(26-89) 
0.014 
145 
(104-203) 
68 
(48-97) 
0.007 
SlrA 
135 
(115-159) 
124 
(97-158) 
0.53 
128 
(99-165) 
136 
(88-211) 
0.70 
141 
(114-174) 
120 
(89-161) 
0.61 
SP 2216 
(PcsB) 
151 
(115-196) 
157 
(120-205) 
0.96 
143 
(90-228) 
142 
(89-226) 
0.95 
156 
(113-215) 
161 
(117-223) 
0.92 
SP 1723 
(StkP) 
30 
(22-41) 
39 
(29-52) 
0.46 
24 
(14-41) 
29 
(16-50) 
0.93 
35 
(24-52) 
43 
(30-60) 
0.40 
SP 2194 
150 
(119-190) 
144 
(113-185) 
0.88 
167 
(116-241) 
240 
(173-334) 
0.41 
140 
(102-191) 
124 
(92-167) 
0.75 
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Table 6.4: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M-/I- children at approximately 24 months of age  
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M-/I- 
vaccinated 
*GMT 
(95 % CI) 
M-/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
*GMT 
(95 % CI) 
Uncolonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT 
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
70 
(59-85) 
158 
(129-192) 
< 0.0001 
48 
(37-63) 
127 
(82-197) 
< 0.0001 
85 
(67-108) 
169 
(135-212) 
< 0.0001 
PspC 
152 
(126-185) 
169 
(152-188) 
0.35 
133 
(95-188) 
146 
(105-205) 
0.69 
160 
(126-203) 
177 
(161-195) 
0.38 
PsaA 
290 
(268-315) 
176 
(150-207) 
< 0.0001 
287 
(258-319) 
152 
(111-209) 
< 0.0001 
293 
(261-328) 
185 
(156-224) 
< 0.0001 
PdB 
111 
(91-135) 
147 
(125-173) 
0.036 
102 
(67-154) 
113 
(79-162) 
0.70 
114 
(92-141) 
160 
(133-191) 
0.018 
SP 2027 
457 
(389-537) 
476 
(403-562) 
0.96 
467 
(337-647) 
680 
(338-1368) 
0.31 
451 
(374-545) 
391 
(253-605) 
0.60 
SP 0609 
106 
(86-130) 
113 
(91-139) 
0.69 
85 
(60-122) 
100 
(65-154) 
0.57 
115 
(89-149) 
117 
(92-150) 
0.91 
SP 0082 
434 
(357-529) 
189 
(116-215) 
< 0.0001 
490 
(359-667) 
179 
(135-236) 
< 0.0001 
409 
(315-531) 
192 
(166-223) 
< 0.0001 
SP 0749 
162 
(122-215) 
106 
(84-134) 
0.020 
139 
(85-228) 
117 
(74-185) 
0.60 
177 
(123-255) 
103 
(78-135) 
0.016 
SP 0498 
(LytB) 
92 
(68-123) 
204 
(176-236) 
< 0.0001 
81 
(45-146) 
184 
(131-259) 
0.019 
97 
(68-139) 
210 
(179-248) 
< 0.0001 
IgA1-proteinase 
73 
(53-99) 
134 
(106-169) 
0.002 
71 
(42-121) 
94 
(55-160) 
0.46 
71 
(47-106) 
150 
(116-194) 
0.001 
PpmA 
146 
(104-205) 
98 
(75-128) 
0.048 
135 
(72-254) 
78 
(45-137) 
0.19 
155 
(101-236) 
105 
(77-143) 
0.13 
SlrA 
93 
(68-126) 
124 
(98-158) 
0.15 
80 
(43-150) 
112 
(67-186) 
0.32 
100 
(70-142) 
126 
(102-156) 
0.31 
SP 2216 
(PcsB) 
275 
(224-338) 
208 
(185-234) 
0.024 
326 
(239-444) 
201 
(151-269) 
0.024 
249 
(189-328) 
210 
(185-239) 
0.22 
SP 1723 
(StkP) 
59 
(41-84) 
61 
(49-75) 
0.99 
57 
(30-108) 
47 
(29-78) 
0.64 
61 
(39-96) 
66 
(52-83) 
0.73 
SP 2194 
74 
(59-93) 
125 
(101-153) 
0.001 
76 
(53-111) 
147 
(99-218) 
0.017 
73 
(54-97) 
118 
(92-151) 
0.012 
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Table 6.5: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M+/I- children at approximately 4 months of age  
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccina ted and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M+/I- 
vaccinated 
*GMT   
(95 % CI) 
M+/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
GMT  
(95 % CI) 
Uncolonized 
unvaccinated 
GMT  
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT  
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
 (95 % CI) 
p 
PspA 
4 
(3-6) 
33 
(29-37) 
< 0.0001 
3 
(2-5) 
31 
(25-40) 
< 0.0001 
6 
(4-8) 
34 
(30-38) 
< 0.0001 
PspC 
9 
(7-12) 
47 
(42-55) 
< 0.0001 
5 
(4-7) 
37 
(29-48) 
< 0.0001 
16 
(12-23) 
54 
(46-63) 
< 0.0001 
PsaA 
11 
(8-14) 
249 
(223-278) 
< 0.0001 
8 
(5-13) 
232 
(186-289) 
< 0.0001 
14 
(10-20) 
258 
(227-293) 
< 0.0001 
PdB 
5 
(5-6) 
35 
(30-41) 
< 0.0001 
7 
(5-10) 
28 
(21-36) 
< 0.0001 
4 
(3-4) 
39 
(32-47) 
< 0.0001 
SP 2027 
227 
(195-268) 
556 
(444-696) 
< 0.0001 
264 
(205-340) 
527 
(339-819) 
0.004 
194 
(159-237) 
570 
(437-743) 
< 0.0001 
SP 0609 
107 
(88-130) 
67 
(56-81) 
0.002 
117 
(90-153 
72 
(50-103) 
0.028 
97 
(72-131) 
65 
(53-81) 
0.024 
SP 0082 
22 
(17-28) 
30 
(24-36) 
0.16 
18 
(13-25) 
25 
(17-35) 
0.20 
28 
(19-40) 
32 
(26-41) 
0.46 
SP 0749 
33 
(27-40) 
107 
(91-126) 
< 0.0001 
33 
(25-44) 
87 
(67-113) 
< 0.0001 
33 
(24-44) 
118 
(96-144) 
< 0.0001 
SP 0498 
(LytB) 
17 
(15-21) 
26 
(21-31) 
0.009 
16 
(13-20) 
22 
(15-31) 
0.14 
19 
(15-25) 
28 
(22-34) 
0.032 
IgA1-proteinase 
13 
(11-16) 
31 
(26-38) 
< 0.0001 
12 
(10-14) 
25 
(18-34) 
< 0.0001 
15 
(11-20) 
35 
(29-44) 
< 0.0001 
PpmA 
9 
(7-11) 
24 
(20-30) 
< 0.0001 
8 
(6-10) 
20 
(13-30) 
< 0.0001 
10 
(7-14) 
27 
(22-33) 
< 0.0001 
SlrA 
29 
(23-35) 
119 
(104-136) 
< 0.0001 
27 
(20-35) 
115 
(87-152) 
< 0.0001 
31 
(23-41) 
122 
(105-141) 
< 0.0001 
SP 2216 
(PcsB) 
21 
(15-28) 
26 
(20-34) 
0.18 
12 
(8-17) 
14 
(8-25) 
0.51 
37 
(25-56) 
35 
(29-45) 
0.71 
SP 1723 
 (StkP) 
12 
(10-14) 
21 
(18-23) 
< 0.0001 
10 
(8-13) 
18 
(14-23) 
0.001 
14 
(11-17) 
22 
(19-25) 
< 0.0001 
SP 2194 
110 
(90-134) 
168 
(145-193 
0.001 
124 
(93-164) 
155 
(116-207) 
0.30 
97 
(73-130) 
174 
(148-204) 
< 0.0001 
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Table 6.6: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M+/I- children at approximately 10 months of age 
 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M+/I- 
vaccinated 
*GMT 
(95 % CI) 
M+/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
*GMT 
(95 % CI) 
Uncolonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT 
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
34 
(28-43) 
101 
(84-120) 
< 0.0001 
29 
(19-43) 
102 
(71-146) 
< 0.0001 
39 
(30-50) 
100 
(82-123) 
< 0.0001 
PspC 
66 
(47-93) 
93 
(78-110) 
0.17 
28 
(15-51) 
70 
(49-101) 
0.016 
119 
(86-166) 
106 
(89-127) 
0.49 
PsaA 
81 
(72-92) 
193 
(167-222) 
< 0.0001 
76 
(61-95) 
179 
(138-233) 
< 0.0001 
85 
(73-99) 
199 
(168-236) 
< 0.0001 
PdB 
31 
(23-43) 
73 
(58-93) 
< 0.0001 
19 
(11-33) 
71 
(45-113) 
< 0.0001 
43 
(30-62) 
74 
(56-98) 
0.014 
SP 2027 
624 
(517-752) 
483 
(366-638) 
0.18 
566 
(402-798) 
459 
(279-755) 
0.49 
666 
(534-829) 
494 
(351-697) 
0.25 
SP 0609 
103 
(86-124) 
136 
(115- 162) 
0.026 
92 
(68-126) 
180 
(136-239) 
0.002 
112 
(88-141) 
120 
(97-148) 
0.71 
SP 0082 
88 
(64-121) 
72 
(58-89) 
0.11 
34 
(21-55) 
61 
(40-91) 
0.06 
170 
(121-238) 
78 
(60-101) 
< 0.0001 
SP 0749 
66 
(47-93) 
56 
(42-75) 
0.52 
69 
(41-114) 
49 
(30-78) 
0.41 
65 
(41-103) 
60 
(42-86) 
0.82 
SP 0498 
(LytB) 
53 
(39-72) 
81 
(67-99) 
0.043 
26 
(15-42) 
89 
(65-121) 
< 0.0001 
87 
(61-123) 
78 
(60-100) 
0.51 
IgA1-proteinase 
32 
(24-44) 
100 
(80-123) 
< 0.0001 
24 
(16-37) 
126 
(86-183) 
< 0.0001 
40 
(26-60) 
89 
(69-116) 
0.001 
PpmA 
37 
(26-52) 
30 
(24-39) 
0.30 
25 
(13-46) 
24 
(16-37) 
0.89 
48 
(32-74) 
34 
(25-45) 
0.14 
SlrA 
62 
(48-79) 
138 
(117-163) 
< 0.0001 
42 
(29-62) 
144 
(108-193) 
< 0.0001 
80 
(58-110) 
135 
(110-166) 
0.005 
SP 2216 
(PcsB) 
70 
(52-94) 
88 
(68-113) 
0.35 
46 
(28-76) 
66 
(40-111) 
0.36 
92 
(64-133) 
100 
(76-134) 
0.67 
SP 1723 
(StkP) 
9 
(7-13) 
22 
(17-29) 
< 0.0001 
5 
(3-9) 
21 
(12-35) 
< 0.0001 
13 
(9-19) 
23 
(17-32) 
0.017 
SP 2194 
105 
(86-128) 
153 
(126-185) 
0.007 
101 
(71-142) 
145 
(103-204) 
0.11 
107 
(83-139) 
157 
(124-198) 
0.030 
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Table 6.7: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M+/I- children at approximately 18 months of age 
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccinated and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue. 
Protein 
M+/I- 
vaccinated 
*GMT   
(95 % CI) 
M+/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
GMT 
 (95 % CI) 
Uncolonized 
unvaccinated 
GMT 
 (95 % CI) 
p 
Colonized 
vaccinated 
*GMT  
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
 (95 % CI) 
p 
PspA 
40 
(33-49) 
111 
(91-135) 
< 0.0001 
41 
(29-58) 
121 
(81-181) 
< 0.0001 
40 
(31-51) 
108 
(85-135) 
< 0.0001 
PspC 
78 
(58-105) 
113 
(95-134) 
0.029 
55 
(29-107) 
93 
(64-135) 
0.15 
92 
(67-127) 
122 
(101-148) 
0.11 
PsaA 
122 
(111-135) 
180 
(155-209) 
< 0.0001 
118 
(101-138) 
159 
(117-215) 
0.10 
124 
(109-140) 
189 
(159-225) 
< 0.0001 
PdB 
81 
(64-103) 
108 
(86-135) 
0.11 
55 
(31-97) 
103 
(65-162) 
0.08 
98 
(79-122) 
109 
(84-143) 
0.56 
SP 2027 
512 
(415-633) 
191 
(125-290) 
< 0.0001 
500 
(362-690) 
332 
(159-690) 
0.32 
518 
(392-685) 
153 
(92-254) 
< 0.0001 
SP 0609 
53 
(40-70) 
171 
(140-209) 
< 0.0001 
57 
(37-87) 
203 
(141-292) 
< 0.0001 
51 
(36-74) 
160 
(125-204) 
< 0.0001 
SP 0082 
224 
(160-314) 
101 
(87-118) 
< 0.0001 
175 
(82-375) 
122 
(98-152) 
0.32 
252 
(176-361) 
94 
(77-114) 
< 0.0001 
SP 0749 
173 
(123-242) 
87 
(62-122) 
0.008 
306 
(169-552) 
76 
(45-128) 
0.001 
131 
(88-196) 
91 
(59-141) 
0.28 
SP 0498 
(LytB) 
72 
(58-88) 
155 
(132-181) 
< 0.0001 
56 
(35-91) 
184 
(142-238) 
< 0.0001 
81 
(65-100) 
144 
(119-176) 
< 0.0001 
IgA1-proteinase 
48 
(33-69) 
121 
(97-151) 
< 0.0001 
42 
(21-86) 
141 
(90-221) 
0.004 
51 
(33-78) 
114 
(88-148) 
0.001 
PpmA 
99 
(78-127) 
42 
(32-56) 
< 0.0001 
120 
(77-187) 
40 
(23-71) 
0.004 
91 
(67-123) 
43 
(31-60) 
0.002 
SlrA 
80 
(67-97) 
96 
(79-116) 
0.21 
76 
(57-103) 
114 
(76-171) 
0.12 
83 
(65-104) 
90 
(72-111) 
0.68 
SP 2216 
(PcsB) 
143 
(98-209) 
142 
(121-166) 
0.92 
82 
(33-206) 
132 
(92-190) 
0.29 
188 
(133-265) 
146 
(123-173) 
0.18 
SP 1723 
 (StkP) 
25 
(17-35) 
34 
(26-45) 
0.14 
21 
(9-44) 
37 
(22-62) 
0.20 
27 
(17-40) 
33 
(24-46) 
0.37 
SP 2194 
90 
(70-116) 
150 
(124-181) 
0.001 
79 
(56-113) 
214 
(156-293) 
< 0.0001 
96 
(69-135) 
131 
(104-164) 
0.11 
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Table 6.8: Comparison of the GMT‟s against the 15 pneumococcal proteins between PCV-vaccinated and unvaccinated M+/I- children at approximately 24 months of age  
*GMT‟s with 95% confidence interval were reported in arbitrary units per ml (U/ml), **for differences between overall vaccina ted and un-vaccinated children, p-values were adjusted for 
nasopharyngeal pneumococcal colonization status. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV exposed, infected children. GMTs in PCV-7 unvaccinated 
children significantly higher than in –vaccinated children are highlighted in red whilst GMTs in PCV-7 unvaccinated children significantly lower than in –vaccinated children are highlighted in blue.  
Protein 
M+/I- 
vaccinated 
*GMT 
(95 % CI) 
M+/I- 
unvaccinated 
*GMT 
(95 % CI) 
**P adj. 
Uncolonized 
vaccinated 
GMT 
(95 % CI) 
Uncolonized 
unvaccinated 
GMT 
(95 % CI) 
p 
Colonized 
vaccinated 
*GMT 
(95 % CI) 
Colonized 
unvaccinated 
*GMT 
(95 % CI) 
p 
PspA 
67 
(54-82) 
119 
(101-140) 
< 0.0001 
86 
(64-115) 
123 
(79-189) 
0.14 
60 
(46-79) 
118 
(99-141) 
< 0.0001 
PspC 
107 
(74-155) 
139 
(126-154) 
0.14 
134 
(100-181) 
115 
(80-166) 
0.58 
98 
(58-163) 
147 
(136-159) 
0.08 
PsaA 
260 
(228-297) 
137 
(116-162) 
< 0.0001 
269 
(244-297) 
124 
(88-177) 
< 0.0001 
257 
(214-308) 
141 
(117-172) 
< 0.0001 
PdB 
98 
(78-125) 
131 
(111-156) 
0.037 
101 
(69-148) 
124 
(82-189) 
0.33 
97 
(72-131) 
133 
( 110-161) 
0.07 
SP 2027 
383 
(308-476) 
449 
(310-648) 
0.10 
361 
(247-527) 
600 
(455-790) 
0.034 
391 
(298-515) 
446 
(365-544) 
0.44 
SP 0609 
77 
(61-99) 
64 
(50-81) 
0.26 
69 
(56-85) 
72 
(43-123) 
0.85 
81 
(58-113) 
61 
(46-81) 
0.19 
SP 0082 
310 
(199-484) 
146 
(125-170) 
0.001 
403 
(242-670) 
117 
(67-205) 
0.002 
280 
(154-508) 
155 
(137-177) 
0.034 
SP 0749 
149 
(105-212) 
99 
(80-121) 
0.050 
201 
(94-430) 
83 
(50-135) 
0.051 
133 
(89-197) 
106 
(84-134) 
0.31 
SP 0498 
(LytB) 
94 
(66-134) 
187 
(159-218) 
< 0.0001 
105 
(56-140) 
179 
(123-261) 
0.13 
90 
(57-140) 
189 
(158-225) 
0.001 
IgA1-proteinase 
76 
(50-116) 
84 
(61-115) 
0.76 
80 
(42-151) 
81 
(43-152) 
0.92 
75 
(44-128) 
84 
(58-123) 
0.71 
PpmA 
120 
(83-174) 
87 
(65-118) 
0.22 
140 
(75-263) 
104 
(52-206) 
0.58 
113 
(71-179) 
83 
(59-117) 
0.27 
SlrA 
101 
(81-125) 
123 
(101-149) 
0.17 
109 
(74-162) 
112 
(67-186) 
0.85 
98 
(75-128) 
126 
(102-156) 
0.14 
SP 2216 
(PcsB) 
216 
(140-335) 
197 
(169-230) 
0.70 
261 
(187-363) 
163 
(98-271) 
0.13 
201 
(110-367) 
208 
(180-240) 
0.90 
SP 1723 
 (StkP) 
55 
(37-81) 
46 
(37-57) 
0.46 
68 
(44-106) 
37 
(24-58) 
0.06 
50 
(30-84) 
49 
(38-63) 
0.96 
SP 2194 
70 
(57-86) 
128 
(100-162) 
< 0.0001 
69 
(51-95) 
111 
(56-220) 
0.12 
71 
(54-92) 
133 
(103-170) 
0.001 
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5. 5 Kinetics of antibodies against pneumococcal proteins in M-/I-, M+/I- and M+/I+ 
children in relation to age and vaccination status 
 
Antibody titers against select pneumococcal proteins differed by age, even when stratified by 
PCV-vaccination and HIV-infection status (figure 7). Antibody production against antigens 
which can be described as “pneumococcus specific”, i.e. homologous proteins that have not been 
identified in related bacteria; such as Ply, and choline-binding proteins PspA, PspC, and LytB 
showed linear increases in titers with age as shown in figure 7a. The GMTs to these antigens at 
24 months (refer to tables 6.4 and 6.8) were significantly higher than at 4 month (refer to tables 
6.1 and 6.5) and 10 month (refer to tables 6.2 and 6.6) age-group time-points.  
 
 
In addition, the kinetics of antibody increases differed with respect to PCV-vaccination status for 
these antigens. Between 4 to 24 months, PCV vaccination was associated with lower antibody 
titers against the choline-binding proteins: PspA, PspC and LytB (figure 7a) and the secreted 
protein PdB (figure 7b) as well as the integral membrane protein, StkP (figure 7c). Conversely, 
PCV-vaccination was associated with higher antibody titers against SP 0082 (figure 7b) and 
PpmA (figure 7c2) at all four time-points. In addition, HIV-infected children consistently had 
lower antibody titers to PspA, PspC, LytB (figure 7a) and PdB (figure 7d) and StkP (figure 7c3) 
compared to HIV-uninfected children. These trends were, to some extent, followed for the 
antigens IgA1-proteinase (figure 7b), and PcsB (figure 7d).   
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a) Choline-binding proteins: 
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b) Sortase-dependent proteins: 
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c) Lipoproteins 
 
1) ABC transporters: 
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2) Cell wall associated lipoproteins (Non ABC transporters): 
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3) Integral membrane lipoproteins: 
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d) Secreted proteins: 
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e) Other pneumococcal proteins: 
 
 
 
 
 
 
Figure 7: Kinetics of antibodies against pneumococcal proteins in PCV-vaccinated and unvaccinated children at 
ages 4, 10, 18 and 24 months. M-/I-: HIV unexposed, uninfected, M+/I-: HIV exposed, uninfected and M+/I+: HIV 
exposed, infected infants. GMT‟s were reported in arbitrary units per ml (U/ml 
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5.6 Prevalence of antibodies against pneumococcal proteins in PCV-9 vaccinated 
and unvaccinated children aged between 4 and 7 years 
 
The median age of children studied in this group was 5.61 years (range: 3.89 to 7.09 
years) and they were stratified according to HIV infection status, PCV-9 vaccination 
history during infancy and nasopharyngeal pneumococcal-colonization status. Samples 
from a total of 286 children; including 212 HIV uninfected (97 PCV vaccinated and 115 
PCV unvaccinated) and 74 HIV infected (28 PCV-vaccinated and 46 PCV-unvaccinated) 
were analyzed. PCV-9 vaccinated children were immunized at 6, 10 and 14 weeks of age. 
The prevalence of pneumococcal colonization in HIV-infected children was higher 
compared to HIV-uninfected counterparts (73 % [54/74] in HIV infected children and 56 
% [107/212] in HIV uninfected children, p = 0.001).  
 
Table 7: Demographic features of the PCV9-vaccinated and -unvaccinated children aged between 4 to 7 
years. Children were stratified according to vaccination, HIV and pneumococcal colonization status at the 
time of blood sampling. 
 
*Nasopharyngeal swabs from children were collected at the same time-point when blood was drawn. NT: total number 
of children whom samples were available for at the time-point (visit). 
Study group 
Total 
number of 
subjects NT) 
Median 
age 
(years) 
Overall 
colonization 
PCV-
vaccinated 
(NT) 
PCV-
unvaccinated 
(NT) 
HIV-uninfected 
children 
212 
6 
(4-7) 
(107/212) 
56 % 
97 
 
115 
HIV infected 
children 
74 
6 
(4-7) 
(54/74) 
73 % 
28 46 
Total number of 
subjects tested 
286   125 161 
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5.6.1 Comparison between HIV-uninfected children and HIV-infected children 
 
Comparison of antibody titers between HIV-infected and -uninfected children was 
adjusted for pneumococcal nasopharyngeal colonization and PCV vaccination status. 
Differences in antibody titers between HIV-infected and -uninfected children were 
antigen specific. HIV-uninfected children had significantly higher antibody titers against 
antigens not associated with the cell membrane such as PdB, which are released through 
cell lysis, and antigens bound to the cell wall through choline and LPXTG peptidoglycan 
binding domains (as shown in Table 6, highlighted in bold/red). These included PspA 
(180 vs 63; p < 0.0001), PspC (176 vs 120, p < 0.0001), PdB (223 vs 178; p = 0.040), SP 
0082 (519 vs 334, p < 0.0001), LytB (193 vs 65; p < 0.0001), IgA1-proteinase (101 vs 
38; p < 0.0001) and PscB (687 vs 372; p < 0.0001). In contrast, membrane associated 
proteins such as PsaA (357 vs 198; p < 0.0001), SP 2027 (513 vs 361; p = 0.007) PpmA 
(214 vs 136; p =0.002) and SlrA (202 vs 133; p = 0.050) were associated with lower 
antibody titres in HIV-uninfected children compared to -infected children (Table 7.2, 
highlighted in bold italics/blue). 
 
The reverse cumulative distribution plots in figure 8 demonstrate the distribution of 
antibody titers against the pneumococcal proteins with respect to HIV and 
nasopharyngeal pneumococcal-colonization status. For HIV-infected children, the 
antibody distribution curves calculated for all cell-wall associated and “secreted” proteins 
(PspA, PspC, SP 0082, PdB, PcsB, LytB, IgA1-proteinase, StkP) were consistently below 
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the antibody distribution curves calculated for HIV-uninfected children; conversely, the 
antibody distribution curves calculated for all membrane associated lipoproteins and 
ABC transporters (PsaA, SlrA, PpmA, SP 0749, SP 0609) for HIV-infected children were 
consistently above the antibody distribution curves calculated for HIV-uninfected 
children. 
 
5.6.2 Comparison between pneumococcal-colonized and –uncolonized children  
 
Comparisons of GMTs between pneumococcal-colonized and –uncolonized children 
were adjusted for PCV-vaccination and HIV infection status. Concurrent colonization 
status was poorly associated with antibody titers in this age group. Higher antibody titers 
against PdB (235 vs 192; p = 0.048) and PcsB (688 vs 516; p = 0.013) were observed in 
children not colonized with pneumococci compared to pneumococcal-colonized children 
as shown in Table 7.2 (highlighted in bold italics/blue). No differences in antibody titers 
against other proteins were observed between children who were colonized with 
pneumococci and children who were not colonized. 
 
For PcsB and PdB, apparent differences were observed between the distribution curves 
calculated for HIV-infected children, with pneumococcal-uncolonized children 
consistently having higher antibody titers compared to -colonized children (Figure 8d). 
For other proteins, the distribution curves calculated for children who were colonized 
with pneumococci were similar and almost parallel and those not colonized, regardless of 
HIV infection status.  
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No differences in antibody titers against all proteins were observed between PCV-
vaccinated and –unvaccinated children (adjusting for HIV infection status and 
pneumococcal nasopharyngeal colonization status).    
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Table 7.2: Geometric mean titers to the 15 pneumococcal proteins in children aged between 4 to 7 years. Children were stratified according to HIV exposure, pneumococcal 
colonization status and vaccination history.  
Protein 
Overall 
*GMT 
(95 % CI) 
HIV 
uninfected 
*GMT 
(95 % CI) 
HIV infected 
*GMT 
(95 % CI) 
**P 
(adjusted) 
Vaccinated 
*GMT 
(95 % CI) 
Unvaccinated 
*GMT 
(95 % CI) 
**P 
(adjusted) 
Colonized 
*GMT 
(95 % CI) 
Uncolonized 
*GMT 
(95 % CI) 
**P 
(adjusted) 
PspA 
137 
(120-157) 
180 
(156-206) 
63 
(48-84) 
< 0.0001 
129 
(103-162) 
144 
(122-170) 
0.19 
133 
(109-162) 
143 
(119-172) 
0.42 
PspC 
159 
(145-176) 
176 
(158-196) 
120 
(98-147) 
< 0.0001 
158 
(138-181) 
160 
(140-184) 
0.66 
146 
(128-167) 
178 
(154-204) 
0.18 
PsaA 
230 
(209-254) 
198 
(179-219) 
357 
(292-436) 
< 0.0001 
241 
(208-279) 
223 
(196-253) 
0.20 
246 
(217-279) 
210 
(181-244) 
0.52 
PdB 
210 
(193-229) 
223 
(203-245) 
178 
(148-214) 
0.040 
194 
(170-221) 
224 
(200-251) 
0.06 
192 
(171-215) 
235 
(206-267) 
0.048 
SP 2027 
396 
(354-443) 
361 
(320-408) 
513 
(397-665) 
0.007 
368 
(311-435) 
419 
(360-488) 
0.32 
406 
(344-478)) 
386 
(331-448) 
0.88 
SP 0609 
101 
(88-115) 
96 
(83-111) 
116 
(87-154) 
0.19 
99 
(81-121) 
102 
(85-122) 
0.85 
101 
(84-120) 
101 
(83-123) 
0.76 
SP 0082 
463 
(428-502) 
519 
(479-562) 
334 
(276-404) 
< 0.0001 
480 
(424-542) 
451 
(406-501) 
0.45 
458 
(409-512) 
469 
(419-525) 
0.81 
SP 0749 
150 
(133-169) 
141 
(122-163) 
179 
(145-221) 
0.07 
150 
(124-181) 
150 
(128-175) 
0.94 
153 
(131-180) 
147 
(122-177) 
0.99 
SP 0498 
(LytB) 
146 
(130-164) 
193 
(175-213) 
65 
(49-85) 
< 0.0001 
132 
(110-159) 
157 
(136-182) 
0.15 
130 
(110-154) 
172 
(149-198) 
0.31 
IgA1-
proteinase 
78 
(67-92) 
101 
(85-119) 
38 
(28-53) 
< 0.0001 
72 
(57-91) 
84 
(68-104) 
0.13 
71 
(57-89) 
90 
(72-112) 
0.62 
PpmA 
153 
(136-172) 
136 
(119-157) 
214 
(172-266) 
0.002 
159 
(133-191) 
148 
(126-174) 
0.37 
162 
(139-188) 
142 
(117-172) 
0.63 
SlrA 
148 
(127-173) 
133 
(110-159) 
202 
(153-268) 
0.050 
146 
(117-183) 
149 
(121-185) 
0.91 
167 
(139-202) 
126 
(97-163) 
0.17 
SP 2216 
(PcsB) 
586 
(541-636) 
687 
(640-738) 
372 
(302-457) 
< 0.0001 
559 
(484-644) 
609 
(556-667) 
0.08 
516 
(455-548) 
688 
(630-750) 
0.013 
SP 1723 
(StkP) 
192 
(167-220) 
188 
(160-254) 
202 
(160-254) 
0.51 
184 
(149-226) 
198 
(166-237) 
0.58 
170 
(142-204) 
217 
(179-270) 
0.06 
SP 2194 
82 
(73-92) 
77 
(67-89) 
95 
(77-118) 
0.21 
77 
(65-91) 
86 
(73-101) 
0.47 
85 
(72-99) 
78 
(65-94) 
0.75 
Children in this group were randomized to receive either PCV-9 or placebo at 6, 10 and 14 weeks of age. Blood was obtained from children at the time of their first visit.  
*GMT‟s were reported in arbitrary units per ml (U/ml), with 95% confidence interval. **P-values for HIV were adjusted for colonization and vaccination statuses, for 
colonization, p values were adjusted for vaccination status and HIV exposure and for vaccination, p-values were adjusted for colonization status and HIV exposure. 
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a) Choline-binding proteins: Children aged between 4 to 7 years colonization data 
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b) Sortase-dependent proteins:  
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c) Lipoproteins: 
 
1.) ABC transporters:  
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2.) Non ABC transporters (cell-wall associated lipoproteins):  
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3.) Integral membrane lipoprotein(s):  
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d) Secreted proteins: 
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e) Other pneumococcocal proteins: 
 
                 
 
Figure 8: Reverse cumulative distribution curves of IgG antibodies against the pneumococcal proteins measured in HIV uninfected and HIV infected children 
aged between 4 to 7 years for comparison of the pneumococcal-colonized and uncolonized groups.  
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5.7 Comparison of antibody titers against pneumococcal proteins in PCV-vaccinated 
and HIV uninfected children between two years of age and older children  
 
Antibodies against PspA, PspC, PdB, SP 0082, LytB, PpmA, PcsB, and StkP showed 
increases in titer with respect to increasing age, and either continued peaking in the 4 to 7 
year old (PspA, PdB, SP 0082, LytB, PcsB and StkP) or declined by 24 months and 
remained constant until 4 to 7 years of age (PspC and PpmA). Antibodies against IgA1-
proteinase declined by 24 months of age and had already reached levels observed in older 
children (4 to 7 years) by 18 months of age (Figure 9). 
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Figure 9: Natural development of antibodies against the choline-binding, sortase-dependent, secreted and 
cell-wall associated pneumococcal proteins in PCV-vaccinated, HIV uninfected children until two years of 
age and children between 4-7 years of age. Children aged between 4 to 24 months were vaccinated with 
PCV-7 and children between 4 to 7 years were vaccinated with PCV-9. GMT = Geometric Mean Titer. 
 
 
Antibody titers against SP 2027, SP 0609, and SP 2194 did not show any relationship to 
age as shown in figure 10. Antibody titers against PsaA, SP 0749 and SlrA showed an 
increase with respect to increasing age and either peaked at 18 months (SP 0749 and 
SlrA) or at 24 months (PsaA) then declined until 4 to 7 years of age. 
 
 
Dynamics of antibodies against the choline-binding-, sortase dependent-, cell wall 
associated lipoproteins and secreted- proteins in PCV-vaccinated, HIV uninfected study 
participants  
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Figure 10: Natural development of antibodies against the ABC transporter lipoproteins, cell-wall 
associated lipoproteins and other pneumococcal proteins in PCV-vaccinated HIV children until two years 
of age and children between 4-7 years of age. Children aged between 4 to 24 months were vaccinated with 
PCV-7 and children between 4 to 7 years were vaccinated with PCV-9. GMT = Geometric Mean Titer. 
 
 
  
 
 
 
 
Dynamics of antibodies against the ABC transporter lipoproteins, cell-wall associated lipoproteins 
and other pneumococcal protein antigens in PCV-vaccinated HIV uninfected study participants 
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5.8 Prevalence of antibodies against pneumococcal proteins in HIV uninfected and 
HIV infected women  
 
The median age of the women was 27 years (range: 15 to 48) and they were stratified 
according to pneumococcal colonization status and HIV infection status. These women 
were the mothers of the PCV-7 vaccinated and -unvaccinated children less than two years 
of age. Thirty five percent (197/565) of the women were HIV-uninfected and 65% 
(368/565) were HIV-infected. Nasopharyngeal and oropharyngeal swabs were collected 
and analyzed for pneumococcal colonization from women at the blood sampling time-
point. The prevalence of pneumococcal colonization was similar between HIV-uninfected 
women [12 % (24/197)] and HIV-infected women [15 % (55/368), p = 0.43] at the blood 
sampling time-point as shown in Table 8.  
 
Table 8: Demographic features of women at the blood withdrawal time-point stratified by HIV exposure 
and pneumococcal colonization status 
 
 
*Nasopharyngeal and oropharyngeal sampling of women for pneumococcal colonization was done at the blood 
withdrawal time. NT: total number of women who were present at each time-point 
 
 
Study group 
Total 
number of 
samples 
(NT) 
Median 
age 
(years) 
Overall 
colonization 
HIV 
infected 
(NT) 
Colonized 
HIV 
infected 
 
HIV 
uninfected 
(NT) 
Colonized 
HIV 
uninfected 
 
Mothers of the PCV-
vaccinated and PCV 
unvaccinated children 
565 
27 
(15-48) 
(79/565) 
14 % 
368 
 
(55/368) 
15 % 
197 
 
(24/197) 
12 % 
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5.8.1 Comparison of antibody titers in HIV-uninfected and HIV-infected women in 
relation to pneumococcal colonization 
 
Higher antibody titers against PspC (211 vs 153; p = 0.029)], SP 2027 [(141 vs 75; p = 
0.009), SP 0082 (357 vs 204; p = 0.008), LytB (191 vs 127; p = 0.048) and PcsB (248 vs 
163; p = 0.020) were evident in HIV-uninfected women not colonized with pneumococci 
compared to pneumococcal-colonized women (see table 9). In contrast, lower antibody 
titers against PsaA 126 vs 200; p = 0.010) were observed in HIV-uninfected 
pneumococcal-uncolonized women compared to –colonized women (table 9). No 
differences in antibody titers against all proteins were evident in HIV infected women 
when comparing pneumococcal-colonized women to women who were not colonized 
with pneumococci. 
 
The reverse distribution plots in figure 11 indicate the distribution of antibody titers 
produced by women in relation to HIV infection and pneumococcal colonization status. 
In HIV uninfected women, distribution curves calculated for pneumococcal-uncolonized 
women against PspC, SP 2027 and SP 0082 were parallel and above the distribution 
curves calculated for women who were colonized with pneumococci. In HIV infected 
women, distribution curves calculated for pneumococcal-colonized women were similar 
to the distribution curves calculated for women who were not colonized with 
pneumococci. 
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Adjusting for HIV infection status, differences in antibody titers were only evident for 
PdB and SP 2027. These included higher antibody titers against PdB (223 vs 157; p = 
0.010) and SP 2027 (195 vs 135; p = 0.039) were observed in women who were not 
colonized compared to those colonized with pneumococci (table 9). For PdB (figure 11d) 
and SP 2027 (figure 11c), the distribution curves were almost parallel but a deviation was 
observed around 100 U/ml, where the distribution curve calculated for women who were 
not colonized indicated a higher proportion above this threshold compared to women who 
were colonized with pneumococci.  
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5.8.2 Comparison of antibody titers in HIV infected and HIV uninfected women  
 
Comparisons of the GMTs between HIV-uninfected and -infected women were adjusted 
for pneumococcal colonization status. HIV-uninfected women had significantly higher 
antibody titers than HIV-infected women against antigens that were associated with the 
cell wall, either through choline-binding domains or LPXTG motifs, and „secreted‟ 
proteins. These included higher antibody titers against PspA (162 vs 103, p < 0.0001), 
PspC (202 vs 138; p < 0.0001), PdB (249 vs 195; p = 0.015), SP 0082 (332 vs 257, p = 
0.015), LytB (181 vs 116, p < 0.0001), IgA1-proteinase (307 vs 212, p < 0.0001), and 
PcsB (235 vs 132, p < 0.0001). Exceptions to this were the membrane anchored proteins 
PpmA (278 vs 187, p < 0.0001) StkP (142 vs 80, p < 0.0001), antibodies against which 
were also elevated in HIV-uninfected women. Lower antibody titers were observed in 
HIV- uninfected women compared to -infected women against the membrane associated 
proteins: SP 2027 (130 vs 222; p < 0.0001) and SP 0749 (140 vs 204; p = 0.004  as 
indicated in Table 10, (highlighted in bold italic/blue).  
 
The distribution curves calculated for PspA, PspC, PdB, SP 0082, LytB, IgA1-proteinase, 
PpmA, PcsB, and StkP in HIV uninfected women were consistently higher than the 
distribution curves calculated in HIV-infected women, whilst the distribution curves 
calculated for SP 2027 and SP 0749 in HIV-uninfected women were lower than those 
observed in HIV-infected women (Figure 11).  
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Table 9: Geometric mean titers (with 95 % confidence interval) of antibodies against pneumococcal proteins in women, stratified by HIV and pneumococcal 
colonization status     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GMT‟s were reported in arbitrary units per ml (U/ml), with 95% confidence interval. *Nasopharyngeal swabs from children were collected at the time-point when blood was 
withdrawn. Swabs were stored in STGG medium at -80°C. **for comparison between overall pneumococcal-colonized and uncolonized women, p-values were adjusted for 
pneumococcal HIV exposure. 
Protein 
Overall 
GMT 
(95 % CI) 
Colonized 
GMT 
(95 % CI) 
Uncolonized 
GMT 
(95 % CI) 
**p 
adjuste
d 
HIV uninfected, GMT (95 % CI HIV, infected, GMT (95 % CI) 
Colonized Uncolonized p Colonized Uncolonized p 
PspA 
120 
(109-133) 
117 
(93-148) 
120 
(108-135) 
0.96 
165 
(115-236) 
162 
(137-192) 
0.93 
101 
(75-135) 
103 
(90-118) 
0.91 
PspC 
158 
(146-170) 
140 
(117-168) 
161 
(148-175) 
0.26 
153 
(121-194) 
211 
(181-245) 
0.029 
134 
(106-171) 
139 
(126-152) 
0.81 
PsaA 
127 
(114-142) 
142 
(113-178) 
125 
(110-141) 
0.41 
200 
(146-272) 
126 
(103-152) 
0.010 
122 
(91-163) 
125 
(107-145) 
0.89 
PdB 
212 
(194-233) 
157 
(119-207) 
223 
(203-246) 
0.010 
174 
(99-308) 
262 
(222-310) 
0.17 
150 
(109-206) 
204 
(182-230) 
0.07 
SP 2027 
185 
(162-211) 
135 
(96-189) 
195 
(169-225) 
0.039 
75 
(49-115) 
141 
(112-178) 
0.009 
175 
(112-272) 
232 
(193-278) 
0.24 
SP 0609 
108 
(97-120) 
94 
(70-126) 
110 
(98-124) 
0.32 
118 
(68-204) 
119 
(95-148) 
0.99 
85 
(59-121) 
106 
(92-122) 
0.24 
SP 0082 
281 
(254-309) 
233 
(184-295) 
289 
(260-322) 
0.15 
204 
(139-299) 
357 
(293-434) 
0.008 
248 
(184-335) 
258 
(228-292) 
0.81 
SP 0749 
179 
(159-202) 
189 
(135-264) 
178 
(156-202) 
0.80 
114 
(71-181) 
145 
(122-172) 
0.33 
237 
(154-366) 
198 
(166-237) 
0.45 
SP 0498 
(LytB) 
135 
(124-147) 
113 
(91-141) 
139 
(127-153) 
0.13 
127 
(88-185) 
191 
(161-226) 
0.048 
108 
(81-142) 
117 
(105-131) 
0.56 
IgA1-
proteinase 
241 
(221-263) 
241 
(194-300) 
241 
(219-265) 
0.91 
274 
(206-363) 
312 
(269-361) 
0.41 
227 
(170-305) 
210 
(186-237) 
0.61 
PpmA 
215 
(194-238) 
218 
(164-288) 
214 
(192-240) 
0.82 
247 
(167-365) 
283 
236-340) 
0.52 
206 
(142-299) 
184 
(161-211) 
0.58 
SlrA 
192 
(174-213) 
163 
(124-214) 
198 
(177-220) 
0.21 
194 
(135-278) 
211 
(177-253) 
0.67 
151 
(105-218) 
190 
(166-219) 
0.24 
SP 2216 
(PcsB) 
161 
(145-179) 
151 
(125-181) 
163 
(144-184) 
0.74 
163 
(123-217) 
248 
(199-309) 
0.020 
146 
(115-185) 
129 
(113-149) 
0.40 
SP 1723 
(StkP) 
97 
(86-111) 
94 
(68-129) 
98 
(85-113) 
0.90 
138 
(77-249) 
142 
(111-182) 
0.93 
79 
(53-116) 
80 
(68-95) 
0.93 
SP 2194 
93 
(84-102) 
97 
(74-128) 
92 
(83-102) 
0.67 
104 
(62-173) 
100 
(84-119) 
0.88 
94 
(67-132) 
88 
(78-100) 
0.70 
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Table 10: Geometric mean titers of antibody titers against pneumococcal proteins in women, stratified by 
HIV and pneumococcal-colonization status at the time of sampling 
*GMT‟s (with 95% confidence interval) were reported in arbitrary units per ml (U/ml).  
**for comparison between HIV uninfected and HIV infected women, p-values were adjusted for 
pneumococcal colonization status. 
 
Protein 
HIV uninfected 
*GMT (95 % CI) 
HIV infected 
*GMT (95 % CI) 
**p 
adjusted 
PspA 
162 
(139-189) 
103 
(91-116) 
< 0.0001 
PspC 
202 
(177-232) 
138 
(126-151) 
< 0.0001 
PsaA 
133 
(112-159) 
124 
(108-142) 
0.51 
PdB 
249 
(212-293) 
195 
(174-218) 
0.015 
SP 2027 
130 
(106-161) 
222 
(188-263) 
< 0.0001 
SP 0609 
119 
(97-145) 
103 
(90-117) 
0.23 
SP 0082 
332 
(277-397) 
257 
(229-288) 
0.015 
SP 0749 
140 
(120-165) 
204 
(173-241) 
0.004 
SP 0498 
(LytB) 
181 
(155-211) 
116 
(105-128) 
< 0.0001 
IgA1-proteinase 
307 
(269-350) 
212 
(189-237) 
< 0.0001 
PpmA 
278 
(235-328 
187 
(165-213) 
< 0.0001 
SlrA 
209 
(178-246) 
184 
(161-209) 
0.25 
SP 2216 
(PcsB) 
235 
(193-286) 
132 
(116-149) 
< 0.0001 
SP 1723 
(StkP) 
142 
(113-178) 
80 
(69-93) 
< 0.0001 
SP 2194 
100 
(85-118) 
89 
(79-100) 
0.24 
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Women‟s current colonization data 
a) Choline-binding proteins: 
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b) Sortase-dependent proteins: 
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c) Lipoproteins 
1) ABC transporters: 
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2) Non ABC transporters (cell-wall associated lipoproteins): 
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3) Integral membrane lipoprotein(s): 
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d) Secreted proteins: 
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e) Other pneumococcal proteins: 
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Figure 11: Reverse cumulative distribution curves of IgG antibodies against the pneumococcal proteins measured in the sera from mothers of the PCV-
vaccinated and PCV-unvaccinated children for the comparison of women who were colonized with pneumococcus at the time of blood withdrawal (cur-col) and 
women who were not colonized at the time of blood withdrawal (not cur-col). Nasopharyngeal and oropharyngeal swabs were collected and stored in STGG 
medium at -80°C .  
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5.9 Kinetics of antibodies against pneumococcal proteins in pneumococcal- 
unvaccinated HIV uninfected children between 2 years of age, older children and adult 
females  
 
Antibodies against PspA, PspC, PdB, SP 0082, LytB, IgA1-proteinase, PpmA, PcsB, and 
StkP showed increases in titer with respect to increasing age, and peaked in either the 4 to 
7 year old and remained constant until adulthood (PspC, PdB and LytB) or declined by 
adulthood (PcsB, SP 0082 and StkP) as shown in figure 12.  
 
 
 
 
 
Figure 12: Natural development of antibodies against the choline-binding, sortase-dependent, secreted and 
cell-wall associated pneumococcal proteins in PCV unvaccinated HIV uninfected infants, older children 
and adults. GMT = Geometric Mean Titer.  
 
Dynamics of antibodies against the choline-binding-, sortase dependent-, cell wall 
associated lipoproteins and secreted- proteins in HIV uninfected study participants 
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In contrast, antibody titers against PsaA, SP 2027, SP 0609, SP 0749, SlrA, and SP 2194 
did not show any relationship to age as shown in figure 13. 
 
 
 
 
Figure 13: Natural development of antibodies against the ABC transporter lipoproteins, cell wall associated 
lipoproteins and other pneumococcal proteins in PCV unvaccinated HIV uninfected infants, older children 
and adults. GMT = Geometric Mean Titer.  
 
Dynamics of antibodies against the ABC transporter lipoproteins, cell-wall associated 
lipoproteins and other pneumococcal protein antigens in HIV uninfected study participants 
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Chapter 6: Discussion 
i) Validation of the Luminex assay 
 
Many pneumococcal proteins have been reported to possess immune protective potential 
(Adrian et al., 2004, Bogaert et al., 2006, Cao et al., 2007, Giefing et al., 2008, Gosink et al., 
2000, Hermans et al., 2006, Holmlund et al., 2006, McCool et al., 2002, Ogunniyi et al., 
2007b, Rapola et al., 2000). Unfortunately most of these studies have come from different 
laboratories which have employed incomparable methods to evaluate different antigens and 
as a result, there are very few studies that compare numerous antigens side by side using 
similar methods to evaluate their potential as possible vaccine candidates. One of the 
priorities of this study was to establish and validate a common platform for the simultaneous 
quantification of IgG antibodies against a variety of pneumococcal proteins in order to 
compare them side by side.  
 
The multiplex Luminex assay was compared and validated against the standard ELISA 
method for four pneumococcal proteins: PspA, PspC, PsaA and PdB. The multiplex Luminex 
method showed good correlation with singleplex ELISAs for all four antigens, with similar 
specificity and was more sensitive than the ELISA method. The broader dynamic range of the 
Luminex method and the capacity to analyse 15 antigens simultaneously made it an ideal 
high throughput platform with which to compare data for these antigens (Pickering et al., 
2002b).  
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ii)  Effects of age on antibody response 
 
In this study, we have shown that the antibody responses to different proteins can differ 
markedly. The immune response to pneumococcal proteins PspA, PspC, PdB, SP 0082, LytB, 
IgA1-proteinase, PpmA, PcsB, and StkP increased linearly with age in the first two years of 
life (refer to Figure 12). Our findings are consistent with the Finnish and Filipino studies, 
where serum antibodies against PspA and PdB were measured at 6, 12, 18 and 24 months of 
age. In these studies, the GMC of serum antibodies against PspA, PspC and PdB increased 
with age (Holmlund et al., 2006, Rapola et al., 2000, Simell et al., 2009). Consistent with our 
findings, studies by Adrian et al and Bogaert et al also showed that antibody responses to 
IgA1-proteinase and PpmA developed early in infancy and increased with age (Adrian et al., 
2004, Bogaert et al., 2006). 
 
Also consistent with findings from Rapola et al (Rapola et al., 2000) and Holmund et al 
(Holmlund et al., 2006) antibodies against PspA never reached levels observed in adults 
within the first 5 years of life, antibodies against PdB reached adult levels by 5 years of age 
and by 10 months of age, antibody titers against PsaA in PCV-vaccinated infants reached 
levels observed in adults and exceeded it afterwards (Rapola et al., 2000). Giefing et al 
(Giefing et al., 2008) studied the natural immune responses against PcsB and StkP in children 
aged between 2 months to 18 years and adults and demonstrated the development of 
antibodies against PcsB and StkP increased linearly with age, peaked in the 4 to 7 year old 
group and declined until adulthood. These observations were consistent with our findings. In 
study, we have also shown that antibodies against SP 0082, which is a new uncharacterized 
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protein, increase linearly with age, peaked in the 4 to year old group and declined until 
adulthood (refer to Figure 12). 
 
iii) Effects of HIV on antibody response 
 
Our data revealed important differences according to HIV exposure and infection status 
among the study subjects. In PCV-vaccinated children, M+/I+ children had lower antibody 
titers to PspA, PspC, SP 0082, LytB, IgA1-proteinase, PpmA, SlrA, PcsB and StkP proteins 
from 4 to 24 months of age compared to M-/I- children (see Tables 4.2 and 4.3). Previous 
studies have demonstrated that M+/I+ infants with low CD4+ T-cells have an impaired 
immune response upon T-cell dependent antigens like the influenza vaccine, tetanus toxoid, 
diphtheria toxoid and the conjugated Haemophilus infuenzea type b (Kroon et al., 1994, 
Kroon et al., 1997). Differences in antibody titers from 4 to 18 months of age were also 
observed between M-/I- and M+/I- children, whereby M-/I- children had higher antibody 
titers against PspA, PspC, IgA1-proteinase and SlrA compared to M+/I- children. 
 
Risk factors contributing to morbidity of M+/I+ and M+/I- children include the severity of 
maternal HIV disease (Kuhn et al., 2005), poor placental transfer of protective maternal 
antibodies (de Moraes-Pinto et al., 1996, de Moraes-Pinto et al., 1998), replacement feeding 
rather than breast feeding (WHO 2000), perinatal exposure to antiretroviral drugs (Feiterna-
Sperling et al., 2007) and increased exposure to pathogens from immune-deficient individuals 
in the household (Mermin et al., 2005). Previous studies have described the clinical profile 
and morbidity of infants born to HIV infected mothers and they reported that 44% of M+/I- 
children had clinical signs suggestive of HIV infection. These included hepatomegaly, 
splenogamy, lymphadenopathy, oral candida and pneumoniae (Adhikari et al., 2006). A 
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Zambian study showed a relationship between advanced maternal HIV disease and increased 
infant morbidity and mortality in the HIV uninfected (M+/I- equivalent) offspring (Kuhn et 
al., 2005). A Zimbabwean study also showed that M+/I- infants had twice the risk of 
mortality compared to M-/I- infants (Marinda et al., 2008).      
 
M+/I- infants have demonstrable HIV-specific cellular immune responses for both CD4
+
 and 
CD8
+
 T-lymphocytes in peripheral and cord blood, suggesting exposure to HIV antigens 
(Cheynier et al., 1992, Kuhn et al., 2002, Rowland-Jones et al., 1993). Both M+/I+ and M+/I- 
infants have reduced IL-12 production in the cord blood, which can also be demonstrable 
until 6 months of age (Chougner et al., 2000). The early age at onset of a wide spectrum of 
infections observed in M+/I- infants suggests an immunodeficiency perhaps of innate 
immune function. The antigen presentation or co-stimulation signals of M+/I- infants 
immune systems may possibly be transiently impaired by HIV exposure (Slogrove et al., 
2010). The difference observed in antibody titers between M+/I+, M+/I- and M-/I- could be 
due to all these factors. 
 
In PCV-unvaccinated children, higher antibody titers against PspA, PspC, PdB, SP 0082, 
LytB, IgA1-proteinase, PpmA, SlrA, PcsB and StkP were observed in M-/I- children 
compared to M+/I- children at 4 months of age. Higher antibody titers against PspA, PspC, 
PsaA, SP 0082 and IgA1-proteinase were observed in M-/I- children compared to M+/I- 
children at 24 months of age. As observed in PCV-vaccinated children, differences in 
antibody titers at 4 months of age were most likely due the risk factors observed in M+/I- 
infants compared to M-/I- infants. Also, the prevalence of colonization in M+/I- children was 
higher compared to M-/I- children, especially at earlier time-points, suggesting that immune 
aberrations may exist in M+/I- children compared to M-/I- children (Madhi et al., 2010). 
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The higher antibody titers against PspA, PspC, PsaA, SP 0082 and IgA1-proteinase in M-/I- 
children compared to M+/I- children observed at 24 months of age could possibly be due to 
enhanced memory responses in the former group induced by preceding nasopharyngeal 
colonization as demonstrated in the figure below.  
 
 
 
M+/I+ children are at an increased risk for pneumococcal infections, especially bacteremia 
(Malaspina, 2003). The poor antibody responses to the proteins may in part be responsible for 
the higher incidence of systemic pneumococcal disease observed among M+/I+ compared to 
M-/I- children. Our findings agree with observations that M+/I+ children have reduced 
antibody responses to systemically administered antigens such as routine childhood vaccines 
compared to M-/I- children (Arpadi et al., 1994, Kale et al., 1995).  
 
In the 4 to 7 year old group, HIV uninfected children had significantly higher antibody titers 
against antigens which are theoretically surface located, such as choline-binding proteins, 
secreted proteins and antigens which posess peptidoglycan binding motifs such as LPXTG 
(PspA, PspC, SP 0082, LytB, IgA1-proteinase, PdB and PcsB) compared to HIV infected 
children. In contrast, antibody titers against antigens which are anchored to the cell 
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membrane e.g. cell-wall associated lipoproteins and ABC transporters (PsaA, SP 2027, 
PpmA and SlrA) were higher in HIV-infected compared to HIV-uninfected children.  
 
These differences suggest that depleted T-cell function in HIV-infected individuals are 
associated with differences in natural immune responses to common pneumococcal proteins 
based on where they are found in the bacterium.  
 
HIV-uninfected women had higher antibody titers against PspA, PspC, PdB, SP 0082, IgA1-
proteinase, PpmA, PcsB, and StkP compared to HIV-infected women. Lower antibody titers 
against membrane associated proteins: SP 2027 and SP 0749 were observed in HIV- 
uninfected women compared to HIV-infected women. Our data are in agreement with 
Amdahl‟s and Sullivan‟s studies where they reported lower antibody titers against PdB in 
HIV-infected adults compared to HIV-uninfected adults (Amdahl et al., 1995).  
 
HIV is a major risk factor to developing invasive pneumococcal disease. The mechanisms 
behind this are poorly understood, especially in the context that the risk of developing 
pneumococcal disease appears to be more closely related to T-cell function than to antibody 
titer. Antibody responses to proteins depend on CD4
+ 
T-cell function (King et al., 1996, 
Feikin et al., 2001). This T-cell dependent response should provide long term protection 
against pneumococcal disease by inducing memory cell response. High HIV loads contribute 
to the loss of memory cell resulting in impaired interactions between B cells and CD4+ T 
cells (Moir and Fauci, 2009).  
 
 
iv)  Effects of colonization on antibody response  
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In children less than 2 years of age, differences in antibody titers between children who were 
colonized with pneumococci and those not colonized were evident for the choline-binding 
proteins, secreted proteins, membrane associated proteins and sortase-depend (LPXTG motif) 
proteins, namely; PspA, PspC, PdB, SP 0082, LytB, IgA1-proteinase, PpmA, PcsB and StkP 
proteins at ages 4 and 10 months. These data suggested that antibody titers against these 
proteins are stimulated by antigen exposure through pneumococcal colonization. At 18 and 
24 months, the differences between colonized children and uncolonized children became less 
apparent. This is expected, since by this age, the majority of children have had prior 
pneumococcal exposure through colonization and thus stimulation of natural antibody 
responses.  
 
Our results are in agreement with Adrian et al (Adrian et al., 2004) whereby antibodies 
against IgA1-proteinase and PpmA increased in response to pneumococcal carriage in the 
first two years of life. Our data are also consistent with findings from Rapola et al (Rapola et 
al., 2000) and Holmlund et al (Holmlund et al., 2006) whereby the increase in antibody titers 
against PspA and PdB was associated with pneumococcal exposure as children who were 
colonized with pneumococci produced more antibody against these proteins compared to 
children who were not colonized with pneumococci.  
 
In children between 4 to 7 years of age, higher antibody titers against PdB and PcsB were 
observed in children who were not colonized with pneumococci compared to pneumococcal-
colonized children (refer to Table 7.2). Similarly, HIV uninfected women who were not 
colonized with pneumococci at the time of blood sampling had significantly higher antibody 
titers than pneumococcal-colonized women against PspC, SP 2027, SP 0082, LytB and PcsB 
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(Table 9). This inverse association between colonization and antibody titers suggests that 
antibodies against these proteins might potentially protect against the risk of future 
acquisition. 
 
In our study, HIVuninfected women who were colonized with pneumococci produced similar 
antibody titers against PspA and PdB, and lower antibody titers against PspC compared to 
women who were not colonized with pneumococci. These findings contrast with those of 
McCool et al (McCool et al., 2002) in which adults colonized with pneumococci were found 
to produce higher titers against PspA, PspC and PdB compared to subject who were not 
colonized with pneumococci.  
 
No differences in antibody titers against the studied pneumococcal proteins were observed in 
HIV-infected women, regardless of their pneumococcal colonization status (Table 9). 
Similarly, no differences in antibody titers against Ply have also been reported in HIV-
infected adults with and without invasive pneumococcal diseases (Amdahl et al., 1995, 
Etuwewe et al., 2009, Sullivan et al., 2001).  
 
v) Effects of vaccination on antibody response 
 
Our data demonstrates that PCV-vaccination dampened the immune response against some of 
the proteins. This was observed in children at 4, 10 and 18 months of age, whereby PCV-
vaccinated children had lower antibody titers against PspA, PspC, LytB, PdB, IgA1-
proteinase, PcsB and StkP compared to PCV-unvaccinated children (Tables 6.1 to 6.3). 
Lower antibody titers observed in PCV-vaccinated children compared to PCV-unvaccinated 
children, could most likely be due to PCV vaccination affecting pneumococcal colonization 
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and modulating the natural immune responses to colonization events resulting in reduced 
antibody induction against some of the proteins.  
 
vi) Evaluation of vaccine candidates in the context of natural immunity 
 
There is no evidence based method for predicting the potential effectiveness of a 
pneumococcal protein as a vaccine candidate against nasopharyngeal colonization. However, 
analysis of the natural immune response in the context of variables such as age, PCV 
vaccination status, HIV status, and colonization status provide data which highlight 
significant differences between antigens. Combining these differences with our knowledge of 
pneumococcal biology, immunology, and dynamics of colonization can help to provide a 
rationale as to which of these antigens are most likely to be effective candidate vaccine 
molecules. 
 
There are numerous limitations to this study in extrapolating natural acquired antibody titers 
to clinical vaccine efficacy. For example there is no guarantee that antibodies that are present 
and antigen-specific in vitro are able to protect against colonization and invasive disease, 
either as a result of the antigen being inaccessible to antibody binding through being „hidden‟ 
by the cell wall and capsule, or from antibody exposure by the cell wall and capsule, or that 
the most reactive epitopes are in a conformation which is able to prevent antibody recognition 
and binding. In general, there is a rule which suggests that the more the antibody is present, 
the more likely there is to be some protective benefit. However, through the use of a pooled 
reference, where titers for each antigen are described as arbitrary units relative to this 
reference, this study design did not allow us to measure the empirical amount of antibody, 
and compare it between antigens. Despite the limitations of the methods used to quantify the 
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antibody responses, we were able to obtain data on responses relative to age, HIV, PCV 
vaccination and colonization status which can assist in identifying antigens which may be 
useful vaccine candidates. A summary of the candidates and their relative responses are 
shown in Table 11.   
 
Age: The risk of getting invasive pneumococcal disease is associated with age, and is at its 
highest in the 4 - 24 month age group, and gradually decreases with age until adulthood is 
reached (Aniansson et al., 1992, Granat et al., 2007, Hammitt et al., 2006). By comparing the 
age-related risk of developing invasive pneumococcal disease to the titers of natural acquired 
antibodies, it is likely that antigens against which there is an inverse correlation between titer 
and risk of developing pneumococcal disease are likely to be effective candidates. Antibodies 
against PspA, PspC, PdB, SP 0082, LytB, IgA1-proteinase, PpmA, PcsB, and StkP showed 
increases in titer with respect to increasing age, and peaked in either the 4 to 7 year old age 
group or in the mothers. Antibodies against PspC, SP 2027, SP 0082, LytB and PcsB proteins 
were inversely associated with pneumococcal colonization in adults. In contrast antibody 
titers against all the ABC transporters; PsaA, SP 0609 and SP 0749, cell wall associated 
lipoprotein; SlrA and uncharacterized pneumococcal proteins; SP 2027 and SP 2194, did not 
show any relationship with respect to age. 
 
The kinetics of pneumococcal antigens which can be described as being “non-pneumococcus 
specific” i.e. conserved antigens with housekeeping functions, and having homologues in 
related species, such as ABC transporters (PsaA, SP 0609, SP 0749), cell-wall associated 
lipoproteins (PpmA and SlrA) and conserved uncharacterized proteins (SP 2027 and SP 
2194) were different from the previously described “pneumococcus specific” antigens, and 
did not show the comparable kinetics with respect to increasing with age or lower titers in 
Project ID: Pneumococcal protein antigens  
    Student: Zanele Ditse  
      Date: 04 October 2011  
 
- 149 - 
 
PCV immunized children. For these antigens, the absence of predictable kinetics may be 
influenced by exposure to homologous antigens present elsewhere in the commensal flora.  
 
PCV vaccination and colonization status: Natural antibody responses induced by contact 
with pneumococci can provide guidance as to selection of effective vaccine candidates. Since 
many of the proposed antigens have homologues in related bacteria which are associated with 
our normal flora, candidates that stand out are those that are unique to the pneumococcus and 
are able to be induced specifically through pneumococcal contact. Since PCV vaccination 
results in prevention of acquisition of vaccine serotypes, one would expect that vaccination 
should act as a probe to measure the effects of pneumococcal exposure on the acquisition of 
natural antibodies against pneumococcal specific antigens (Obaro et al., 1996). 
 
There are limitations to relating antibody titers to concurrent colonization, because the 
duration of colonization  prior to antibody measurement is thought to play a major role in 
determining serum antibody concentrations (Cauchemez et al., 2006). Without detailed 
colonization data which includes both the time of acquisition and a quantitative measure of 
colonizing organisms, the usefulness of antibody titers in relation to colonization is 
frequently compromised (Kauppi-Korkeila et al., 1996, Lloyd-Evans et al., 1996). In 
addition, many antigens are heterogeneous to the point where there is limited cross-reactivity 
between the different clades and families of an antigen (Brooks-Walter et al., 1999, Crain et 
al., 1990). This has potential to mute the comparisons of natural responses to pneumococcal 
exposure through colonization, as there is no information matching the antigen family used in 
the immunoassay with that of the colonizing types. Despite this, our data showed good 
agreement between the effects of vaccination and concurrent colonization in that significantly 
higher antibody titers to PspC, LytB, PdB, PcsB, PpmA and StkP were directly associated 
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with concurrent colonization in the first year of life (Table 5.1), and PCV vaccination had the 
greatest effect on titers to PspA, PspC, LytB, PdB, IgA1-proteinase, PcsB, and StkP in the 
first 18 months of life (Tables 5.1 to 5.3). 
 
In the older age groups one would expect that all individuals have had at least some contact 
with pneumococci, and thus acquired some level of antibody against pneumococcal antigens 
by the age of 2 years. With this in mind, ideal vaccine candidates can potentially be identified 
as antigens against which elevated titers protect against colonization. High antibody titers 
against PcsB and PdB were associated with lower prevalence of colonization, suggesting a 
protective effect. In addition, high titers of antibodies against PspC, SP 2027, SP 0082, LytB 
and PcsB were associated with lower prevalence of colonization in mothers (refer to Table 9).  
 
HIV status: HIV is a major risk factor to developing pneumococcal disease, and hence by 
inference, one would expect that antigens against which titers were suppressed in the HIV 
infected groups may well be involved in protection from disease. In the 4 to 7 year old group, 
HIV-uninfected children had significantly higher titers to antigens which are theoretically 
surface located, such as choline-binding proteins, and antigens which posess peptidoglycan-
binding motifs such as LPXTG. In contrast, antibody titers against antigens which are 
anchored to the cell membrane e.g. lipoproteins and ABC transporters were higher in HIV- 
infected children. These differences are possibly related to depleted cellular immunity in 
HIV- infected individuals, whereby antibody titers are driven by direct contact between 
immune cells and the outer surface of pneumococci. Interestingly, in 2 year olds and mothers, 
the lipoprotein PpmA and membrane anchored StkP were exceptions to this rule, and this 
might be because young children and mothers (adults) may have been on antiretroviral 
therapy, unlike the 4 to 7 year old group. 
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PspC, PdB, LytB, SP 0082, PcsB and StkP are exceptionally conserved among clinical 
isolates. Previous studies have shown that antibodies against PcsB and StkP are cross-
protective against different serotypes in lethal sepsis and pneumonia in human models, and 
they play a crucial role in bacterial growth (Giefing et al., 2008). PspC is a highly variable 
antigen and previous studies have shown that PspC is cross-reactive and cross-protective 
among heterologous strains, however the suitability of this antigen as a vaccine candidate 
might be limited by the fact that it is present in only 75% of S. pneumoniae strains (Brooks-
Walter et al., 1999), therefore a vaccine containing this antigen may need to represent more 
than 1 family of this heterogeneous antigen.  
 
Ply is produced by all strains of pneumococci. Previous studies (Bogaert et al., 2004a, Rapola 
et al., 1997) and our study have shown that PdB is potentially a good vaccine antigen; 
however, PdB might not provide enough protection to be an effective stand-alone vaccine 
antigen as it is not located on the surface of the pneumococcus. Antibodies against Ply are 
predicted to provide protection by neutralizing the biological properties of the toxin, rather 
than by stimulating opsonophagocytic clearance of the invading bacteria (Rubins and Janoff, 
1998). Therefore a vaccine combining surface proteins and PdB would be more effective than 
a vaccine consisting of PdB alone.  
 
SP 0082 is a highly conserved surface anchor protein. It contains an LPXTG binding motif 
and is therefore predicted to play a role in pneumococcal adherence and colonization. Like 
other proteins that are located on the surface of the pneumococcus (choline-binding proteins), 
it is presumed to elicit opsonophagocytic antibodies.  
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LytB is a highly conserved choline-binding hydrolase that plays a crucial role in cell division 
and pneumococcal colonization (Gosink et al., 2000). A vaccine containing LytB and SP 
0082 will potentially prevent against nasopharyngeal colonization, which is the crucial step in 
the pathogenesis of S. pneumoniae. 
 
Based on the results presented in this study, a subunit vaccine comprising a combination of 
the antigens highlighted in table 11 (PspC, PdB, LytB, SP 0082, PcsB and StkP) consistently 
match our hypothesised criteria in terms of titers increasing with an increase in age and the 
association of antibody titers against these proteins with HIV infection status, PCV 
vaccination history and pneumococcal colonization in young children.  
 
In conclusion, pneumococcal proteins offer the potential advantage of being immunogenic 
even when administered early in life, providing serotype independent protection and being 
less expensive compared to polysaccharide-based vaccines. This study contributes 
significantly to the identification of potential candidates in the development of a protein-
based pneumococcal vaccine. Therefore, the development of a vaccine composed of PspC, 
PdB, LytB, SP 0082, PcsB and StkP might protect against pneumococcal colonization and 
consequently prevent pneumococcal disease. 
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Table 11: Summary of differences in natural antibody responses in relation to age, HIV, PCV vaccination and colonization status. Antigens with potential as vaccine 
candidates are highlighted in red. 
* Incr. = Increase in antibody titers. Decr = Decrease in antibody titers. Suppr. = suppressed acquisition of antibody titers. Enhanc. = enhanced acquisition of antibody titers.  
ND = no differences. NC = no change. 
Proteins 
PCV-vaccinated children PCV-unvaccinated children 
Response to 
vaccination 
Older children Adults (Women) 
Titers 
↑ with 
age? 
Effect 
of HIV 
on titer 
Response to 
colonization 
 
Titers 
↑ with 
age? 
Effect 
of HIV 
on titer 
Response to 
colonization 
 
4 to 10 
months 
18 to 24 
months 
Effect of 
HIV on titer 
Titer 
suppressed 
by PCV? 
Titers 
protect from 
colonization
? 
Effect 
of HIV 
Titers protect 
from 
colonization? 
PspA Y Incr. Incr. Y Incr. NC Suppr. Suppr. Incr. No ND Incr. ND 
PspC Y Incr. Incr. Y Incr. Incr. Suppr. Suppr. Incr. No ND Incr. Yes 
PsaA Y Decr. Incr. N Decr. NC Suppr. Enhanc. Decr. No ND ND ND 
PdB Y Incr. Incr. Y Incr. Incr. Suppr. Suppr. Incr. No Yes ND ND 
SP 2027 N NC NC N NC NC Suppr. Enhanc. Decr. No ND Decr. Yes 
SP 0609 N NC ND N Decr. Decr. Enhanc. NC ND No ND ND ND 
SP 0082 Y Incr. Incr Y Incr. Incr. Enhanc Enhanc. Incr. No ND Incr. Yes 
SP 0749 N Decr. Decr. N NC  Suppr. Enhanc. ND No ND Decr. ND 
SP 0498 
(LytB) 
Y Incr. Incr. Y Incr. Incr. Suppr. Suppr. Incr. No ND Incr. Yes 
IgA1-
proteinase 
N Incr. ND Y NC NC Suppr. Suppr. Incr. No ND Incr. ND 
PpmA Y Incr. Incr. Y Incr. Incr. Suppr. Enhanc. Decr. No ND Incr. ND 
SlrA N Incr. NC N Decr. Decr. NC NC Decr. No ND ND ND 
SP 2216 
(PcsB) 
Y Incr. Incr. Y Incr. Incr. NC Enhanc. Incr. No Yes Incr. Yes 
SP 1723 
(StkP) 
Y Incr. Incr. Y Incr. Inc. Suppr. NC ND No ND Incr. ND 
SP 2194 N NC NC N NC NC NC NC ND No ND ND ND 
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Limitations 
 
The findings in this study do not suggest that the measured antibody titers represent the 
mechanism for protection. Also, through the use of a pooled reference, where titers for each 
antigen are described as arbitrary units relative to this reference, this study design did not 
allow us to measure the empirical amount of antibody, and compare it between antigens. 
Another limitation of this study is that a large number (15) of proteins was investigated, due 
to this; some of the statistical differences observed could have been purely by chance.  
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Appendices 
Appendix A 
 
Enzyme-linked immuno-sorbent assay (ELISA) 
 
1. Protein dilution buffer (1X Phosphate buffer saline, pH 7.3) 
 
 8 g of sodium chloride (NaCl) 
 0.2 g of potassium chloride (KCl) 
 1.1g sodium phosphate (dibasic salt) Na2HPO4 
 0.3 g potassium phosphate (monobasic salt) KH2PO4 
 Make up to 1 liter with distilled water 
 
2. Assay buffer (Phosphate buffer saline containing 10% foetal bovine serum and 0.05% 
sodium azide) 
 
 Measure 100 ml of foetal bovine serum (FBS) 
 Add 0.5 g of sodium azide 
 Make up to 1 liter with 1X PBS 
 
3. Wash buffer (Phosphate Buffer Saline containing 0.05% Tween 20)  
 
 Measure 500 µl of Tween 20 
 Make up to 1 liter with 1X phosphate buffer saline 
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4.  Secondary antibody (alkaline phosphatase-conjugated goat anti-human IgG, γ-chain 
specific) 
 
 Dilute 10 µl of the secondary antibody in 10 ml to make a 1: 1000 dilution    
 
5. Substrate [(4- nitrophenyl phosphate disodium salt hexadydrate (1.14 mg/ml)] 
 
 Weigh 0.098 g 4- nitrophenyl phosphate disodium salt hexadydrate 
 Make up to 70 ml with carbonate buffer, pH  9.1  
 
6. 0.05M Carbonate buffer, pH 9.6 
 
 Weigh 1.59 g of sodium carbonate  
 Weigh 2.93 g of sodium hydrogen carbonate 
 Make up to 1 liter with distilled water 
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Appendix B 
 
Multiplexed fluorescent covalent microsphere immunoassay (FCMIA) 
 
1. Conjugation buffer , 1X PBS, pH 6.1 
 
 Weigh 8 g of NaCl   
 Weigh 0.2 g of KCl   
 Weigh 1.1 g of NaH2PO4  
 Weigh 0.3 g of KH2PO4  
 Make up to 1 liter with distilled water  
 
 
2. 50 mg/ml 1-ethyl-3 (3-dimethylamino-propyl) carbodiimide-HCl  
 
 1 ampule contains 10 mg EDC 
 Dilute with 200 µl 1X PBS, pH 6.1 to make a 50mg/ml solution  
 
  
3. 50 mg/ml N-hydroxy-sulphosuccinimide   
 
 Weigh 0.05 g of N-hydroxy-sulphosuccinimide  
 Make up to 1 ml with  1X PBS, pH 6.1 
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Appendix C 
Other trials referred to in protocol 
 
HREC reference number: 040703 
Abbreviated title: CIPRA 2  
Trial title: A randomized trial to evaluate strategies for providing antiretroviral therapy to 
infants shortly after primary infection in a resource poor setting. 
Date of initial approval: Ethics: 24 August 2004                    MCC: 21 September 2004  
 
 
HREC reference number: 040704 
Abbreviated title: CIPRA 4 
Trial title: Evaluation of quantitative and qualitative antibody responses to Streptococcus 
pneumoniae and Haemophilus influenza type B conjugate vaccines amongst HIV-1-exposed-
infected children that are receiving vs. those not receiving antiretroviral therapy, as well as 
among HIV-1-exposed-uninfected children and HIV-1-unexposed-uninfected children. 
Date of initial approval: Ethics: 30 August 2004                     MCC: 8 November 2004 
 
 
HREC reference number: 031013 
Abbreviated title: Durability study  
Trial title: Durability of antibody response and measurement of anamnesis responses to a 
nonavalent Pneumococcal Conjugate Vaccine among HIV infected and uninfected children 
Date of initial approval: 08 December 2003 
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HREC reference number: M06-03-59 
Abbreviated title: M2C unvax  
Trial title: Dynamics of pneumococcal colonization in HIV-exposed and HIV unexposed 
infants and their mothers.  
Date of initial approval: 03 April 2006 
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